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In 1972, Brazeau et al. isolated somatostatin (somatotropin release-inhibiting factor, SRIF), a cyclic polypeptide with two biologically active
isoforms (SRIF-14 and SRIF-28). This event prompted the successful quest for SRIF receptors. Then, nearly a quarter of a century later, it was
announced that a neuropeptide, to be named cortistatin (CST), had been cloned, bearing strong resemblance to SRIF. Evidence of special CST
receptors never emerged, however. CST rather competed with both SRIF isoforms for specific receptor binding. And binding to the known
subtypes with affinities in the nanomolar range, it has therefore been acknowledged to be a third endogenous ligand at SRIF receptors.
This review goes through mechanisms of signal transduction, pharmacology, and anatomical distribution of SRIF receptors. Structurally,
SRIF receptors belong to the superfamily of G protein-coupled (GPC) receptors, sharing the characteristic seven-transmembrane-segment
(STMS) topography. Years of intensive research have resulted in cloning of five receptor subtypes (sst1-sst5), one of which is represented by two
splice variants (sst2A and sst2B). The individual subtypes, functionally coupled to the effectors of signal transduction, are differentially expressed
throughout the mammalian organism, with corresponding differences in physiological impact. It is evident that receptor function, from a
physiological point of view, cannot simply be reduced to the accumulated operations of individual receptors. Far from being isolated functional
units, receptors co-operate. The total receptor apparatus of individual cell types is composed of different-ligand receptors (e.g. SRIF and non-
SRIF receptors) and co-expressed receptor subtypes (e.g. sst2 and sst5 receptors) in characteristic proportions. In other words, levels of individual
receptor subtypes are highly cell-specific and vary with the co-expression of different-ligand receptors. However, the question is how to quantify
the relative contributions of individual receptor subtypes to the integration of transduced signals, ultimately the result of collective receptor
activity. The generation of knock-out (KO) mice, intended as a means to define the contributions made by individual receptor subtypes,
necessarilymarks but an approximation. Furthermore, wemust now take into account the stunning complexity of receptor co-operation indicated
by the observation of receptor homo- and heterodimerisation, let alone oligomerisation. Theoretically, this phenomenon adds a novel series of
functional megareceptors/super-receptors, with varied pharmacological profiles, to the catalogue of monomeric receptor subtypes isolated and
cloned in the past. SRIF analogues include both peptides and non-peptides, receptor agonists and antagonists. Relatively long half lives, as
compared to those of the endogenous ligands, have been paramount from the outset. Motivated by theoretical puzzles or the shortcomings of
present-day diagnostics and therapy, investigators have also aimed to produce subtype-selective analogues. Several have become available.
D 2003 Elsevier B.V. All rights reserved.Keywords: Somatostatin receptor; Amino acid; Lipid; Carbohydrate
1. Introduction somatoliberin (somatotropin-releasing factor, SRF). But dur-In 1972, the search for releasing factors of the hypothal-
amus was at its height, strongly encouraged by the recent
characterisation of neurosecretory peptides regulating the
thyroid axis and reproduction. The existence of distinct
release-inhibiting factors, on the other hand, had still not
gained the acceptance of the scientific community at large, let
alone been corroborated by anything but indirect evidence [1].
Brazeau et al. [2] for their part undertook to find the putative0005-2736/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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E-mail address: holst@mfi.ku.dk (J.J. Holst).ing the course of their investigations, they were compelled to
revise the original working hypothesis, having recorded the
consistently antisecretory response of somatotrophs to hypo-
thalamic extracts, and it was instead the negative regulator of
pituitary somatotropin (growth hormone, GH) release that
was finally isolated from ovine hypothalami. It was named
somatostatin (somatotropin release-inhibiting factor, SRIF),
according to its hypophysiotropic actions, and eventually
turned out to be a cyclic polypeptide with two biologically
active isoforms: the tetradecapeptide SRIF-14 and the amino-
terminally extended octacosapeptide SRIF-28. The heteroge-
neity of the regulatory peptide derives from differential
2 The neuropeptide urotensin II, which is at least structurally similar to
SRIF, if not ‘‘evolutionarily related’’ [504], did not have any known
receptor for a while. It has been isolated from the CNS of lampreys,
elasmobranchs, and amphibia. Finally, the cloned GPR14, an orphan GPC
receptor closely related to opioid and SRIF receptors, turned out to bind
urotensin II with high affinity, and it was accordingly renamed UII-R1a
[505]. Bachner et al. [506] reported the endogenous ligand at orphan
somatostatin-like receptor 1 (SLC-1) to be the neuropeptide melanin-
concentrating hormone (MCH). Binding affinity is in the nanomolar range.
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116 amino acids [3,4].1 The single human SRIF gene is
located on chromosome 3q28 [5,6].
In the years to follow, a steady flow of reports disclosed
the ubiquitous functions of SRIF. High-affinity, specific
SRIF receptors have been identified throughout the organ
systems of various mammals, sometimes with discrete
species variations in distribution and density. Structurally,
those receptors belong to the so-called ‘‘superfamily’’ of G
protein-coupled (GPC) receptors.
As for the physiological lineaments, SRIF is classically
known to inhibit the secretion of a wide range of hormones,
including the pituitary GH [7–13], prolactin (PL) [9], and
thyrotropin (thyroid-stimulating hormone, TSH) [9,14], vir-
tually every major hormone of the gastrointestinal tract
(GIT), e.g. cholecystokinin (CCK), gastric inhibitory pep-
tide (GIP), gastrin, motilin, neurotensin, and secretin [15–
20], and glucagon, insulin, and pancreatic polypeptide (PP)
of the pancreatic islets of Langerhans (PIL) [21–24].
Inhibition extends to the exocrine activity of salivary
glands (amylase), gastrointestinal mucosa (hydrochloric
acid, pepsinogen, intrinsic factor) [25,26], pancreatic acini
(enzymes, bicarbonate) [16,20,26–29], and liver (bile)
[26,29–31]. Similarly, intestinal absorption of key nutrients
(glucose, fat, and amino acids) is inhibited by SRIF [32–
34]. But with regard to gastrointestinal motility, the phar-
macodynamic actions of SRIF are fairly complex, breaking
with simplistic notions of a universal inhibitor. While
delaying the late phase of gastric emptying, weakening
gallbladder contraction [26,30], and prolonging small-intes-
tinal transit time, SRIF thus accelerates early gastric emp-
tying [35,36] and shortens the interval between migrating
motor complexes [37]. At the bottom line, however, a stable
SRIF analogue such as octreotide (SMS 201–995) induces a
3- to 4-fold increase in orocecal transit time [26,34,38].
Mesenteric hemodynamics, similar to intestinal absorption
and motility, has also proved to be responsive to SRIF, with
a drop in portal (and variceal) pressure [39–43].
Various parameters of renal function respond to SRIF. At
least when applied in pharmacological doses, SRIF appears
to have a largely antidiuretic effect in canine [44] as well as
human subjects [45,46]. Furthermore, renin secretion is
inhibited in man [47–49]. In dogs, however, SRIF inhibits
antidiuresis induced by adiuretin (vasopressin/antidiuretic
hormone, ADH) [50,51].
Then SRIF is believed to modulate such activities of the
central nervous system (CNS) that underlie cognition and
locomotion [52–56]. Among the later findings is the inhi-
bition of immunoglobulin synthesis and lymphocyte prolif-
eration in lymphoid tissues [57,58]. Last but not least, SRIF
has revealed an antiproliferative potential, reversing the
impact of mitogenic signals delivered by substances such1 Studies performed by Patel et al. have indicated that pro-SRIF is
processed into SRIF-14, SRIF-28, and pro-SRIF [1–10] via separate
biosynthetic pathways in 1027-B2 rat islet tumour cells [503].as epidermal growth factor (EGF) and somatomedin C/
insulin-like growth factor 1 (IGF-1) [59–63].
Twenty-three years after the discovery of SRIF, de Lecea
et al. [64] could announce that they had cloned a rat
neuropeptide bearing strong resemblance to SRIF, at least
in purely structural terms. With a double reference to its
distribution pattern in the CNS and neurodepressant actions,
this novel peptide transmitter was named cortistatin (CST).
A tetradecapeptide itself, corresponding to the highly con-
served carboxyl terminus of prepro-CST, the rodent homo-
logue shares as many as 11 amino acids with SRIF [65,66].
Unlike SRIF, however, CST seems so far to be confined to
rather well-defined neuronal subpopulations of the CNS. As
an invariant feature of its expression by inhibitory inter-
neurones of the cerebral cortex and hippocampus, CST has
been reported to show cellular colocalisation with gamma-
aminobutyric acid (GABA), both transmitters interfering
with pyramidal cell firing [65,67,68]. In the hippocampal
formation, however, CST is typically colocalised with SRIF
as well [66,69]. But transcription of CST and SRIF genes, as
it appears from comparison of upstream promoter regions, is
subject to widely different regulation [66]. Although various
physiological parameters, including transitions between
sleep phases [64,70,71], consolidation of short- and long-
term memory [67,68], and locomotor activity [71], respond
in a clearly transmitter-specific manner to SRIF and CST,
the latter is nevertheless recognised to be an endogenous
ligand at SRIF receptors, binding each subtype with an
affinity in the nanomolar range. Evidence of special CST
receptors has never emerged [72–74].2 The prepro-CST
gene maps to a region of the mouse chromosome 4 showing
conserved synteny with human 1p36 [65]. The human
homologue of CST really seems to be a heptadecapeptide
(CST-17). It displays an arginine for lysine substitution,
compared to rat and mouse CST (CST-14), and it is amino-
terminally extended by three amino acids [65,75]. By
analogy with SRIF, there may also be a naturally occurring
larger isoform of CST, i.e. a nonacosapeptide (CST-29).
This assumption is mainly based on the presence of dibasic
amino acids in the carboxyl-terminal region of prepro-CST
(Lys–Lys and Lys–Arg for processing into CST-14 and
CST-29, respectively), representing potential sites of post-
translational cleavage by precursor convertases [75,76].3There is indirect evidence that the GPC receptor in question couples to
either Gi or Gq.
3 By comparison, cleavage sites for processing of the 102-residue pro-
SRIF (as distinct from the 116-residue prepro-SRIF) into SRIF-14 and
SRIF-28 are the dibasic Arg–Lys and monobasic Arg, respectively [507].
L.N. Møller et al. / Biochimica et Biophysica Acta 1616 (2003) 1–84 32. Molecular biology of somatostatin receptors
For several years, SRIF receptors must be said to be
pharmacological entities without structural correlates. So
their existence, strictly speaking, remained exclusively a
matter of deduction. Unable to penetrate the phospholipid
bilayer, a peptide transmitter like SRIF would require a
readily accessible cell-surface receptor in order to deliver its
signal for further propagation beyond the plasma membrane.
Furthermore, binding studies involving iodinated radioli-
gands apparently succeeded in labelling receptor subpopu-
lations, with a display of differential selectivity.
2.1. Cloning of somatostatin-receptor subtypes (sst1–5)
Nearly a decade has now elapsed since Yamada et al. [77]
first managed to identify the fundamental topography of the
SRIF receptor, beginning with a pool of GPC receptor-like
sequences derived from human PIL mRNA.4 Human sst1
and sst2 receptors turned out to be related monomers of 391
and 369 amino acids, respectively. As a matter of fact, they
failed to introduce any novel principles of receptor construc-
tion. They rather conformed to the structural pattern of
alternating hydrophopic and hydrophilic segments, which
is characteristic of the seven-transmembrane segment
(STMS) receptor superfamily [78]. The investigators initially
estimated sequence identity between sst1 and sst2 receptors
to be 46% (a later report by the same team says 48% [79]),
similarity 70% [77].5 Lin et al. [80] have recently cloned the
goldfish sst1 receptor. Goldfish are tetraploid, and the isola-
tion of two sst1 isoforms from the brain probably reflects
transcription of duplicate genes rather than differential splic-
ing of a common transcript. Goldfish sst1A and sst1B recep-
tors both consist of 367 amino acids, displaying 98%
sequence similarity with each other, 76% and 75% with
human and rat homologues, respectively, and 39–55% with
other mammalian receptor subtypes. Comparison of goldfish
and mammalian sst1 receptors has highlighted the ATN as a
region of major sequence heterogeneity.
The mouse sst2 receptor, though identical in size to the
human homologue according to the first reports [77], was4 The discoveries made by Yamada et al. [77] were to mark a turning
point. Nucleotide sequences were amplified by reverse transcription in
conjunction with the polymerase-chain reaction (RT-PCR), and full-length
clones encoding two novel putative receptor proteins were subsequently
isolated from a human genomic library by hybridisation with the RT-PCR
probes. Genes encoding the respective receptors were inserted into vectors.
Transfected cells were then tested for binding of radio-iodinated ligands,
and one clone specifically bound [125I]Tyr11-SRIF-14 with high affinity and
was termed ‘‘SSTR1’’ (later to be changed according to international
conventions into ‘‘sst1’’ receptors). By ‘‘specific’’, unless otherwise
indicated, is meant displaceable rather than selective when applying to
binding of ligand to receptor. In the past, numerous synthetic SRIF
analogues have been alleged to be selective of particular receptor subtypes,
while, in fact, they were selective of a receptor subclass at most.
5 Sources of conflicting homology estimates may include variations in
software programme used for determining nucleotide or amino acid
sequences, allelic diversity, and methodological artefacts.found to be differentially spliced upon transcription. In this
respect, the receptor subtype concerned still appears unique.
Thus, the mouse sst2A receptor comprises 369 amino acids,
the sst2B receptor 346 amino acids [81,82]. The mouse sst2B
cDNA was first cloned from neuroblastoma glioma (NG
108–15) cells. The sst2B receptor represents a truncated
isoform of the sst2 receptor, lacking about 300 nucleotides
between transmembrane segment (TMS)-VII and the carbox-
yl terminus. Likewise, sst2B mRNA translates into an amino
acid sequence 23 residues shorter than that of sst2A receptors
(see Fig. 2). Furthermore, the two splice variants differ in 15
residues carboxyl-terminally to Lys331 [81].6 But it is now
known that differential splicing of mouse sst2 receptors is not
an isolated phenomenon after all. Analysis of the extended 3V
nucleotide sequence of the human sst2 gene has thus uncov-
ered highly conserved intron–exon boundaries, suggesting
that human and murine homologues may in fact be equally
capable of generating spliced variants [83]. Concurrent with
the discovery of human sst1 and sst2 receptors, Kluxen et al.
[84] used an expression-cloning strategy to isolate the cDNA
of a rat SRIF receptor from cerebral cortex and hippocampus.
The 2116-bp cDNA contained an open reading frame of 1107
bp, with a predicted protein of 369 amino acids and 41.2 kDa
(leaving aside the additional weight of carbohydrates).7 So
Kluxen et al. had obviously come across the longer splice
variant of the rat sst2 receptor. First to discover the rat sst2B
receptor, isolated from gastric mucosa, Schindler et al. [85]
could describe a posttranslational product whose CTT con-
sisted of a pentadecapeptide differing in composition from
the 38 amino acids of the known rat-sst2A CTT. A sst2 gene
has also long since been isolated from a porcine genomic
library. Similar to human and rodent homologues, the de-
duced amino acid sequence yields a receptor protein of 369
residues. Sequence analysis revealed the presence of seven
hydrophobic segments. The porcine SRIF receptor showed
96.5% identity (99.2% similarity) with the human sst2 recep-
tor, differing with regard to only 13 amino acid residues [86].
Following the initial breakthrough, screening of half a
million clones from a human genomic library (Stratagene)
with a 32P-labelled fragment of the human sst2 gene soon led
to the isolation of a 2.4-kilobase (kb) nucleotide sequence
containing an open reading frame of 1254 bp. It was a third
receptor subtype, i.e. the human sst3 receptor. A protein of
418 amino acids, it displays 45% and 46% sequence identity
(58% and 59% similarity) with human sst1 and sst2 receptors,
respectively [79]. According to Corness et al. [87], the
deduced amino acid sequence of human sst3 receptors dis-
plays the following degrees of similarity with other members6 The carboxyl-terminal pentadecapeptide of sst2B receptors has been
thought to be responsible for functional coupling to adenylyl cyclase (AC)
[82]. However, both splice variants mediate inactivation of this effector
even though a shorter CTT may confer an advantage inasmuch as it is less
likely to bar ICL-III from GP coupling (see below).
7 First, COS-1 cells were transfected with pools of cDNA clones.
Then, a positive clone could be detected by receptor autoradiography
(RAG) following successful binding of radiolabelled SRIF [84].
10 Yamada et al. [94] had previously reported the amino acid sequence of
human sst5 receptors to be slightly longer, i.e. 364 residues. Sequence identity
between human receptor subtypes allegedly ranges from 42% to 60%, and the
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(sst4)—results that slightly deviate from those of Yamada et
al. Similar to human sst1 receptors, the human receptor
subtype sst3 lacks introns in the protein-coding region. By
far the largest member of the SRIF-receptor family, the
murine homologue is 10 amino acids longer than human
sst3 receptors. The three human receptor proteins were
reported by Yamada et al. to display extensive sequence
heterogeneity, only 34% of the residues being invariant.
Another 14% of the residues represent conservative amino
acid substitutions. Particularly resistant to mutations are the
putative membrane-spanning regions [79]. The amino acid
sequence of a cloned mouse sst3 receptor was reported to
show 46% and 47% identity with mouse sst1 and sst2
receptors, respectively [88]. Using a combination of the RT-
PCR and genomic-library screening of the gymnotiform
(teleost) fish Apteronotus albifrons, Zupanc et al. [89,90]
isolated one of the few nonmammalian SRIF receptors
known to date. The deduced amino acid sequence shows
59% identity with the human sst3 receptor. The predicted
protein consists of 494 amino acid residues, sharing the
topographic characteristics of GPC receptors. Though clearly
belonging to the pharmacological subclass of SRIF receptors
known as SRIF1 receptors (see below), the fish sst3 receptor
behaves like the human sst5 receptor rather than any of its
mammalian homologues, including the human sst3 receptor.
The human sst4 receptor was first cloned by Rohrer et al.
[91] after screening of a human genomic library (Stratagene)
with the entire coding region of the 32P-labelled human sst1
gene. A different approach was adopted by Xu et al. [92]. In
search of a human receptor homologue, they used a 1.2-kb
fragment of the rat sst4 gene containing the full open reading
frame to screen a human genomic library. The genomic
clone isolated consists of a 1164-bp open reading frame,
encoding a protein of 388 amino acids, with a predicted
molecular mass of 42 kDa [91–94].8 The amino acid
sequence of the human sst4 receptor was reported by Rohrer
et al. [91] to display 58%, 43%, and 41% identity (75%,
66%, and 67% similarity) with the sequences of previously
cloned human sst1, sst2, and sst3 receptors, respectively.
9
Screening of a rat genomic library resulted in cloning of a8 The sst4 receptor shares several conserved sequence elements typical
of GPC receptors, e.g. the Asp-Arg-Tyr motif (see Fig. 1), which has been
assigned a central part in coupling to the G protein (GP) [146]. In bovine
rhodopsin, however, the corresponding sequence reads Glu134-Arg135-
Tyr136 [133].
9 Slight disagreement pertains to this point: Demchyshyn et al. [93]
reported sequence similarity of the human sst4 receptor to amount to 69%,
56%, and 58% with human sst1, sst2, and sst3 receptors, respectively, while
Xu et al. [92] claimed that the human sst4 receptor shows 61%, 46%, and
47% sequence identity with sst1, sst2, and sst3 receptors, respectively.
Finally, Yamada et al. [94] reported the amino acid identity between the
human sst4 receptor and human sst1, sst2, and sst3 receptors to be 60%,
43%, and 42%, respectively. According to Demchyshyn et al. [93], the
human receptor protein displays an overall deduced amino acid homology
of 86% with the previously cloned rat homologue of the sst4 receptor. By
way of comparison, sequence identity with the rat sst4 receptor was found
to be as high as 89% (94% similarity) by Xu et al. [92].novel brain-specific SRIF receptor, i.e. the rat sst4 receptor,
coding for a protein of 384 amino acids. Structurally, a
member of the GPC-receptor superfamily, the sst4 receptor
showed an amino acid sequence identity of 60% and 48%
with sst1 and sst2 receptors, respectively [95].
Combining the PCR with screening of a human genomic
library allowed cloning of human sst5 receptors by Panetta
et al. [96]. The predicted amino acid sequence of the
receptor protein displays 75% identity with the cloned rat
homologue, i.e. the rat sst5 receptor [97]. Consisting of 363
residues, the human sst5 receptor exhibits the putative
STMS topography characteristic of GPC receptors. As a
member of the minor SRIF-receptor family, the human sst5
receptor shows the following sequence identities with pre-
viously cloned human receptor subtypes: 42% (sst1), 48%
(sst2), 47% (sst3), and 46% (sst4) [96].
10 But before the
human sst5 receptor could be added to the list of cloned
receptor subtypes, a cDNA fragment, rAP236, was isolated
from a rat pituitary cDNA library by means of a PCR with
degenerate primers. Sequence analysis indicated a phyloge-
netic relationship to receptor proteins belonging to the
superfamily of GPC receptors. Eventually, a full-length
cDNA, rAP6–26, was obtained from the library, encoding
a protein of 383 amino acids. The deduced amino acid
sequence displayed 56–66% homology to sst1–3 receptors.
Final confirmation that the clone actually represented a
novel SRIF receptor was provided by specific binding of
the radioligand [125I]Tyr11-SRIF-14 [97].11 Baumeister et al.
[98] cloned the mouse sst5 receptor whose molecular weight
(MW) they predicted to be 42.5 kDa. Consisting of as many
as 385 amino acids,12 the protein backbone is 21 and 22
residues longer than respective human and rat homologues.
Additional length owes to an initiation codon located further
upstream. With regard to the overlapping portion, the mouse
sst5 receptor displays 81.7% and 96.7% sequence identity
with human and rat sst5 receptors, respectively.results are not quite in agreement with those of Panetta et al. Thus, the human
sst5 receptor showed 45%, 52%, 53%, and 49% identity with human sst1, sst2,
sst3, and sst4 receptors, respectively. The finding byO’Carroll et al. [210] that
human sst5 and rat sst5 receptors display an 80.5% amino acid sequence
homology does not fit the results of Panetta et al. either.
11 The announcement of ‘‘a novel rat pituitary SRIF receptor, termed
SSTR4, that has marked preferential affinity for SRIF-28’’, gave rise to a
long-standing confusion regarding the classification of receptor subtypes
[192]. Thus, the rat sst4 receptor proper is the receptor cloned by Bruno et
al. [95]; the receptor subtype identified by O’Carroll et al. [97] is the rat sst5
receptor.
12 Gordon et al. [116] later reported the mouse sst5 receptor to consist
of 362 residues alone, with Lublin et al. [461] having characterised a mouse
sst5 receptor of 363 amino acids 8 months in advance of Baumeister et al.
According to Lublin et al., the mouse sst5 receptor showed 97% and 81%
sequence identity with rat and human homologues, respectively, figures
resembling those of Baumeister et al. Sequence identity with other murine
receptor subtypes could be estimated to 48%, 55%, 56%, and 52% for
mouse sst1, sst2, sst3, and sst4 receptors, respectively.
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By analysing their segregation in a panel of reduced
human–hamster somatic cell hybrids, the human genes
encoding sst1, sst2, and sst3 receptors were mapped to
chromosome 14, 17, and 22, respectively. Fluorescence in
situ hybridisation (ISH) applied to metaphase chromosomes
pinpointed the locations of the genes to 14q13, 17q24, and
22q13.1, respectively [99] (see also Ref. [87]). Along
similar lines, the human sst4 (‘‘SSTR5’’) gene was mapped
to 20p11.2 [93,100]. The human sst5 gene is located on
chromosome 16, i.e. 16p13.3 [96].
Investigating the rat sst1 gene, Hauser et al. [101]
identified AP-2 and pituitary-specific transcription factor 1
(Pit-1) binding sites, apart from the consensus TRE between
 97 and  81 bp downstream from Pit-1. Baumeister and
Meyerhof [102] reported that at least four regions in the 2.2-
kb sequence upstream from the rat sst1 gene matter to cell
type-specific promoter activity in GH3 cells,
13 and RIN
cells. The 48-bp region located between  165 and  117
contains positive regulatory elements that are operative in
both of these neoplastic strains. This region is recognised by
Pit-1, which is estimated to represent a key regulator of GH
secretion at the genetic level. It thus regulates transcriptional
activity at genes encoding both GH itself and such receptors
that operate signalling pathways in somatotrophs. In GH3
cells, Baumeister et al. [103] reported a promoter fragment
of 2 kb to be sufficient to drive the expression of a reporter
gene, with positive and negative cis-regulatory elements
contributing to promoter activity. Two functional binding
sites for Pit-1 could be identified among those elements. But
while the proximal site mediated transcriptional activation,
the distal site played the part of a negative regulatory
element with regard to transcription of reporter-gene con-
structs. Mutations in the proximal site blocked expression of
the reporter gene. Functional elimination of Pit-1 mRNA by
antisense oligonucleotides caused inhibition of transcription
of reporter-gene constructs containing the proximal Pit-1-
binding site. Furthermore, expression of the endogenous rat
sst1 gene was blocked. At the functional level, this was
reflected in a much attenuated antisecretory response of
GH3 cells to SRIF and CH-275. In rat pituitary GH4C1 cells,
dexamethasone dose-dependently regulates expression of
endogenous sst1, sst2, and sst3 receptors at the level of
transcription.14 Whether posttranscriptional regulation is
also a reality, has not yet been determined. Sustained
exposure (24–48 h) to dexamethasone (1 AM) thus invari-
ably leads to a lasting decrease in expression of sst1 and sst2
receptors (50% and 30% of controls, respectively). The
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tumour, secretion comprising PL. By the RT-PCR and NB, Garcia and
Myers [188] found endogenous rat sst1 and sst2 receptors to be predominant
in GH3 cells, with lacking evidence of the sst3 receptor.
14 Scho¨nbrunn et al. [508], having developed receptor-specific antisera,
reported the expression of endogenous sst1 and sst2 receptors alone in the
GH4C1 strain. However, both receptor subtypes coupled to some GP.decrease in expression of the sst3 receptor observed by 24
h (30% of control) is but temporary. After 48 h, levels of sst3
mRNA are found to have increased dramatically (350% of
control). Progesterone, by contrast, increases levels of sst1
mRNA, decreases those of sst3 mRNA, with sst2 expression
being resistant to this steroid hormone. Estrogen and
testosterone both stimulate expression of all three receptor
subtypes [104]. Glos et al. [105] isolated genomic clones
containing the 5V-flanking promoter region of the rat sst3
receptor with a cDNA probe. A 5.4-kb sequence directly
upstream from the start codon turned out to contain two
introns located in the 5Vuntranslated region of the cDNA.
By 5V rapid amplification of cDNA ends (RACE) and
combined primer extension and ribonuclease-protection
analysis (PE-RPA), two initiation sites of transcription
could be mapped to position 1040 (tsp1) and  856
(tsp2) relative to the initiation site of translation. Similar
to the promoters of other GPC receptors, the 5V-flanking
region of the rat sst3 gene lacks TATA (Hogness) and CAAT
motifs while abundant in repetitive GC boxes. There is
evidence that a 107-bp sequence upstream from tsp2 is
sufficient to drive transcription. A 562-bp sequence extend-
ing from position  1304 to  1865 upstream from the
ATG start codon exerted a negative regulatory effect on
transcriptional activity.
Greenwood et al. [106] carried out a sequence analysis of
the 5V-flanking promoter region of the human sst2 gene. A
3.8-kb sequence directly upstream from the start codon
shared a number of characteristics with the promoters of
other genes encoding GPC receptors, including the repetitive
GC motif (constitutive genes tend to have GC boxes in their
promoters), binding sites for various transcription factors,
and the absence of coupled TATAA and CAAT sequences.
Having cloned the 5V-flanking promoter region of the human
sst2 gene, Pscherer et al. [107] identified a hitherto unknown
initiator element, i.e. SSTR2inr. Transcriptional activity at
this element, which is located close to the initiation site of
transcription, filling the vacancy of the absent TATA box,
depends on a binding site (E-box) for basic helix-loop-helix
(bHLH) transcription factors. Isolated from a mouse-brain
cDNA library, the bHLH transcription factor SEF-2 bound to
the E-box of SSTR2inr both in vitro and vivo, with the
ability to stimulate transcription. A single point mutation
within the E-box suffices to abolish SEF-2 binding, resulting
in a complete loss of transcriptional activity at SSTR2inr. In
T47D cells,15 Xu et al. [108] reported expression of the sst2
receptor to be regulated by 17beta-estradiol in a time- and
dose-dependent manner. They isolated a genomic clone
containing more than 5.3 kb of the 5V-flanking region of
the sst2 gene. The 5V-flanking region, which contains both
positive and negative regulatory elements, lacks both TATA
and CCAAT boxes. Two initiation sites of transcription
could be identified by PE-RPA, both located within an15 T47D cells derive from an estrogen receptor-positive human breast
cancer.
18 It had been known for some time that transcription of certain genes
increased in parallel with cAMP accumulation when the concept of a
specific CRE in the genome was introduced. The first report on CRE
containing genes was published by Montminy et al. [510] in 1986
Apparently, the CRE exhibits the properties of a classical enhance
sequence, stimulating transcription at a distance and functioning independ
ently of orientation. Transcriptional induction by cAMP, however, requires
modification rather than de novo synthesis of specific nuclear factors. Tha
the activated C subunits of PK-A ultimately must be held responsible fo
modifying these factors was demonstrated in cell lines lacking PK-A
transcription failed to increase in response to cAMP accumulation [510]
Furthermore, microinjection of C subunit into cells was shown specifically
to increase transcription of CRE-containing genes [511]. Polyclona
antibodies raised against a synthetic putative CRE-binding (CREB) protein
recognised a nuclear phosphoprotein of 43 kDa in PC-12 cells. And the RT
PCR produced a full-length cDNA containing a single long open reading
frame of 1023 bases, encoding a protein of 341 amino acids. The predicted
amino acid sequence of the CREB protein may be divided into three
domains on functional grounds: (1) a transactivation domain containing a
cluster of phosphorylation sites; (2) a DNA-binding domain consisting
primarily of basic amino acids; and (3) a ‘‘leucine-zipper’’ dimerisation
domain [512]. Mutational analysis has suggested that phosphorylation o
the CREB protein at a single residue, i.e. Ser133, within the PK-A motif, is
essential to transcriptional activation [513]. In the presence of PK-A
purified CREB protein binds to the CRE, with a concomitant increase in
transcription [514]. In nuclear extracts of PC-12 cells, however, it was
found that CRE binding of nuclear factors remained unaffected by prio
exposure of intact cells to forskolin. This observation is quite essential to
the understanding of CREB-protein action. It conveys the notion tha
cAMP-dependent phosphorylation modulates the transcriptional activity o
the CREB protein rather than its DNA-binding as such. In other words
modification by PK-A does not heighten the affinity of the nuclear facto
for DNA but merely transforms it into a more active effector [515]
Phosphorylation of nuclear extracts with C subunit was reported to induce a
10- to 15-fold stimulation of CRE-dependent transcription, strongly
supporting the model that the CREB protein induces transcription upon
phosphorylation. Although the CREB protein can bind to DNA as either a
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translational methionine (Met1) of the ATN. Transcriptional
regulation by 17beta-estradiol seemed to be mediated by a
distal 1.5-kb segment located 3.8 kb from the initiation sites
of transcription. Though fully operative in T47D cells, the 5V-
flanking region never showed any sign of promoter activity
in MB-435 cells derived from another human breast cancer,
which does not express sst2 receptors. Petersen et al. [109]
isolated a genomic clone including the human sst2 gene and
sequenced 1.5 kb of the 5V-flanking promoter region in search
of binding sites for transcription factors. The initiation site of
transcription turned out to be located 93 bp upstream from
the initiation site of translation. The investigators determined
the nucleotide sequence of the entire gene in addition to 0.5
kb of the 3Vregion. A potential poly-adenylation signal was
identified. A 1100 fragment of the sst2 promoter drove
luciferase expression at significant levels in both GH4 (rat
pituitary) and Skut1-B (endometrium) cells, whereas only
low promoter activity could be detected in JEG3 (choriocar-
cinoma) or COS-7 (monkey kidney) cells. A minimal  252
promoter fragment drove a cell-specific expression. There
was no evidence of regulation of the sst2 gene by SRIF,
forskolin,16 TRH, TPA, T3, or 17beta-estradiol. However,
glucocorticoids potently inhibited promoter activity at the
sst2 gene. A glucocorticoid-responsive element has appar-
ently been mapped to a location between  905 and  707
and between  252 and  163.
Having cloned the 5Vupstream regulatory region of the
mouse sst2 gene, Kraus et al. [110] discovered two previ-
ously unrecognised exons, separated by introns larger than
25 kb, and three tissue- and cell-specific alternative pro-
moters (TCSP 1–3). Located in front of exon 1, TCSP-1 is
operative in AtT-20 cells17 only. TCSP-2, located 5Vto exon
2, is operative in brain, pituitary, adrenals, pancreas, NG
108–15, and AtT-20 cells. It contains putative initiator
elements for regulation by estradiol and cAMP. TCSP-3,
which is located in exon 3, is additionally operative in lung,
kidney, and spleen. A glucocorticoid-responsive element
mapped to position  1044 of TCSP-2 mediates induction
by dexamethasone [111]. In the 5V-flanking promoter region
of the sst5 gene, Dorflinger et al. [112] identified a TC-rich
enhancer element that appears to be highly conserved
among mammals. Having screened a mouse-brain cDNA
expression library, they cloned a cDNA encoding the
transcription factor MIBP-1. MIBP-1 interacts specifically
with both the TC box of the sst2 promoter and the SEF-2
initiator-binding protein to enhance transcription from the
basal sst2 promoter. In both adult and immature mouse
brains, expression patterns of MIBP-1 and SEF-2 widely
differ. While SEF-2 is distributed throughout neuronal and
nonneuronal tissues, MIBP-1 expression coincides with that
of the sst2 receptor in the frontal cortex and hippocampus.
monomer or a dimer, results obtained with gel-retardation assays argue tha
the dimeric form alone is transcriptionally active [512]. It is now clear tha
the CREB protein is but one member of a family of related gene products
including CREB-341 (see above), CRE-BP1, HB-16, and ATF1-ATF8
[512,516,517].
16 A diterpene, forskolin interacts directly with AC, activating the
enzyme and thereby stimulating cAMP accumulation [509].
17 AtT-20 cells derive from a mouse pituitary (corticotroph) tumour.The nucleotide sequence proximal to the rat sst4 gene has
been examined in a study by Xu et al. [113]. The putative
promoter region of the gene, characterised by PE-RPA,
contains multiple initiation sites of transcription. The five
major ones map between  126 and 18 relative to the
ATG initiation codon. The region lacks TATA and CCAAT
promoter elements, displays an abundance in GC boxes, and
has a number of potential SP-1 binding sites. Furthermore,
potential AP-2, CGF, and PuF binding sites and an octimer
motif have also been identified. As pointed out by Xu et al.,
structural similarity between the promoter of the rat sst4
gene and analogous regions of highly regulated growth-
factor receptors and oncogenes is evident. Greenwood et
al. [114] sequenced 2.2 kb of the 5V-flanking region of the
human sst5 gene, identifying widely distributed promoter
elements such as AP-1, AP-2, AP-3, E-2A, GCF, and SP-1
consensus sequences. Responsiveness to cAMP is proba-
bly due to the presence of multiple AP-1 and AP-2 sites
rather than a cAMP-responsive element (CRE) proper.18-
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19 There is more to it than size, however. Polarity of the ligand also
matters. And then there are arrangements that seem entirely arbitrary. For
instance, Ca2 + interacts with the prominent ATN of a class-C receptor (see
below) rather than the extracellular loops or transmembrane alpha helices
[518].
L.N. Møller et al. / Biochimica et Biophysica Acta 1616 (2003) 1–84 7Sasi et al. identified two restriction-fragment length poly-
morphisms (RFLP) with high heterozygosity values in
the 5V-flanking region of the human sst5 gene. Functional
implications of this arrangement are as yet uncertain
[115].
Baumeister et al. [98] reported the 5V-flanking promot-
er region of the mouse sst5 gene to be devoid of both
TATA and CAA boxes while displaying putative binding
sites for AP-1, AP-2, and SP-1 besides glucocorticoid-
and phorbol ester-responsive elements. The initiation site
of transcription is mapped to position  95 relative to the
translational start codon. Gordon et al. [116] cloned the
coding region of the mouse sst5 receptor, corresponding
to 362 amino acids at the translational level, and 12 kb
of upstream DNA. In transfected TtT-97 thyreotrophs,
where transcription from the sst5 gene is induced by
thyroxine, and GH3 cells, high levels of basal promoter
activity could be localised to a 5.6-kb sequence upstream
from the initiation site of translation. Shorter fragments
displayed but low activity. Gordon et al. identified the
initiation site of transcription with RACE and PE-RPA.
From sequence comparison between cDNA and gene, it
became evident that the mouse sst5 gene contains three
exons and two introns, with the entire coding region
being mapped to exon 3. Two differently sized RACE
products revealed alternate exon splicing of two untrans-
lated exons in TtT-97 cells. Linked to a luciferase
reporter, a promoter fragment from  290/ 48 displayed
600- and 900-fold higher activity than a promoter-de-
prived control in GH3 and TtT-97 cells, respectively. A
larger fragment extending to  6400, however, failed to
contribute with any additional promoter activity.
2.3. Setting apart of somatostatin-receptor components
SRIF receptors, similar to other members of the super-
family of GPC receptors, are composed of amino acids,
carbohydrates, and a lipid. Functional integration by these
structural components is a prerequisite for normal biological
activity. But there are also reversible modifications such as
the phosphorylation catalysed by a number of kinases at
specific sites in the protein backbone.
2.3.1. The amino acid component
GPC receptors are integral membrane proteins. The
beta-adrenoceptor, a 64-kDa protein, represents the clas-
sical model of the seven-helix motif characteristic of
GPC receptors. A structural pattern of alternating hydro-
philic and hydrophobic segments conditions the forma-
tion of putative membrane-spanning helices, altogether
seven in number. Each right-handed alpha helix is
stabilised by hydrogen bonds. For the purposes of
understanding, the protein backbone of the receptors
may be likened to a sea serpent with neck and tail.
The amino-terminal neck (ATN), protruding from the
outside of the plasma membrane, features a variablenumber of N-linked oligosaccharides—two such appen-
dages in the case of the beta-adrenoceptor. The carboxyl-
terminal tail (CTT) resides on the inside. The binding
site for epinephrine (EN) is pocket-like, formed by some
of the helices [78,117–119]. However, the chemically
diverse receptor ligands must have different binding
requirements. As for the GPC receptor, the topography
resulting from tertiary structure folding of the posttrans-
lational product supplies numerous binding site epitopes.
While smaller transmitters such as monoamines, lipids,
and purines penetrate relatively deep into the receptor
body, surrounded by alpha-helical residues, the regulatory
peptides and chemokines are restricted to interacting with
the external portion. Some glycosylated peptides thus
derive the greater part of their binding energy from
interaction with the long ATN characteristic of their
particular receptors. In the case of medium- and small-
sized neuropeptides, the binding-site epitopes tend to be
more evenly distributed along the exofacial regions, i.e.
both the ATN and extracellular loop (ECL)-I, -II, and -
III. However, widely separated determinants in the pri-
mary structure are brought into close proximity to each
other in the folded protein of the relatively compact
receptor body. Mutational analysis allowed Greenwood et
al. [120] to suggest that the ligand-binding pocket of the
human sst5 receptor is formed by residues in TMS-III, -
IV, -V, -VI, and -VII and ECL-II. At least with regard to
SRIF-14, the binding pocket derives from much the same
structural elements in all receptor subtypes [121]. Apart
from the respective extremes, the midsequence loops
rising from either side of the phospholipid bilayer have
been found to vary considerably in length according to
ligand and effector specificities. However, intracellular
loop (ICL)-III has been shown to participate in GP
activation [122,123]. Although most of the STMS recep-
tors identified so far may indeed couple to some GP, the
heptahelical template per se should not be considered an
invariant correlate of GP-dependent signal transduction.
On either side of the plasma membrane, evolution has
seen a high degree of modification. Obviously, the
binding requirements of ligands differ widely, and
smaller transmitters such as catecholamines interact with
regions of the integral membrane protein, which, on
stereometric grounds alone, are inaccessible to the larger
peptide transmitters.19 Similarly, the cytosolic aspect of
the receptor body may have evolved alternative mecha-
nisms of signal transduction, i.e. even beyond the cou-
pling to different GP subforms (see below). As opposed
to the GPC receptors, the physicochemical activators of
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practically covering the entire range of known trans-
mitters.20 Some compounds activate both STMS recep-
tors and ligand-gated ion channels (e.g. acetylcholine,
GABA, and serotonin).
At present, more than 1000 different GPC receptors have
been incorporated in a rapidly expanding catalogue. GPC
receptors are divided into families and subfamilies accord-
ing to structure and ligand specificity. Five receptor families
emerging in this way are alphabetically termed class A–E:
(1) rhodopsin-like receptors (class A) form the largest
family; (2) secretin-like receptors (class B) represent a less
branched family tree;21 (3) metabotropic glutamate recep-
tors and chemosensors responsive to extracellular Ca2 +
(class C) combine to form a well-defined family;22 (4)
pheromone receptors (class D), themselves both family
and subfamily, have been isolated from yeast and, more
recently, from moth [124]; and (5) cAMP receptors (class
E), also a family of their own, are known so far to be
expressed solely by Dictyostelium discoideum. Most neuro-
peptides, including SRIF, depend for the transduction of
signals on rhodopsin-like receptors. (These, again, were
formerly subdivided into A1–5, SRIF and opioid receptors
belonging to A5.
23) Despite the relatively high degree of
sequence homology among rhodopsin-like receptors, a20 Ligands are the following: (1) nonglycosylated regulatory peptides
neuropeptides (e.g. ADH, angiotensin, bradykinin, calcitonin, calcitonin
gene-related peptide (CGRP), CCK, corticoliberin (corticotropin-releasing
factor, CRF), corticotropin (adrenocorticotropic hormone, ACTH), beta
endorphin,enkephalins,galanin,gastrin,gastrin-releasingpolypeptide(GRP)
GIP, glucagon, glucagon-like peptide 1 (GLP-1), gonadoliberin (luteinising
hormone-releasing factor, LHRF), melanotropin (melanocyte-stimulating
hormone,MSH),melatonin,motilin,neurokininA,neurokininB,neuromedin
B, neuropeptideY (NP-Y), neurotensin, oxytocin, PP, parathyrin (parathyroid
hormone, PTH), peptide YY, pituitary AC-activating peptide (PACAP)
secretin, SRF, SRIF, substance P, thyroliberin (thyrotropin-releasing factor
TRF), and vasoactive intestinal polypeptide (VIP)); (2) glycosylated peptides
(e.g. choriongonadotropin, follitropin (follicle-stimulating hormone, FSH)
lutropin (luteinising hormone, LH/interstitial cell-stimulating hormone
ICSH), and TSH); (3) chemokines (e.g. complement C5a, formyl-Met-Phe
Leu, and interleukin 8); (4) proteases (e.g. thrombin); (5) amino acids (e.g
GABA and glutamate); (6) mono-amines [e.g. acetylcholine, dopamine, EN
histamine, melanin, norepinephrine (NEN), and serotonin]; (7) lipids [e.g
anandamide (endogenous canabinoid), leukotrienes, platelet-activating facto
(PAF), prostaglandins, and thromboxane]; (8) purines (e.g. adenosine and
ATP); (9) ions (e.g.Ca2 +); (10) steroids (e.g. progesterone); (11) odorants; and
(12) light. More recently, Hoon et al. [519] have reported even gustatory
sensation to be mediated by GPC receptors.
21 A special feature of class-B receptors is a relatively long ATN
(f 100 residues) rich in cysteine residues, which are thought to form a
network of disulfide bridges [143,520].
22 Class-C receptors are characterised by an extremely long ATN
(f 500–600 residues). The ATN has been reported to show remote
sequence homology with periplasmic binding proteins of bacteria [521,522]
23 Within the superfamily, the opioid– receptor proteins msl-1 (i.e
kappa receptor: 380 amino acids) and msl-2 (i.e. delta receptor: 372 amino
acids) are most closely akin to the SRIF receptors, displaying an amino acid
sequence identity of 35% with the sst1 receptor. Both opioid-recepto
subtypes have the potential to mediate the inhibition of forskolin-stimulated
cAMP accumulation, implying GP coupling [523].
24 Numbering is based on the 348-residue bovine rhodopsin (f 40
kDa) where the complete tripeptide reads Glu134-Arg135-Tyr136. The
residues of this highly conserved A-class motif participate in severa
hydrogen bonds with surrounding residues. The carboxylate of Glu134
forms a salt-bridge with guanidium of Arg135. But this residue is also linked
to Glu247 and Thr251 in TMS-VI [133].
25 Similar to most GPC receptors, all subtypes of the SRIF receptor
with the notable exception of mouse and rat sst2 receptors, lack introns in
their coding region [85,91].
26 In contrast with the membrane-spanning regions, which basically
form the props of the GPC-receptor scaffold, with little room for genetic trial
theATN,CTT, and ICL-III represent truly fertile testing grounds of evolution
with a multitude of surviving mutations. ICL-III and the CTT are both
involved inGPcouplingand subsequent effector activation [119].Having said
this, however, there is a dipeptidemotif shared by all receptor subtypes cloned
so far, i.e. the carboxyl-terminal Ser-Glu in ICL-III (residues 265–266, 250–
251, 251–252, 253–254, and 242–243 in human sst1, sst2, sst3, sst4, and sst5
receptors, respectively). To some extent, sequence heterogeneity of the
regions specified reflects differential coupling of SRIF receptors to separate
effector systems.
27 Formation of receptor homodimers has been reported for class-A
receptors such as beta2 adrenoceptors [524], delta-opioid [525], and the
chemokine receptors CCR2b, CCR4, and CCR5 [526,527]. But homo
dimers are also formed by class-C receptors such as metabotropic glutamate
5 [528] and Ca2 + receptors [529,530]./
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rparticular arginine (residue 13524) in rhodopsin, bordering
on the cytosolic aspect of TMS III, is the sole residue to
have been invariably conserved by members of the family
[123]. It corresponds to the middle residue in the Asp–
Arg–Tyr motif of SRIF receptors (see below).
GPC receptors are monomeric, usually decoded from
genes devoid of introns,25 but they have been proposed to
behave somewhat like dimers in the plasma membrane.
These functional dimers, as it were, are supposedly made
up of two domains, i.e. A and B. It is partly the length of the
loops, partly the disulfide bridge that define this spatial
arrangement. Both ICL-I and ECL-I, which link TMS-I to
TMS-II and TMS-II to TMS-III, respectively, are relatively
short, their length being well conserved in spite of evident
sequence heterogeneity. Similarly, TMS-VI and TMS-VII
are linked together by a short loop, i.e. ECL-III. The
disulfide bridge, formed between a cysteine residue just
above the external pole of TMS-III and a similar residue
somewhere in the middle of ECL-II, which by itself is fairly
long, is responsible for generating two shorter loops closely
linking TMS-III to both TMS-IV and TMS-V. The A
domain thus comprises the helices amino-terminally to
ICL-III. In GPC receptors lacking the disulfide bridge, such
as the ACTH and MSH receptors, a mere dipeptide separates
TMS-IVand TMS-V. This alternative arrangement preserves
the overall structure of two domains. ICL-III, which sepa-
rates the two domains, is relatively long and poorly con-
served as regards both length and sequence [125].26 Recent
studies have strongly hinted at the functional implications of
dimerisation at the intermolecular level, i.e. beyond the
intramolecular arrangements of the individual receptor
monomer. Apparently, GPC receptors are thus capable of
direct protein–protein interaction, resulting in phenomena
such as receptor homo- and heterodimerisation.27 It seemsl
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somewhat unpredictable properties on the receptor dimers,
dependent on the participants. In some cases of receptor
heterodimerisation, the properties of one participant may
seem entirely to predominate, implying dimer-specific
inactivation of the other participant [126].28 Indeed, the
notion of subtle, higher-level integration of external
stimuli or so-called ‘‘cross-talk’’ between receptor sub-
populations is intriguing. In their first study, Rocheville et
al. [127] found evidence of agonist-induced dimerisation
of SRIF receptors. Both homo- and heterodimerisation
could be observed, the latter being selective.29 They also
found that dimerisation fundamentally implied the synthe-
sis of a novel receptor with a pharmacological profile of
its own.30 Then, in their second study, the investigators
went on to characterise hetero-oligomerisation of receptors
activated by either SRIF or dopamine, i.e. different-ligand
as opposed to identical-ligand receptors.31 Formation of28 Pfeiffer et al. [126] reported both sst2A and sst3 receptors to occur as
homodimers in HEK-293 cells. But whereas the sst2A–sst3 heterodimer
rather displayed the binding properties of the monomeric sst2A receptor, it
differed from both sst2A and sst3 homodimers with regard to desensitisation,
being relatively slow to undergo agonist-induced internalisation.
29 While reluctant to interact directly with the human sst4 receptor,
the human sst5 receptor formed dimers with itself (homo-) and the human
sst1 receptor (hetero-) in stably transfected CHO-K1 cells [127]. And it is
evident that the molecular determinants of dimerisation vary considerably
among GPC receptors. Hebert et al. [524] thus observed that a peptide
derived from TMS-VI could inhibit both activation and homodimerisation
of beta2 adrenoceptors. A similar observation was made with regard to D2
receptors [531]. In the case of D1 receptors, however, a peptide derived
from TMS-VI completely failed to interfere with dimerisation [532].
Indeed, either extreme of the polypeptide chain may apparently play a
part in receptor dimerisation. Cvejic and Devi [525] reported that
homodimerisation of delta-opioid receptors could be abolished by deletion
of 15 amino acids belonging to the CTT. Then again, when dealing with
class-C receptors, dimerisation of both metabotropic glutamate and Ca2 +
receptors seems to depend on formation of intermolecular disulfide
bridges between cysteine residues of the long ATN [528–530]. Further
evidence that receptor dimerisation is a rather complex phenomenon,
having evolved along different lines and subject to ligand-specific
regulation, is derived from the observation that agonist stimulates
dimerisation of beta2 adrenoceptors [524] and the chemokine receptors
CCR2, CCR4, and CCR5 [526,527], i.e. agonist is seen to stabilise the
receptor dimer, while inhibiting the formation of delta-opioid receptor
dimers [525].
30 A similar observation has been made by Jordan and Devi [533] with
regard to heterodimerised delta- and kappa-opioid receptors.
31 Rocheville et al. [128] investigated human sst5 and D2 (longer splice
variant) receptors, which are colocalised in various neurones of the cerebral
cortex, striatum, and limbic system, but it is in fact uncertain whether the
receptor subtypes specified form heterodimers or larger, super-receptor
hetero-oligomers. For some time, thanks to Ng et al. [531], D2 receptors
have been known to occur in a dimeric form. Oligomerisation has been
characterised by the same team for D1 receptors [532]. Unlike the hetero-
oligomer formed by SRIF and dopamine receptors, which requires the
presence of agonist, the dopamine-receptor homodimer is supposedly
preformed. Apart from dimers, D3 receptors have even been reported to
form tetramers [534].the double-ligand hetero-oligomer, contrary to the putative
dopamine-receptor homodimer, seemed to be strictly de-
pendent on ligand binding to either of the receptor
subtypes taking part. The hetero-oligomer displayed rela-
tively high affinity for both SRIF and dopamine, with
reciprocal induction of significantly heightened affinity by
either ligand, and synergism also extended to GP coupling
and receptor-mediated regulation of AC activity [128].32
Another example of double-ligand dimerisation was provid-
ed by Pfeiffer et al. [129], illustrating the phenomenon of
cross-regulation. In HEK-293 cells, heterodimers consisting
of the sst2A receptor and the mu-opioid receptor largely
preserved the individual binding properties of the partici-
pants. But whereas the sst2A-selective ligand L-779,976
induced phosphorylation, internalisation, and desensitisation
of both participants, the mu-selective ligand [D-Ala2, Me-
Phe4,Gly5-ol]enkephalin induced but phosphorylation and
desensitisation in either case. However, it did not induce
internalisation of the sst2A receptor.
GPC receptors are not likely to be static structures.
There seems to be a dynamic interchange of different
conformations. But high-resolution images or fully reliable
three-dimensional (3D) pictures had long been in want as
crystallisation eventually became a reality.33 Highly con-
served proline residues in the membrane-spanning helices
are thought to destabilise overall protein folding in such a
way as to modulate both ligand binding and GP coupling.
Proline, containing a secondary rather than a primary
amino group, is an imino acid that often occurs in bends
of folded polypeptide chains. Consensus prolines are
distributed in human sst1–5 receptors as depicted in Fig.
1.34 The cycle of conformational changes may also in part32 In a study by Cattaneo et al. [535], using subtype-selective agonists,
they note that combined activation of human sst2 and sst5 receptors is
necessary to inhibit platelet-derived growth factor (PDGF)-stimulated Ras
activity to any significant degree, and they argue that this observation may
reflect the synergism of receptor heterodimerisation.
33 The first of the GPC receptors, i.e. rhodopsin, has only recently been
crystallised by Palczewski et al. [133]. In the past, high-resolution images
has been available for bacteriorhodopsin alone [536]. And bacteriorhodop-
sin, despite the appropriation of a heptahelical template, is not a GPC
receptor at all (see below). Furthermore, its tertiary structure deviates
significantly from that of rhodopsin [537].
34 Pro112, Pro97, Pro98, Pro101, and Pro94 in TMS-II of human sst1, sst2,
sst3, sst4, and sst5 receptors, respectively; Pro
124, Pro109, Pro110, Pro113, and
Pro106 in ECL-I of human sst1, sst2, sst3, sst4, and sst5 receptors,
respectively; Pro162, Pro147, Pro148, Pro151, and Pro144 in ICL-II of human
sst1, sst2, sst3, sst4, and sst5 receptors, respectively; Pro
191, Pro176, Pro177,
Pro180, and Pro173 in TMS-IV of human sst1, sst2, sst3, sst4, and sst5
receptors, respectively; Pro213, Pro198, Pro196, Pro203, and Pro191 in ECL-II
of sst1, sst2, sst3, sst4, and sst5 receptors, respectively; Pro
235, Pro220, Pro218,
Pro223, and Pro213 in TMS-V of human sst1, sst2, sst3, sst4, and sst5
receptors, respectively; Pro286, Pro271, Pro272, Pro274, and Pro263 in TMS-
VI of human sst1, sst2, sst3, sst4, and sst5 receptors, respectively; Pro
320,
Pro309, Pro310, Pro308, and Pro301 in TMS-VII of human sst1, sst2, sst3, sst4,
and sst5 receptors, respectively.
Fig. 1. Molecular biology of somatostatin receptors. Amino acid sequences of cloned human somatostatin-receptor subtypes.
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hydrates and lipids. On the basis of sequence-divergence
analysis of 42 GPC receptors (i.e. angiotensin, opioid, andSRIF receptors), Alkorta and Loew [130] proposed a
model for the 3D structure of the transmembrane domain
of the delta-opioid receptor. It turned out to be similar to
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TMS-VII helices are most buried in the bundle, with TMS-
I and TMS-IV helices being most exposed to the lipid
phase. Using electron cryomicroscopy of two-dimensional
(2D) crystals, Unger et al. [131,132] proposed low-resolu-
tion images of bovine and frog rhodopsin. As viewed from
an extracellular point, the seven alpha helices seemed to be
arranged sequentially in a counterclockwise manner. They
found that TMS-III took up a central position in the
receptor body. With both TMS-IV and-VII traversing the
plasma membrane at nearly right angles, TMS-I, -II, and -
III are tilted 27–30j. TMS-V is tilted at 23j. Towards the
internal pole, TMS-VI seemed almost perpendicular to the
plane of the membrane. However, the investigators
reported it to bend towards TMS-V near the exoface. As
viewed from an intracellular point, the helices seemed
tightly packed, with TMS-II and -III positioned between
TMS-IV, -VI, and -VII. Towards the exoface of the
receptor body, the helices spread to form the binding
pocket of retinal. The binding pocket seemed to be lined
by TMS-III, -IV, -V, -VI, and -VII. With the arrival of 3D
images of bovine rhodopsin, characterising the crystal35 The question whether GP transduction is necessarily preceded by
formation of a ligand– receptor (L–R) complex is obsolete. Numerous
studies have been designed to capture the true dynamism of receptor
function. A fundamental thesis incorporated by the two-state model is that
such conformational changes as are required for transduction to take place
are not induced by the receptor ligand per se. By so-called ‘‘isomer-
isation’’, receptors are capable of changing to the active conformation in
the absence of agonist. An equilibrium thus exists between alternative
conformations. An ‘‘allosteric ternary complex’’ is formed by agonist,
receptor, and GP, accounting for receptor-mediated regulation of cellular
metabolism by transmitters. A minor fraction of receptors, however, will
bind the GP in an agonist-independent manner, forming a constitutively
signalling ‘‘binary complex’’. Both agonist and GP will display high
affinity for the isomerised form of the receptor. Conversely, agonists will
bind to the GP-uncoupled receptor with significantly lower affinity
inasmuch as this receptor is likely to represent an inactive conformation.
Agonists really appear to act by stabilising the active conformation.
Displaying almost complementary binding requirements, antagonists bind
either GP-independently or with higher affinity for the GP-uncoupled
receptor. Substitution of Asn111 with glycine in TMS III of the AT1
receptor has been shown to render it constitutively active. During agonist-
dependent receptor activation, Asn111 interacts specifically with Tyr4 of
the octapeptide angiotensin II [538]. The conformation induced by the
above mutation mimics the partially active state (R’) of the parent
receptor, and transition to the fully active state (R*) can take place in the
absence of the angiotensin-II Tyr4. The property responsible for Asn111
function as a conformational switch in the parent receptor appears to be
neither polarity nor hydrogen-bonding potential but the size of the side
chain [539]. In the alpha1B adrenoceptor, Asp
142 forms part of the highly
conserved Asp-Arg-Tyr sequence. Mutational analysis showed that
substitution with any other natural amino acid in position 142 invariably
generated a mutant receptor with constitutive activity. Scheer et al. [540]
concluded that the hydrophobic/hydrophilic character of Asp142, which
could be regulated by protonation/deprotonation of this residue, must be
an important modulator of the transition between the states R and R* of
the alpha1B adrenoceptor.structure of the receptor at 2.8 A˚ngstro¨m (A˚) on the basis
of diffraction data, details of the 2D representation have
had to be corrected. Importantly, the alleged asymmetry
along the perpendicular axis of rhodopsin has been contra-
dicted. The exoface and the endoface of the receptor body
are nearly equal in cross section. Consistent with expect-
ations, TMS-I, -IV, -VI, and -VII are bent at proline
residues, though with varying consequences for protein
folding [133].
In later years, compiling evidence has tended to ques-
tion the validity of the extended ternary-complex model of
GPC-receptor activation, also known as the two-state
model. It is based on the observation that receptors may
assume an active conformation and couple to the GP
heterotrimer in the absence of agonist. In other words,
conformational changes seem to occur spontaneously. An
equilibrium is proposed to exist between an inactive (R)
and an active conformation (R*), though with the former
being predominant in the absence of agonist. The receptor
is thus likened to a simple on–off switch. Receptor ligands
bind according to the spontaneous conformations of the
receptor, shifting the equilibrium in favour of GP trans-
duction or functional receptor blockade. While agonists
stabilise the R* state, to which they bind with the highest
affinity, inverse agonists (also known as negative antago-
nists) stabilise the R state [134–136].35 However, it is now
realised that GPC receptors may actually assume multiple
conformations, some of which correlate with spontaneous
receptor activity. Strictly speaking, the agonist maintains or
perpetuates the activity of the individual receptor rather
than inducing receptor activation.36 A scale of conforma-
tion-dependent, ligand-specific receptor activity may be
described [137–141]. A multistate model has been intro-
duced by Schwartz et al. [142] to accommodate the
phenomena. This revised model easily accounts for the
observation that some agonists are more potent than others
despite comparable binding affinities and half lives. It is a
key point that, sharing the ability to perpetuate receptor
activity and GP transduction, agonists may not necessarily
bind to common epitopes of the receptor or stabilise
identical conformations. In fact, with the fabrication of
highly potent nonpeptide analogues for GPC receptors that
are otherwise liganded by native polypeptides, it has
become clear that identical or functionally equivalent
conformations of the receptor are stabilised in a distinctly36 There is a sense in which the individual GPC receptor can be
said to recruit the ligand that specifically stabilises the spontaneous
conformation of the moment. However, there is also evidence that the
GPC receptor may recruit the GP along similar lines, transduction being
subject to ligand-specific perpetuation in the presence of agonist [465].
So GPC receptors may not only be characterised by multiple active
confirmations. GP transduction is conformation-specific, with different
GP subforms being recruited according to the active conformations of
the receptor.
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competitive antagonists need not have overlapping binding
epitopes either. By stabilising different conformations of the
receptor, with reciprocal obstruction of receptor binding,
however, they cannot kinetically be distinguished from
agonists and antagonists competing for overlapping binding
epitopes [142,143].
Regulation of receptor activity takes various forms.
Agonist-induced receptor phosphorylation, internalisa-
tion,38 and desensitisation, however, may really constitute
different aspects of the same cellular response (if not
indeed consecutive steps in this response) rather than
alternative adaptation strategies (see below). At any rate,
phosphate groups covalently bound to serine and threonine
residues, particularly in the CTT, somehow interfere with
GP coupling. Typically, GPC receptors, including the beta-37 With a view to the discussion on pharmacology (see below), it is of
major interest to identify the molecular determinants of high-affinity ligand
binding, the analysis applying to an individual analogue or group of
analogues. Thus, ECL-III and the adjacent alpha-helical segments are
thought to contain structural elements essential to binding of hexapeptide and
octapeptide analogues to mouse sst2 receptors - and, by extension, to human
sst2 receptors. A stretch of amino acid residues, i.e. Phe-Asp-Phe-Val
(residues 294–297), in TMS-VII has been reported to determine affinity for
the sst2-selective SRIF analogues [541]. Correlating with their respective
pharmacological properties, human sst1 and sst2 receptors display total
sequence heterogeneity in this region. The same applies to the murine
homologues. Thus, both mouse sst1 and human sst1 receptors read Ser-Gln-
Leu-Ser at the corresponding sites (residues 305–308). Within the above
motif of sst2 receptors, the position of a phenylalanine, i.e. Phe
294, has been
thought to be essential to binding of octapeptides [542]. And the sst1 receptor
can actually bind SMS 201–995 with moderately heightened affinity after
substitution of Ser305 with phenylalanine in the analogous region of this
receptor subtype, yielding the mutant receptor SSTR1S305F. However,
SSTR1S305F retains the low affinity of sst1 receptors for a number of SRIF1-
selective hexapeptides, implying separate binding requirements for their part
[541]. The receptor subtype sst3 shares but a single amino acid of the Phe-
Asp-Phe-Val motif of sst2 receptors, i.e. valine in the sequence Tyr-Phe-Leu-
Val (residues 295–298 and 304–307 in human sst3 andmouse sst3 receptors,
respectively). Interestingly, the human sst5 receptor shares fully two amino
acids of the TMS-VII motif of sst2 receptors, i.e. phenylalanine and valine in
Tyr-Phe-Phe-Val (residues 286–289). By contrast, human sst4 receptors
shares none, the analogous sequence reading Asn-His-Val-Ser (residues
293–296). Merely judging from their conformity to the Phe-Asp-Phe-Val
motif—supposedly a determinant of high affinity for peptide analogues of
SRIF—sst1 and sst4 receptors must be said to form a receptor subclass of their
own, sst5 receptors are more closely related to sst2 receptors, and sst3
receptors are somewhere in between. This structure-based classification of
receptor subtypes is apparently reflected at the functional level, i.e. with
regard to binding of agonist.
38 Internalisation, also known as receptor endocytosis, represents a
regulatory mechanism shared by GPC receptors and structurally unrelated
receptor families. As a rule, GPC receptors are internalised in coated
vesicles. Confocal microscopy relying on specifically bound fluorescent
ligand has revealed internalisation of the ligand– receptor complex and
subsequent trafficking of labelled vesicles in the cytosol. Beaudet et al.
[543] have reported receptor-dependent internalisation of delta- and mu-
selective opioids, neurotensin, and SRIF. In zona-glomerulosa cells of the
rat adrenal cortex, the AT1 receptor has been reported to be mostly
internalised. Redistribution to the plasma membrane, however, is
constitutive or regulated by unknown factors [544].adrenoceptor, display some degree of agonist regulation,
i.e. a variant of the desensitisation or adaptation described
for sensory systems [144]. When, for an extended period
of time (e.g. 12, 18, or 24 h), receptors are exposed to
agonist at high or constant levels (e.g. in the micromolar
range), they gradually cease to catalyse the GTP–GDP
exchange, giving way to agonist-induced desensitisation.39
As regards SRIF receptors, potential phosphorylation sites
are found in ICL-I, ICL-II, ICL-III, and the CTT.40 In
total, phosphorylation sites in human sst1–5 receptors are
distributed as depicted in Fig. 1.41 According to Yamada et
al. [94], there are two sites (i.e. Ser161 and Ser253)42 for
phosphorylation by protein kinase A (PK-A) in ICL-II and
ICL-III of human sst4 receptors and three such sites (i.e.
Ser242, Thr247, and Ser325) in ICL-III and the CTT of sst5
receptors [91,94]. But, as indicated by Vanetti et al. [145],
it may be questioned whether serine/threonine residues on
the very fringe of the phospholipid bilayer are proper
substrates of phosphorylation, analogous with glycosyla-
tion of asparagines.
A common denominator of human sst1–5 receptors is the
recurrence of highly conserved key residues, some of them
located outside the alpha-helical segments. They include the
tripeptide Asp–Arg–Tyr, which is specific to class-A
receptors, though with room for Asp-to-Glu and Tyr-to-39 The CTT of the beta-adrenoceptor is essential to the process of
adaptation. A specific protein kinase, i.e. beta-adrenergic receptor kinase
(beta-ARK), is at least partly responsible for down-regulating modification,
acting solely on the ligand– receptor complex; the unliganded receptor
provides no substrate [545–548]. By similar mechanisms, phosphorylation
of serines and threonines takes place in photoactivated rhodopsin [549–551].
Signal transduction is terminated by this phosphorylation which renders the
ligand–receptor complex incapable of catalysing theGTP-GDP exchange. In
turn, sensitivity is restored upon removal of phosphates by a phosphatase
[78,119]. Both beta-ARK isozymes, which are relatively specific for GPC
receptors, with an alleged preference for modifying residues in the CTT, and
cAMP-dependent protein kinase (i.e. PK-A) participate in regulating receptor
activity. It is recognised, however, that functional consequences of
phosphorylation may vary considerably among GPC receptors.
40 One such site is a consensus residue present in ICL-III (Ser265,
Ser250, Ser251, Ser253, and Ser242 in human sst1, sst2, sst3, sst4, and sst5
receptors, respectively). Another consensus residue available for kinases is
threonine in ICL-I (Thr93, Thr78, Thr79, Thr82, and Thr75 in human sst1, sst2,
sst3, sst4, and sst5 receptors, respectively).
41 sst1 receptors (Thr
91 and Thr93 in ICL-I; Ser265 in ICL-III; Ser333,
Ser341, Thr356, Ser360, Ser364, Ser375, Thr383, Thr385, Ser386, Thr389, and
Thr390 in the CTT); sst2 receptors (Thr
76 and Thr78 in ICL-I; Ser150 in ICL-
II; Ser237, Ser238, Ser244, Ser245, and Ser250 in ICL-III; Ser322, Ser333,
Thr335, Ser341, Ser343, Ser348, Thr353, Thr354, Thr356, Thr367, and Ser368 in
the CTT); sst3 receptors (Thr
73, Ser75, Ser77, and Thr79 in ICL-I; Thr149,
Ser151, and Thr156 in ICL-II; Ser235, Ser244, and Ser251 in ICL-III; Ser332,
Ser337, Thr341, Thr348, Ser361, Ser375, Thr378, Thr382, Ser383, Ser390, Ser394,
Ser405, Thr406, Ser410, Ser411, Thr412, and Ser416 in the CTT); sst4 receptors
(Thr80 and Thr82 in ICL-I; Thr156 in ICL-II; Ser253 in ICL-III; Ser321,
Thr349, Ser353, Thr383, Thr385, Thr386, and Thr387 in the CTT); and sst5
receptors (Thr73 and Thr75 in ICL-I; Ser146 and Ser147 in ICL-II; Ser242 in
ICL-III; Ser314, Ser325, Thr333, Thr347, Thr361, and Ser362 in the CTT) [94].
42 Despite a perfect match of amino acid sequences, as presented in
tabular form by Rohrer et al. [91] and Yamada et al., the former erroneously
write: ‘‘Ser162 and Ser253’’, respectively.
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subregion of ICL-II [143], if not rather the internal pole of
TMS-III [133].44 It has been speculated that it might be a
codeterminant of GP coupling [146]. Cysteine residues in
ECL-I45 and ECL-II46 may form a disulfide bridge
[94,147].47 An aspartic-acid residue in TMS-III48 is also
highly conserved among GPC receptors for nonpeptide
ligands and has been shown to be required for ligand
binding in the case of beta-adrenoceptors [148]. Finally, a
highly conserved residue is an asparagine in TMS-I.49 The
side chain of this residue, which contributes to the stability
of the receptor body, forms interhelical hydrogen bonds with
both an aspartic acid in TMS-II50 and the peptide carbonyl
of an alanine in TMS-VII.51 By a water molecule, the
aspartic acid of TMS-II may also be linked to the peptide
carbonyl of a glycine in TMS-III.52 However, this residue
fails to recur in human SRIF receptors [133].
Basedonobservationsmadewith therat sst2 receptor,Zitzer
et al. [149] provided the first evidence that GPC receptors
interact with constituents of the cytoskeleton. Thus, mediated
by the PDZ (PSD-95/discs large/ZO-1) domain, cortactin-
binding protein 1 (CortBP1) would seem to bind to the CTT
of the sst2 receptor. Coprecipitation could be demonstrated in
transfected human embryonic kidney (HEK)-293 cells. For-
mationof this complexofGPCreceptor andCortBP1,which is
otherwise diffusely distributed throughout the cytosol accord-
ing to confocal-microscopy studies, is significantly increased
in the presence of SRIF. It is thought that, presumably on
conformational grounds, ligand binding increases the acces-
sibility of the CTT to the PDZ domain of CortBP1.43 The motif reads X-Arg-Y, with X being represented by aspartic or
glutamic acid, Y by tyrosine or tryptophan.
44 The Asp-Arg-Tyr motif corresponds to residues 154–156, 139–
141, 140–142, 143–145, 136–138 in human sst1, sst2, sst3, sst4, and sst5
receptors, respectively.
45 The ECL-I cysteine corresponds to Cys130, Cys115, Cys116, Cys119,
and Cys112 in human sst1, sst2, sst3, sst4, and sst5 receptors, respectively.
46 The ECL-II cysteine corresponds to Cys208, Cys193, Cys191, Cys198,
and Cys186 in human sst1, sst2, sst3, sst4, and sst5 receptors, respectively.
With regard to the human sst4 receptor, Rohrer et al. [91] erroneously write:
‘‘Cys199’’.
47 By analogy, the high-affinity state of the beta2 adrenoceptor is
claimed to depend on unique interaction between conserved and non-
conserved extracellular-loop cysteines [552], and assembly of functional
rhodopsin requires a disulfide bridge between Cys110 and Cys187 [553].
48 The TMS-III aspartic acid, though absent in bovine rhodopsin,
corresponds to Asp137, Asp122, Asp123, Asp126, and Asp119 in human sst1,
sst2, sst3, sst4, and sst5 receptors, respectively.
49 The TMS-I asparagine corresponds to Asn55 in bovine rhodopsin
and Asn76, Asn61, Asn62, Asn65, and Asn58 in human sst1, sst2, sst3, sst4,
and sst5 receptors, respectively.
50 The TMS-II aspartic acid corresponds to Asp83 in bovine rhodopsin
and Asp104, Asp89, Asp90, Asp93, and Asp86 in human sst1, sst2, sst3, sst4,
and sst5 receptors, respectively.
51 The TMS-VII alanine corresponds to Ala299 in bovine rhodopsin
and Ala318, Ala307, Ala308, Ala306, and Ala299 in human sst1, sst2, sst3, sst4,
and sst5 receptors, respectively.
52 The TMS-III glycine corresponds to Gly120 in bovine rhodopsin,
though absent in human SRIF receptors.2.3.2. The carbohydrate component
Apart from sharing the seven-helix motif of GPC recep-
tors, SRIF receptors are membrane-bound glycoproteins.
Both integral membrane proteins and certain secretion-
bound proteins, including hormones, antibodies, and clot-
ting factors, undergo glycosylation. This is a posttransla-
tional modification initiated in the rough endoplasmic
reticulum (rER) and completed in the Golgi apparatus (GA).
Preliminary studies revealed that rat-brain SRIF receptors
subjected to so-called ‘‘solubilisation’’53 and lectin-affinity
chromatography met the qualitative requirements for inter-
action with wheat-germ agglutinin columns, testifying to the
presence of carbohydrates [150,151]. In a series of experi-
ments, Rens-Domiano and Reisine [152] subsequently man-
aged to identify these molecules. The inability of con-
canavalin A to bind to the receptors positively ruled out
glycosylation of the high-mannose type. Similarly, GalNAc,
Fuc, and O-linked oligosaccharides had to be rejected as
likely candidates on account of negative results with the
lectins Dolichos biflorus agglutinin, Ulex europaeus I, and
Jacalin, respectively. On the other hand, receptors specifically
bound Sambucus nigra lectin. Terminal Sia residues in an
alpha-2,6 conformation are recognised by this particular
lectin. If to a somewhat lesser extent, the two lectins R.
communis I and II also bound to the receptors, suggesting the
presence of the (GlcNAc)n polysaccharides characteristic of
hybrid- and complex-type glycosylation. As to the physio-
logical properties conveyed by the carbohydrate molecules, it
turned out that peptide-N-glycosidase F as well as endogly-
cosidase F and H reduced specific binding of the iodinated
SRIF analogue seglitide ([125I]MK-678) to solubilised SRIF
receptors by 24.6F 8.2%, 53.9F 11.9%, and 39.9F 13.1%,
respectively. Furthermore, incubation of solubilised receptors
with neuraminidase from Vibrio cholerae abolished high-
affinity agonist binding. The bacterial neuraminidase cleaves
nonreducing terminal Sia residues in alpha-2,3, alpha-2,6,
and alpha-2,8 conformations. By contrast, the neuraminidase
of Newcastle-disease virus, which completely failed to re-
duce high-affinity binding of [125I]MK-678, cleaves only
physica Acta 1616 (2003) 1–84 1353 First to characterise the ‘‘solubilized somatostatin receptor in an
active form’’, He et al. [150,151] incubated rat-brain SRIF receptors with
the detergent 3-[(cholamidopropyl)dimethylammonio] 1-propane sulfonate
(CHAPS). That the solubilised receptors retained any biological activity,
considering normal protein folding across the phospholipid bilayer, must
surely have been something of a surprise. Contrary to expectations,
however, they appeared to share the elementary pharmacology of
membrane-bound receptors, binding [125I]MK-678 specifically and with
high affinity. Furthermore, solubilised receptors could be shown to depend
on GP coupling for such high-affinity binding to take place. GTP-gamma-S
thus abolished binding of [125I]MK-678 to solubilised SRIF receptors.
Among the numerous members of the superfamily of GPC receptors, the
interdependence between GP coupling and high-affinity binding is far from
simple. In the case at hand, He et al. tested for GP coupling by an
immunological approach as well. Hence, antibodies directed against a
synthetic peptide corresponding to a sequence in the carboxyl-terminal
region of Gi-alpha, specifically immunoprecipitating the subunit concerned,
coprecipitated more than 24% of the solubilised receptors.
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tions. Thus, it was proposed that Sia residues are at least
partly responsible for maintaining the receptor body in a
high-affinity state with regard to specific agonists. This
conclusion is further corroborated by studies on SRIF recep-
tors in AtT-20 cells. Incubation of AtT-20 cells with neur-
aminidase significantly reduces high-affinity binding of
[125I]MK-678. However, it appears as if this treatment does
not affect the maximal ability of SRIF to inhibit forskolin-
stimulated cAMP accumulation in intact AtT-20 cells. In
other words, desialylated SRIF receptors would appear to
retain but the purely transductional aspect of their functional
integrity, displaying lowered affinity for agonists [152,153].
The recognition sequence for N-linked glycosylation is
either of the two tripeptides Asn-X-Ser and Asn-X-Thr. Such
motifs are usually concentrated in the ATN of GPC receptors
but may occur elsewhere in the protein backbone. Potential
N-glycosylation sites in SRIF receptors are distributed as
depicted in Fig. 1.54
Subtype-specific antisera directed against human sst1, sst2,
sst3, sst4, and sst5 receptors reacted with broad bands of 53–
72, 71–95, 65–85, 45, and 52–66 kDa, respectively, during
Western blotting (WB). By enzymatic deglycosylation, Hel-
boe et al. [154] found that sst1, sst2, and sst5 receptors are
subjected to N-linked glycosylation. The sst4 receptor, how-
ever, seemed not to be glycosylated. Characterising the rat
sst3 receptor, Nehring et al. [155] found that mutation of both
N-linked glycosylation sites (i.e. Asn18–Thr and Asn31–Thr)
resulted in reduced high-affinity binding and attenuated
inhibition of cAMP accumulation. Using WB, Schreff et al.
[156] showed, however, that antibodies raised against the
CTT of the rat sst4 receptor reacted specifically with a broad
bandmigrating at approximately 70 and 50 kDa, respectively,
before and after enzymatic deglycosylation.
2.3.3. The lipid component
SRIF receptors may also be defined as lipoproteins. The
lipid component of GPC receptors is formed by palmitate
(n-hexadecanoate). Covalently bound to a cysteine residue
in the CTT (CH3(CH2)14CO-S-R), this fatty acid is claimed
somehow to interact with the plasma membrane, adding a
fourth intracellular loop to the receptor topography. Func-
tional implications of this arrangement are as yet purely
hypothetical. Thus, palmitoylation may play a part in
desensitisation, regulating the accessibility of potential54 Two potential N-glycosylation sites are located in the ATN of human
sst3 receptors, more precisely at Asn
17 and Asn30. The sequences of human
sst1 and sst2 receptors contain three (Asn
4, Asn44, and Asn48) and four
(Asn9, Asn22, Asn29, and Asn32) potential sites, respectively, for N-
glycosylation in the ATN. Other extracellular asparagines are found in
ECL-II of human sst1 (Asn
201 and Asn209) and sst2 (Asn
186 and Asn196)
receptors. Human sst4 and sst5 receptors display one and two potential N-
glycosylation sites, respectively, in the ATN (Asn24 in sst4 receptors and
Asn13 and Asn26 in sst5 receptors); a single extracellular asparagine residue
is located in ECL-II of the respective receptor proteins (Asn199 and Asn187
in sst4 and sst5 receptors, respectively).phosphorylation sites. Possibly, palmitate should be thought
of in terms of a functional-state attribute, on a par with
phosphate, rather than an intrinsic component of the recep-
tor such as sialic acid.
Either of the receptor subtypes sst4 and sst5 contains a
particular cysteine residue (Cys327 and Cys320 in human sst4
and sst5 receptors, respectively) flanked by two leucines in
the CTT; analogous with a similar motif in the beta-adreno-
ceptor, it may serve for palmitoylation [94,157]. Similar
residues are present in human sst1 (Cys
339) and sst2 (Cys
328)
receptors; in human sst3 receptors, the corresponding cyste-
ine is absent while two leucines are juxtaposed (Leu328 and
Leu329). Palmitoylation of residues in bovine opsin is anoth-
er case in point [158]. Mutational analysis has revealed that
simple substitution of Cys320 in the human sst5 receptor with
alanine results in a loss of functional effector coupling.
Similarly, key mechanisms of agonist-induced receptor
desensitisation and internalisation are impaired [159].3. Mechanisms of signal transduction
One major signalling pathway integrating the cellular
response to external stimuli is the AC cascade. Another is
the phosphoinositide (PI) cascade. AC and phospholipase C
(PL-C) are both enzymatic amplifiers catalysing the synthe-
sis of second messengers. Receptor-mediated regulation of
either cascade is conditional on specific guanyl nucleotide-
binding proteins (G proteins). These heterotrimers also have
a share in transduction mechanisms converging at ion
channels. Since GPC receptors depend on noneffector
intermediaries for transduction, receptor–effector (R–E)
coupling is purely functional by nature, without a trace of
direct protein–protein interaction. Apart from AC, phos-
pholipases, and ion channels, effector systems responsive to
GP transduction are commonly surmised to include ‘‘more
distal sites in exocytosis’’ [78,160]. But several of these ill-
defined sites probably do not represent separate transduction
pathways. In fact, the very cascade-like character of intra-
cellular signalling is prone to complicate the distinction
between direct and indirect effects of GP activation.
3.1. Specialisation of guanyl nucleotide-binding proteins
Bacteriorhodopsin is a proton pump, without a trace of
GP coupling.55 But with regard to most ligand-activated
receptors sharing the seven-helix motif, the molecular basis
of selective R–E coupling is provided by functionally55 Actually, bacteriorhodopsin (derived from Halobacterium hal-
obium), long believed to be the bacterial homologue of vertebrate
rhodopsin, is no exception from the rule of GP coupling inasmuch as it
does not belong to the family of genuine GPC receptors in the first place.
Sequence analysis thus calls into question any phylogenetic relationship
with the GPC receptors. The recurrence of the heptahelical template must
be considered accidental unless it confers some functional advantage as yet
neglected [143].
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approach to possible receptor–GP (R–GP) associations,
several layers of complexity become evident: (1) the same
ligand may activate different receptor subtypes in the same
cell or in different cells; (2) different receptor subtypes may
activate different GP subforms in the same cell or in
different cells;57 (3) the same receptor subtype may activate
different GP subforms in the same cell or in different
cells;58 and (4) different receptor subtypes may activate
the same GP subform in the same cell or in different cells.
The GP–E association does not necessarily represent a
simple one-to-one relationship, further adding to the
difficulties of analysis: (1) the same GP subform may
couple a single receptor subtype to different effectors or
different receptor subtypes to different effectors or a single
effector; and (2) different GP subforms may couple
different receptor subtypes to a single effector or a single
receptor subtype to a single effector or different effec-
tors.59 A GPC receptor may operate divergent pathways of
signal transduction, i.e. signals potentially diverge at various
sites distal to the ligand-binding epitope of the receptor,
including the endofacial determinants of GP coupling, with
the possibility of alternating R–GP complexes being formed
[161]. Less proximal sites of transductional divergence
typically allow of signal amplification (e.g. as when Gi-alpha56 Similar to GPC receptors, which may be organised systematically in
a superfamily comprising each and every GPC receptor, families
comprising different-ligand receptors (e.g. SRIF or dopamine receptors),
and receptor subtypes (e.g. sst1 or D1 receptors), GP heterotrimers may be
organised in a superfamily comprising each and every GP heterotrimer,
families comprising different-signal transducers (e.g. Gi or Go), and GP
subforms (e.g. Gi-alpha-1 or Go-alpha-1). More or less well-characterised GP-
effector (GP-E) associations include the following: (1) transducin (Gt) and
photoactivated cGMP phosphodiesterase; (2) Gs or Gi and AC; (3) Gq and
PL-C [554]; (4) Gi (?) and phospholipase A2 (PL-A2); and (5) Gi, Go, or Gs
and voltage-gated ion channels [238,555].
57 Different-ligand receptors that have been shown to couple to more
than one GP subform include the following: (1) alpha2 adrenoceptors [233];
(2) calcitonin [556]; (3) delta opioid [161]; (4) LH [557]; (5) tachykinin;
and (6) TSH receptors [558]. The respective GP specificities of identical-
ligand receptors such as the SRIF receptors are dealt with below [166].
58 Using synthetic agonists at the D1-like receptor of Drosophila
melanogaster, Reale et al. [465] reported the highly intriguing phenomenon
of ligand-specific signal transduction. The observations are explained in
terms of the variety of active conformations stabilised by different agonists.
Apparently, different GP subforms are recruited according to the
spontaneous conformations of the receptor, irrespective of ligand binding.
59 The attempt to unite individual GP subforms with relevant receptor-
subtype cofactors in signal transduction has aroused a lot of controversy
over the years. However, conflicting results must be said typically to
originate from the comparison of cell lines and model systems that represent
unique products of biological differentiation and specialisation. As the
affinity of GPC receptors for agonists, native or synthetic, are variably
sensitive to miscellaneous factors such as extracellular Na+, GP inventory,
GTP analogues, etc, this applies equally well to pharmacological studies. In
fact, with regard to the latter, the demand for standardised conditions should
be even higher. Needless to say, functional R–E coupling in cells
transfected with cloned receptors cannot be expected in the absence of the
appropriate GP. In addition to receptor and effector, experimental designs
must therefore include coexpression of the relevant signal transducers, if
not to yield a false-negative result.interacts with AC while the released G-beta-gamma complex
binds G
s-alpha
). By contrast, pathways of signal transduction
may sometimes converge at some common effector system,
e.g. Ca2 + channels [162]. Such transductional convergence
may either imply metabolic synergism—additive rather
than supraadditive—or antagonism (e.g. as when Gs-alpha
and Gi-alpha compete for interaction with AC). Nondiver-
gent, nonconvergent mechanisms include the counterbal-
anced actions of enzymes, e.g. kinases and phosphatases.
Interest has tended to centre rather one-sidedly around the
GTP-binding alpha subunit (G alpha) of the heterotrimeric
GP. In the case of an effector such as AC, it may seem rather
obvious, of course, that G alpha confers the dominant part of
the regulatory specificity of the GP. However, normal GP
function does not depend on the identity of G alpha alone.
Although the G alpha subform has traditionally been made to
define the GP heterotrimer as a whole, numerous subforms
of both beta and gamma subunits (G-beta and G-gamma,
respectively) have been identified. The G-beta-gamma
dimers have often been thought of in terms of a pool of
nondescript vehicles for GP-dependent signal transduction.
But that is a misunderstanding. The cDNA of several G-beta
subforms has long since been cloned. On the other hand,
functional versatility of the G-beta-gamma complex is per-
haps more likely to derive from the gamma subunits whose
amino acid sequences display a considerably higher degree
of heterogeneity than can be observed within the family of
beta subunits. But if the subunit constellation is fixed, with
G-beta-gamma acting in the dimeric form alone, the regula-
tory specificities of G-beta and G-gamma are identical.
The first evidence that SRIF receptors couple specifically
to other subunits of the GP than G-alpha is due to Law et al.
[163] who solubilised receptors from rat brain and AtT-20
cells.60 Using peptide-directed antisera against different
subunits (i.e. alpha, beta, and gamma, respectively) of the
GP heterotrimer, they tested if the individual R–GP com-
plex, as defined by the participating GP, could be immuno-
precipitated.61 The investigators, still ignorant of the
existence of multiple receptor subtypes with overlapping
expression patterns, found that SRIF receptors coupled to
both Gi-alpha-1 and Gi-alpha-3, though apparently unable to
form any complex with Gi-alpha-2. With regard to Gi-alpha-3, it60 Kleuss et al. [224] approached subunit specificity of GP coupling in
a different manner. To determine if the G-beta-gamma complex is really
interchangeable in the GP, Kleuss et al. microinjected antisense
oligonucleotides into the nuclei of a rat pituitary strain, selectively blocking
the expression of individual beta subunits. Out of four G-beta subforms
tested, two proved to be intrinsic to transduction of inhibitory signals from
muscarinic cholinoceptors (M4) and SRIF receptors to voltage-gated Ca
2 +
channels, i.e. Gbeta-1 and Gbeta-3, respectively.
61 One antiserum, 8730 (i.e. anti-Gi), is directed against the carboxyl-
terminal region of Gi-alpha and interacts indiscriminately with all Gi-alpha
subforms. Proper subform-selective antisera include 3646 (i.e. anti-Gi-1),
1521 (i.e. anti-Gi-2), and 1518 (i.e. anti-Gi-3), interacting with Gi-alpha-1,
Gi-alpha-2, and Gi-alpha-3, respectively. The antisera 3646 and 1521 recognise
internal regions of Gi-alpha-1 and Gi-alpha-2, respectively. Antiserum 2353 (i.e.
anti-Go-A) indiscriminately interacts with Go-alpha subforms [163].
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GP coupling varied from rat brain to AtT-20 cells.62 At any
rate, the R–GP complex could be seen to respond in a
distinctly cell-specific manner to antiserum, being either
precipitated in toto or induced to dissociate into receptor and
GP. However, SRIF receptors coupled to some Go-alpha
subform in AtT-20 cells alone, where they could be copre-
cipitated, without any sign of R–GP coupling in rat brain.
Furthermore, the investigators noted the ability of SRIF
receptor to couple specifically to Gbeta-36, Ggamma-2, and
Ggamma-3.
63 A subsequent study by the same investigators
expanded on these observations, applying a similar tech-
nique to rat–brain R–GP complexes.64 Interestingly, Law et
al. found that antiserum directed against Gi–alpha–2 copre-
cipitated the liganded SRIF receptor alone. By contrast, Gi–
alpha–1 and Gi-alpha-3 couple to the SRIF receptor, irrespec-
tive of ligand binding. It would seem that, unlike Gi-alpha-1
and Gi-alpha-3, Gi-alpha-2 simply cannot couple to the SRIF
receptor in the absence of agonist, a similar observation
applying to Go-alpha when tested in rat brain [164].
6562 With both antiserum and the specifically precipitated GP subform
(i.e. Gi-alpha-3) being identical in rat brain and AtT-20 cells, observations
lend themselves to the conclusion that, in rat brain, the antiserum interacted
directly with a part of the GP involved in subtype-specific receptor
coupling, inducing the R–GP complex to dissociate by competition for the
GP epitope. Alternatively, antiserum may induce a conformational change
in Gi alpha 3 that makes a difference to coupling of this GP subform to some
receptor subtypes alone. What can be concluded with absolute certainty is
that Gi alpha 3 couples to some SRIF receptor in both AtT 20 cells and rat
brain. When exposed to antiserum, however, the R GP complex displays a
cell-specific behaviour. Hence, more than one receptor subtype must be
involved in R–GP coupling.
63 Initial results from immunoprecipitation of the solubilised R–GP
complex by Law et al. [163]: (1) antiserum 8730/anti-Gi maximally and
specifically immunoprecipitated R–GP complexes in both rat brain and
AtT-20 cells; (2) antiserum 3646/anti-Gi-1 immunoprecipitated R–GP
complexes in both rat brain and AtT-20 cells; (3) antiserum 1521/anti-Gi-2
immunoprecipitated Gi-alpha-2 in both rat brain and AtT-20 cells while
failing to coprecipitate receptors in either place (on the basis of these results
alone, hence, Gi-alpha-2 would appear not to couple to SRIF receptors); (4)
antiserum 1518/anti-Gi-3 immunoprecipitated R–GP complexes in AtT-20
cells while uncoupling them in rat brain (confirmed by another Gi-alpha-3-
selective antiserum, i.e. SQ); (5) antiserum 2353/anti-Go-A immunopreci-
pitated R–GP complexes in AtT-20 cells while neither immunoprecipitat-
ing nor uncoupling them in rat brain; (6) antiserum directed against Gbeta-36
selectively immunoprecipitated solubilised rat-brain receptors; (7) anti-
serum directed against Gbeta-35 failed to immunoprecipitate solubilised rat-
brain receptors; and (8) rat-brain receptors coprecipitated with Ggamma-2 and
Ggamma-3.
64 Another antiserum directed against Go-alpha was introduced, i.e. 9072
(i.e. anti-Go-B); it interacts selectively with the carboxyl-terminal region of
the GP subunit [164].
65 Additional results from immunoprecipitation by Law and Reisine
[164]: (1) both of the antisera 8730/anti-Gi and 3646/anti-Gi-1 immuno-
precipitated solubilised R GP complexes in the absence of agonist; (2)
coprecipitation of the receptor did not occur following addition of the
antisera 1521/anti-Gi-2 or 9072/anti-Go-B; (3) upon binding of agonist to
solubilised receptors, antisera 1521/anti-Gi-2 and 9072/anti-Go-B, as well
as antisera 8730/anti-Gi and 3646/anti-Gi-1, proved capable of immuno-
precipitating R–GP complexes; and (4) antiserum 1518/anti-Gi-3 un-
coupled receptors from Gi-alpha and immunoprecipitated neither liganded
nor unliganded rat brain receptors.Eventually, coupling of the SRIF receptor to the entire
series of GP subforms tested, i.e. Gi-alpha-1, Gi-alpha-2, Gi-
alpha-3, and some Go-alpha, had been established.
66 But it had
also become obvious that SRIF receptors coupled differen-
tially to the GP. Apparently, notions such as cell-specific
and agonist-dependent GP coupling had to be considered.
Several factors could account for the observations made. In
rat brain, binding of agonist made a difference to formation
of a R–GP complex by the SRIF receptor and either Gi-alpha-
2 or Go-alpha. This observation indicated that the receptor
might be required to undergo an agonist-induced conforma-
tional change for GP coupling to take place. In AtT-20 cells,
however, antiserum directed against Go-alpha did coprecipi-
tate the SRIF receptor in the absence of agonist. So what
cell-specific conditions would determine receptor coupling
for Go-alpha? The answer is, of course, that AtT-20 cells and
rat brain express varying levels of the individual receptor
subtypes. With each receptor subtype being unique, display-
ing varying degrees of sequence heterogeneity in the GP-
coupling regions, there is room for differential coupling to
any GP subform, including Go-alpha. The molecular deter-
minants of GP coupling that could be seen to vary from AtT-
20 cells to rat brain are indeed represented by the structur-
ally and functionally diverse receptor subtypes themselves.
Attempting to identify the specific GP subforms coupling
to brain SRIF receptors, Murray–Whelan and Schlegel
[165] solubilised these receptors in GP-coupled form.
Uncoupling of receptor and GP results in lowered binding
affinity of receptor agonists, and binding of the synthetic
SRIF analogue MK-678 was thus completely inhibited by
the nonhydrolysable GTP analogue guanosine 5V-O-thiotri-
phosphate (GTP-gamma-S) (half-maximal inhibitory con-
centration (IC50) = 100 nM).
67 Antibodies raised against
specific carboxyl-terminal peptides of the GP subforms
Gi-alpha-1, Gi-alpha-2, Gi-alpha-3, Go-alpha, and Gz-alpha admitted
of suitable differentiation between varieties of GP coupling.
Antibodies interacting with the carboxyl-terminal regions of
Gi-alpha-1 and Gi-alpha-2 (antibody AS) and Gi-alpha-3 (antibody
EC) inhibited binding of [125I]MK-678 (75 pM) by 57F 4%
and 48F 5%, respectively. When acting in concert, AS and66 By way of comparison, endogenous Gi-alpha-2 (alpha subunit: 40
kDa) and a Go-alpha (alpha subunit: 39 kDa) are activated by opioid
receptors [559].
67 The heterotrimeric GP is stabilised by GDP but dissociated upon
treatment with GTP-gamma-S, i.e. a GTP analogue resistant to hydrolysis
[560]. Similar to agonists, the GP would seem to stabilise the active
conformation of the receptor. At any rate, GTP analogues, which uncouple
the GP from the STMS receptor, almost consistently reduce high-affinity
binding of SRIF. The respective effects of agonist and GP on the isomerised
receptor may thus be characterised as reciprocal. Although sustained signal
transduction depends on receptor binding of the agonist, this ligand may in
fact be no more capable of activating the receptor than the GP. Contrary to
the constitutively signalling binary complex, the ternary complex represents
agonist-dependent perpetuation of GP transduction by the isomerised form
of the receptor, with consecutive GP heterodimers cycling between the
receptor complex and the effector (i.e. when transduction does not include
an entire series of intermediate steps).
68 For a characterisation of CREB proteins, see above.
69 Purified from Bordetella pertussis, PTX blocks inhibition of cAMP
accumulation by covalent modification of Gi. More specifically, PTX
catalyses ADP ribosylation of a cysteine side chain belonging to Gi-alpha.
This covalent modification locks Gi in the GDP form. PTX irreversibly
ADP-ribosylates and inactivates GP subforms of the Gi-like subfamilies,
including Go [160,178].
70 Metabolic events induced by SRIF and insulin are mainly
antagonistic. Their respective receptors operate transduction pathways that
have been found to intersect as far as the modification of target-protein
tyrosine residues is concerned [332]. Competitive antagonism in the
pharmacological sense, of course, is out of the question. To begin with,
SRIF and insulin simply do not have any receptors in common. Furthermore,
unlike identical- or different-ligand receptors sharing the STMS topography
(see above), SRIF, and insulin receptors have never been known to interact
directly at the level of the plasma membrane. But physiological antagonism,
by contrast, would be evident if the opposing regulatory pathways
represented by tyrosine kinase (TK) and PTP, i.e. when activated by insulin
and SRIF, respectively, were operative in the same cells (see below).
71 An acetylcholine analogue, carbachol is known as an activator of the
PI cascade.
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carboxyl-terminal region of either Go-alpha (GO) or Gz-alpha
(QN) failed to interfere with high-affinity agonist binding. A
so-called ‘‘locked conformation’’ occurred if the receptor
was labelled with [125I]MK-678 prior to antibody exposure,
i.e. a ligand-R-GP complex insensitive to antibody. The
brain receptor characterised by Murray–Whelan and Schle-
gel appears to be either one of the receptor subtypes sst2 and
sst5, possibly sst3, merely judging from its pharmacological
profile. It certainly could not be sst1 or sst4.
Gu and Scho¨nbrunn [166] raised antibodies against
two overlapping peptide motifs within the CTT of the
sst2A receptor: (1) peptide 2C(SG), containing the resi-
dues 334–348; and (2) peptide 2C(ER), containing the
residues 339–359. Only antibodies specific for peptide
2C(ER) actually precipitated the receptor. Unlike the
interaction between receptor and GP, immunoprecipitation
proved to be completely insensitive to ligand binding,
and antibodies precipitated the entire ternary complex
consisting of ligand, receptor, and GP. By immunoblot-
ting with GP antibodies, it was found that both G-alpha
and G-beta bound to the L–R complex. This, of course, is
in agreement with theory. The notion of isomerisation was
nicely illustrated by Gu and Scho¨nbrunn: on the one hand,
GP subunits were coprecipitated only with the ligand-
binding receptor; on the other hand, GTP-gamma-S induced
ligand dissociation from the GPC receptor. In other words,
both ligand and GP, though from either aspect of the
integral membrane protein, help stabilising the active con-
formation of the GPC receptor. The isomerised form is
assumed spontaneously, i.e. in the absence of both ligand
and GP. Once the ternary complex is deprived of a com-
ponent such as the ligand or the GP, accordingly, it is
destabilised. Subtype-specific antibodies helped identify the
GP subforms interacting with the sst2A receptor: Gi-alpha-1,
Gi-alpha-2, and Gi-alpha-3. By contrast, Go-alpha, Gz-alpha, and
Gq-alpha all failed to form any detectable complex with the
receptor subtype analysed.
3.2. Functional couplings of somatostatin receptors
The classical survey of SRIF action covered a fairly
narrow range of effectors, i.e. AC, calcium (Ca2 +) and
potassium (K+) channels, a sodium–proton antiporter
(SPA), and a number of phosphatases, e.g. phosphotyrosine
phosphatase (PTP) [167,168]. But there is also evidence that
receptor-mediated regulation of the PI and mitogen-activated
protein kinase (MAPK) cascades should be taken into
account. With special reference to these transduction path-
ways, it needs saying that not every report published is
readily understood in the light of antisecretory and antipro-
liferative actions generally ascribed to SRIF. Apparently
paradoxical outcomes, however, may sometimes owe to
the absence of key transducers or effectors in the bioassay,
e.g. a single enzyme [63]. Finally, SRIF appears to modulate
excitatory postsynaptic (EPS) potentials generated via (R,S)-alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic ac-
id (AMPA)/kainate receptors.
3.2.1. Regulation of the adenylyl-cyclase cascade
Studying rat hepatocytes, Raper et al. [169] characterised
an aspect of the relationship between cAMP and mitotic
activity.68 They found that incorporation of tritiated thymi-
dine ([3H] Thd) into DNA increased by 230% in the presence
of insulin—but could be almost abolished by SRIF. Similar-
ly, insulin-stimulated cAMP accumulation decreased from
190% to 108% of control following the addition of SRIF-14.
However, pertussis toxin (PTX) blocked inhibitory signals
for both cell proliferation and cAMP accumulation.69 In
addition to its postreceptor antagonism of insulin action,
which represents divergent pathways of transduction,70 SRIF
inhibits the secretion of insulin itself from B cells in the PIL.
Transmitter-induced stimulation of insulin secretion depends
on Gs. Apart from SRIF, transmitters such as EN, prosta-
glandin E2 (PG-E2), and galanin inhibit this secretion, the
signal being transduced by Gi [160]. Karnik and Wolfe [170]
showed gastrin secretion to be regulated by SRIF at the level
of transcription. In response to immunoneutralisation of
antral SRIF, basal transcriptional activity at the gastrin gene
could be seen to increase by 34F 3.3%. Furthermore, in a
parallel experiment, SRIF significantly inhibited gene tran-
scription stimulated by the permeant cAMP analogue dibu-
tyryl cAMP (DB-cAMP) and carbachol.71 Having added
antisera directed against SRIF, the investigators observed
maximal induction after 60 min, at which time gastrin-
mRNA levels had increased by 184F 6.0%. Upon addition
of a SRIF analogue, however, gastrin mRNA soon returned
to basal. By regression analysis of RNA induction and
deinduction profiles, Karnik and Wolfe demonstrated a
292F 40.6% increase in gastrin–mRNA turnover induced
by SRIF. With regard to gastrin, SRIF would thus seem to
regulate both gene transcription and mRNA balance. How-
ever, the dominant part of the antisecretory response to SRIF
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acceleration of mRNA turnover.
The secretion of numerous gastrointestinal neuropeptides
is regulated by SRIF and catecholamines such as EN and
NEN. Typically, SRIF receptors and beta-adrenoceptors
mediate opposite signals for secretory activity. In a primary
culture of canine ileal mucosal cells, Barber et al. [171]
reported secretion of neurotensin-like immunoreactivity to
be stimulated by EN in a dose-dependent manner (0.01–100
AM).72 Forskolin markedly stimulated secretory activity,
potentiating the response to EN. By contrast, the acetylcho-
line analogue carbachol and SRIF dose-dependently
inhibited EN-stimulated neurotensin secretion, the inhibition
varying in size according to the agent applied: 68% (100 AM
carbachol) and 96% (100 nM SRIF).73 In a subsequent study,
using a similar bioassay of canine ileal endocrine cells, the
investigators found the secretion of enteroglucagon-like
immunoreactivity to be stimulated by the adrenergic agonists
EN and isoproterenol in a dose-dependent manner.74 For-
skolin stimulated secretion dose-dependently. Both carbachol
and SRIF inhibited the secretory response to EN. Also
forskolin-stimulated secretion was inhibited by SRIF [172].
When properly specified, the effector systems responsible for
secretion of neurotensin and enteroglucagon, respectively,
display striking similarities. Thus, peptide secretion and
cAMP accumulation are stimulated in parallel by EN. In
either respect, stimulation is potently reversed by carbachol
as well as SRIF. Without affecting the relative inhibitory
profiles of carbachol and SRIF, 3-isobutyl 1-methylxanthine
(IBMX) can be shown to potentiate the action of EN.75
Perhaps the evidence of single-path transduction upstream
from cAMP accumulation, PTX completely blocks the in-
hibitory effect of carbachol on both peptide secretion and
cAMP accumulation.76 By contrast, PTX imposes but partial
blockade on SRIF-induced inhibition of peptide secretion
while completely disinhibiting cAMP accumulation. Further-72 The secretory response to EN was competitively inhibited by the
beta-adrenergic antagonist propranolol, resulting in a parallel rightward
shift of the EN dose– response curve. Basal neurotensin secretion
responded to neither of the alpha-adrenergic agonists methoxamine (10
AM) and clonidine (10 AM). Stimulation by EN was not significantly
inhibited by the alpha-adrenergic antagonists prazosin (10 AM) or
yohimbine (10 AM) [171].
73 The effect of carbachol was partially blocked by the selective
muscarinic antagonist atropine (0.1 AM) [171].
74 Binding of EN was competitively inhibited by propranolol, reflected
in a rightward shift of the dose– response curve. Methoxamine and
clonidine failed to raise enteroglucagon secretion above basal [172].
75 An unspecific inhibitor of 3V,5V-cyclic nucleotide phosphodies-
terases, IBMX protects cAMP against rapid degradation [561].
76 Of course, PTX might block transduction of signals for other
effectors than AC, e.g. Ca2 + and K+ channels. That would have to be tested
separately. At any rate, signals do diverge at multiple sites distal to AC,
with activation of PK-A, cytosolic enzymes, nuclear transcription factors,
etc. So the data really amount to the information that carbachol is dependent
on PTX-sensitive GP coupling for any signal transduction to take place. By
contrast, the SRIF receptor seems to operate additional PTX-resistant, if not
actually GP-independent pathways.more, PTX only partially blocks SRIF inhibition of forskolin-
and Ca2 + ionophore-stimulated peptide secretion. By way of
conclusion, inhibition of peptide secretion mediated by
cholinergic receptors depends entirely on PTX-sensitive
transduction. In comparison, the antisecretory response to
SRIF is evoked by activation of at least two divergent path-
ways. There must, on the one hand, be some PTX-sensitive Gi
to account for the decrease in cAMP. On the other hand, it
cannot be said whether SRIF-induced inhibition of peptide
secretion, when viewed from the proximal site of the receptor,
reflects, say, double- or triple-path transduction [173].
In C cells of the strain rMTC 6–23,77 both cAMP
accumulation and calcitonin secretion were found to be
dose-dependently stimulated by rat SRF. By contrast, SMS
201–995 inhibited SRF-stimulated cAMP accumulation and
calcitonin secretion in a dose-dependent manner but failed to
block calcitonin secretion stimulated by 8-bromo-adenosine
3V,5V-cyclic monophosphate (8Br-cAMP). PTX imposed par-
tial blockade on inhibition by SMS 201–995. This disinhi-
bitory effect, however, could not be accounted for by
alterations in the degradation of cAMP—as was the case
upon addition of IBMX [174]. Glucagon is a secretagogue at
multiple sites. With a maximal effect at 1.0 AM, glucagon
stimulates cAMP accumulation and secretion of calcitonin in
medullary C cells. Glucagon-stimulated calcitonin secretion
returned to control following the addition of the cAMP
antagonist RpcAMPs. Hence, no effector system besides
AC seems to be involved. SMS 201–995 applied in growing
doses inhibited cAMP accumulation and calcitonin secretion,
maximal effect being achieved at 0.1 AM (40% and 29% of
control values, respectively). PTX (100 ng/ml, 24 h) blocked
the inhibitory effect of SRIF on either score (82% and 58% of
control values, respectively) [175]. In rat neocortical neuro-
nes, SRIF, MK-678, and CGP-23,996 inhibited forskolin-
stimulated cAMP accumulation by 25–30% [176].
The stomach is a prominent site of SRIF action. Signals
are delivered mainly from populations of endocrine cells. A
number of compounds—including SRIF, PG-E2 [177], EGF,
and 12-O-tetradecanoylphorbol 13-acetate (TDPA)—inhibit
histamine-stimulated secretion of hydrochloric acid in rat
parietal cells.78 To determine the extent of GP transduction,
the cells had pretreatment with PTX (100 ng/ml, 2 h). The
antisecretory response to near maximally effective concen-
trations of SRIF, PG-E2, and EGF decreased by 72%, 83%,
and 70%, respectively. However, inhibition of acid secretion
by TDPA dropped a mere 12%. On closer inspection,
inhibitory signals delivered by PG-E2 and EGF were clearly
distinguishable in terms of transduction mechanisms: addi-
tion of IBMX selectively blocked secretory inhibition by the
latter [178]. In isolated rat gastric chief cells, SRIF inhibits the77 rMTC 6–23 cells derive from a rat medullary thyroid carcinoma
secretion comprising calcitonin.
78 Unlike SRIF and prostaglandin-E2 receptors, the EGF receptor does
not belong to the superfamily of GPC receptors but contains a TK which
forms its cytosolic aspect (see below).,
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the secretory response evoked by secretin and forskolin was
closely paralleled by an increase in cAMP. SRIF potently
inhibited the purely secretory effect of the two secretagogues.
But, interestingly, it did not interfere with forskolin-stimu-
lated cAMP accumulation; this finding specifically rules out
Gi activity. Nevertheless, PTX blocked SRIF-induced inhi-
bition of secretin-stimulated pepsinogen secretion. However,
inhibition of forskolin-, carbachol-, and CCK octapeptide-
stimulated secretion was apparently resistant to PTX treat-
ment. Hence, more than one signalling pathway would seem
to be operative in regulating pepsinogen secretion. With
regard to the inhibition of secretin-stimulated secretion, some
PTX-sensitive GP has to be involved, but it cannot be Gi. In
addition, some PTX-resistant mechanism—and not necessar-
ily a GP—must account for the inability of PTX to disinhibit
the stimulatory response to the other secretagogues. Further
down the GIT, SRIF has been reported to regulate Cl
secretion from colonic enterocytes by multiple-path trans-
duction.79 Inhibition of cAMP accumulation thus represents a
single transduction pathway in the HT29-19A cells80 studied
by Warhurst et al. [180].
Fukusumi et al. [75] reported human CST-17 to behave
like the somatostatins at SRIF receptors, inhibiting forskolin-
stimulated cAMP accumulation. Interestingly, CST has also
been reported by Sanchez-Alavez et al. [68] to stimulate
cAMP accumulation. This cellular response could be ob-
served in rat hippocampal neurones where SRIF, however,
must be credited with the opposite effect. On the assumption
that either ligand interacts with the same receptors, further
investigation is required to interpret these observations of
apparent transmitter-specific transduction. A single amino
acid, however, is held responsible for the widely different
effects on cortical physiology by SRIF and CST [71].
3.2.2. Receptor subtypes associated with the adenylyl-
cyclase cascade
In pioneering reports on signal transduction, investigat-
ing specific R–E associations, observations apply to SRIF1
and SRIF2 receptors alone.
81 Binding sites labelled specif-
ically by iodinated MK-678 are referred to as SRIF1
receptors [181–183]. In the pituitary, cortex, and hippo-
campus, these receptors account, at least in part, for the
ability of SRIF to inhibit forskolin-stimulated cAMP accu-79 It is not established by the investigators whether the transduction
pathways involved radiate from the same receptor subtype or different
receptor subtypes [180].
80 HT29-19A cells derive from a human colonic adenocarcinoma.
81 Developments in recombinant technology never rendered the
original distinction between SRIF1 and SRIF2 receptors superfluous. With
the emergence of cloned receptor subtypes, considering their sequence
heterogeneity and individual properties, it might be thought that SRIF1 and
SRIF2 receptors are obsolete and—for all practical purposes—somewhat
vaguely defined categories. But if they are seen for what they really are, this
is not so. Properly speaking, SRIF1 and SRIF2 receptors thus represent two
pharmacological subclasses of SRIF receptors, without any implications at
the structural level.mulation. And Raynor and Reisine [182] reported MK-678
to be a potent inhibitor of AC activity in those tissues. In the
striatum, however, MK-678 contributed insignificantly to
receptor-mediated regulation of this activity. Specific label-
ling of receptors in that particular region of the CNS was
abolished by high concentrations of GTP-gamma-S, sug-
gesting GP coupling, if nothing else. Also in GH3 cells, as
reported by the same investigators, binding of the radio-
ligand [125I]MK-678 to SRIF1 receptors was abolished in
the presence of GTP-gamma-S. By contrast, specific bind-
ing of [125I]CGP-23,996 to SRIF2 receptors showed no sign
of sensitivity to this GTP analogue. Forskolin-stimulated
cAMP accumulation was inhibited to the same extent by
SRIF and MK-678 in GH3 cells [184]. From these obser-
vations, it might seem as if SRIF2 receptors must be
incapable of operating any GP subform at all, let alone
AC. Alternatively, SRIF2 receptors simply coupled to the
GP in a different way from SRIF1 receptors.
Turning to the cloned receptor subtypes, the rat sst1
receptor displays an unmistakable, if not invariant feature
of GP coupling, i.e. sensitivity of high-affinity agonist
binding to GTP-gamma-S [185]. But this is a comparatively
recent insight; for a time, the sst1 receptor consistently
eluded functional analysis, and—for want of better alter-
natives—it was hypothesised that it might associate with
some SPA [168,186]. The deadlock was first broken by
Kaupmann et al. [187] who reported successful inhibition of
cAMP accumulation in HEK-293 cells expressing human
sst1 receptors.
82 Garcia and Myers [188] used the same
strain, i.e. HEK-293, to demonstrate PTX-sensitive regula-
tion of cAMP accumulation by activation of either rat sst1 or
sst2 receptors. Results published at the same time by Had-
cock et al. [185], based on stably transfected Chinese
hamster ovary (CHO) K1 cells, further narrowed the sus-
pected gap between the sst1 receptor and the remaining
receptor subtypes.83 Functional coupling of the rat sst1
receptor to AC was established. Confirming this apparent
interaction of sst1 receptors with some GP of the inhibitory
type, PTX abolished 80% of specific binding of the radio-
ligand [125I]SRIF-14. Coupling of sst1 receptors to PTX-
resistant GP subforms may then be responsible for the
residual binding observed (i.e. 20%), leaving a little room
for the antiporter hypothesis. The source of conflicting
results, as far as the sst1 receptor goes, is most likely the
varied preferences in terms of biological model system.
Commonly used strains derived from CHO vary to such an
extent in their GP inventory that it matters to the study of
potential transduction mechanisms. CHO-K1 cells have thus
been found to express detectable amounts of Gi-alpha-2 and
Gi-alpha-3 whereas neither Gi-alpha-1 nor Go-alpha has been82 HEK-293 cells are reported to express endogenous Gi-alpha-1 and
Gi-alpha-3 by Law et al. [198]. In the absence of exogenous SRIF receptors,
cAMP accumulation defies SRIF-induced inhibition in HEK-293 cells
[188].
83 In wild-type (WT) CHO-K1 cells lacking SRIF receptors, SRIF
analogues do not influence forskolin-stimulated cAMP accumulation.
88 Peptide-directed GP antisera included the well-known 8730/anti-Gi,
3646/anti-Gi-1, 1521/anti-Gi-2, 1518/anti-Gi-3, and 9072/anti-Go-B (see
above). But two additional antisera needed to be introduced to distinguish
between Go-alpha subforms: (1) an antiserum directed against the decapeptide
Glu-Tyr-Pro-Gly-Ser-Asn-Thr-Tyr-Glu-Asp (residues 290–299), recognis-
ing Go-alpha-1; and (2) an antiserum directed against another such peptide,
Glu-Tyr-Thr-Gly-Pro-Ser-Ala-Phe-Thr-Glu (residues 290–299), recognis-
ing Go-alpha-2. In CHO-DG44 cells, immunoblotting showed the various GP
subforms to be rather unequally expressed: relatively high levels of Gi-alpha-3,
low levels of Gi-alpha-1, and no Gi-alpha-2 at all. Go-alpha-2 but not Go-alpha-1
immunoreactivity was detectable in CHO-DG44 cells. The following results
from immunoprecipitation were obtained: (1) antiserum 8730/anti-Gi
uncoupled sst2 receptors from Gi-alpha; (2) antiserum 9072/anti-Go-B
uncoupled sst2 receptors from Go-alpha; (3) antiserum 1518/anti-Gi-3
uncoupled sst2 receptors from Gi-alpha-3; (4) neither of the antisera 3646/anti-
Gi-1 and 1521/anti-Gi-2 uncoupled sst2 receptors from Gi-alpha; and (5) all
of the antisera 3646/anti-Gi-1, 1521/anti-Gi-2, and 1518/anti-Gi-3 immu-
noprecipitated a minor amount of R–GP complexes [198]. Uncoupling of
sst2 receptors from Gi-alpha and Go-alpha by the antisera 8730/anti-Gi and
9072/anti-Go-B, respectively, was additive. It would appear that carboxyl-
terminally directed antisera, i.e. 8730/anti-Gi and 9072/anti-Go-B, specif-
ically uncouple the R–GP complex rather than immunoprecipate it as a
whole. But such a notion would not easily fall into line with the conclusion of
earlier studies. Whether uncoupling or coprecipitation of the receptor occurs,
may thus in fact depend on the presence of agonist, apparently irrespective of
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cells may very well account for the observed coupling of the
rat sst1 receptor to some GP and AC. However, both Gi-alpha-2
and Gi-alpha-1 have been implicated in functional coupling
of SRIF receptors and other GPC receptors to AC
[185,190,191].85 Additional proof of a regulatory associa-
tion between the sst1 receptor and AC was delivered by
Hoyer et al. [192]. In HEK-293 cells transiently transfected
with human sst1 receptors, a variety of SRIF analogues and
short synthetic peptides potently inhibited forskolin-stimu-
lated cAMP accumulation. Also in mouse Ltk fibroblasts
stably expressing human sst1 receptors, however, the func-
tional coupling to AC has been verified [193]. Kubota et al.
[194] showed that Gi-alpha-3, similar to Gi-alpha-1 and Gi-alpha-2,
had a part in negative regulation of cAMP accumulation.
In CHO cells stably transfected with human sst1 receptors,
an antiserum (EC/2) directed against Gi-alpha-3 thus blocked
SRIF-induced inhibition of cAMP accumulation. By con-
trast, an antiserum (AS/7) directed against Gi-alpha-1/Gi-alpha-2
failed to restore the activity of AC. In GH4C1 cells,
endogenous SRIF receptors mediated inhibition of forsko-
lin-stimulated cAMP accumulation, signals being trans-
duced by both Gi-alpha-1 and Gi-alpha-3 in isolation [195].
86
In COS-7 cells transiently expressing goldfish sst1A or sst1B
receptors, two native goldfish SRIF isoforms (i.e. SRIF-14
and Pro2-SRIF-14) both inhibited forskolin-stimulated
cAMP accumulation [80]. Finally, Stark and Mentlein [24]
characterised the regulation of insulin secretion from
RINm5F cells87 by GLP-1 and SRIF, i.e. two peptide
transmitters known to display postreceptor antagonism with
regard to secretion and cell proliferation. Whereas the
former, i.e. the secretagogue, stimulated cAMP accumula-
tion and CREB activity, the latter inhibited either effect,
though not beyond basal levels. Receptor-mediated inhibi-
tion was fully reproducible with the sst1-selective nonpep-
tide SRIF analogue L-797,591.
Rens-Domiano et al. [196] managed to demonstrate GP
coupling for human sst2 receptors. In contradistinction to
human sst1 receptors, binding of high-affinity agonists to
sst2 receptors was reduced by pretreatment of transfected
CHO-DG44 cells with either GTP-gamma-S or PTX. Seem-
ingly, differential GP coupling had been established. But
neither in stably transfected CHO-DG44 cells nor in tran-
siently transfected COS-1 cells did sst1 or sst2 receptors
mediate inhibition of cAMP accumulation. With COS-184 By comparison, Rens-Domiano et al. [196] could detect Gi-alpha-3 but
not Gi-alpha-1, Gi-alpha-2 or Go-alpha in the CHO-DG44 strain. With GP-
specific antisera, Law et al. [198] later detected both Gi-alpha-1, if only at low
levels, and Go-alpha-2 in CHO-DG44 cells. High levels of Gi-alpha-3, however,
could be confirmed, with Gi-alpha-2 being absent.
85 In GH3 cells, as reported by Johansen et al. [191], both SRIF and
dopamine inhibited cAMP accumulation, transduction being dependent on
the constellation of Gi-alpha-2, Gbeta-1, and Ggamma-3.
86 By comparison, Gi-alpha-2 supplied the shorter splice variant of the
D2 receptor with GP transduction of inhibitory signals for cAMP
accumulation, Gi-alpha-3 the longer splice variant [195].
87 RINm5F cells derive from a rat insulinoma.cells expressing every known member of the Gi subfamily
(i.e. Gi-alpha-1, Gi-alpha-2, and Gi-alpha-3) on an endogenous
basis, methodological artefacts must account for the nega-
tive results. However, Strnad et al. [197] proved sst2
receptors to be associated with AC. In CHO-K1 cells stably
transfected with the cDNA of rat sst2 receptors, SRIF-14
inhibited forskolin-stimulated cAMP accumulation by 75%
in a dose-dependent manner (EC50 = 350 pM). This was
another minor breakthrough. In a review published by Bell
and Reisine [168] a few months earlier, they had assigned a
regulatory part to the sst2 receptor with regard to Ca
2 + and
K+ channels, reflecting on the repeated failures to function-
ally couple this receptor subtype to AC. However, on the
evidence of its coupling to Go-alpha-2 and Gi-alpha-3, respec-
tively, such R–E associations seemed perfectly reasonable.
Trying out their successful double-line approach of
receptor solubilisation and immunoprecipitation, Law et
al. [198] set out to characterise potential R–GP couplings
in two separate strains: (1) CHO-DG44 cells stably trans-
fected with mouse sst2 receptors; and (2) HEK-293 cells
expressing endogenous sst2 receptors.
88 They found that the
sst2 receptor may couple to both Gi-alpha and Go-alpha.
Furthermore, it could be seen that the sst2 receptor alsoantigenic determinants. In this respect, the antisera 8730/anti-Gi and 9072/
anti-Go-B behave differently [164]. The ability of antiserum 1518/anti-Gi-3
to uncouple R–GP complexes was virtually equivalent to that of antiserum
8730/anti-Gi. Because of high-level expression of both Gi-alpha-3 and sst2
receptors in CHO-DG44 cells, however, the possibility of undue favouring
of this particular R–GP association had to be ruled out. Endogenous sst2
receptors are expressed at only low levels in HEK-293 cells. Immunoblotting
revealed similar levels of Gi-alpha-1 and Gi-alpha-3 immunoreactivity in these
cells but no Gi-alpha-2. Neither Go-alpha-1 nor Go-alpha-2 was detectable with
peptide-directed antisera. Results with peptide-directed antisera were as
follows: (1) antiserum 1518/anti-Gi-3 significantly immunoprecipitated R–
GP complexes; and (2) neither of the antisera 3646/anti-Gi-1 and 1521/anti-
Gi-2 immunoprecipitated any such complexes [198].
Fig. 2. Molecular biology of somatostatin receptors. Splice variants of the mouse sst2 receptor and a truncated mutant receptor.
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ways, being either uncoupled from it, which is the typical
response, or coprecipitated with it by the same GP-specific
antiserum (i.e. 1518/anti-Gi-3). But it had to be concluded
that Gi-alpha-3 is the Gi subform most consistently entering
complex formation with sst2 receptors. Neither in WT nor in
sst2-transfected HEK-293 cells, SRIF showed any capability
of inhibiting forskolin-stimulated cAMP accumulation. To
all appearances, this is inconsistent with the findings of
Kaupmann et al. [187], deriving from HEK-293 cells trans-
fected with any of the human homologues of sst1–4 recep-
tors. However, Law et al. may have expressed the longer
splice variant of the mouse sst2 receptor (i.e. sst2A).
The findings of Vanetti et al. contrast with those of Rens-
Domiano et al. [196] and Law et al. [198]. No evidence of
functional coupling of mouse sst2A receptors to AC after
stable transfection in CHO-DG44 cells or transient trans-
fection in COS-1 or HEK-293 cells emerged. Gi-alpha-1 has
been shown to be required for coupling SRIF receptors to
AC in AtT-20 cells [190]. Lack of Gi-alpha-1 in CHO-DG44
may partly account for the failure of mouse sst2A receptors
to mediate inhibition of cAMP accumulation. But in COS-1
cells, which express all Gi-alpha subforms, and HEK-293
cells, which do express Gi-alpha-1, the unspliced mouse sst2A
receptors also failed to mediate SRIF inhibition of cAMP
accumulation [196,198]. The primary structure of the re-
ceptor itself, i.e. shorter or longer CTT, may partly account
for these observations.
In a preliminary report published by Vanetti et al. [199],
the shorter isoform of the mouse sst2 receptor, i.e. sst2B,
mediated potent inhibition of cAMP accumulation after
stable transfection in CHO-K1 cells. Then, in a subsequent
study using the same strain, this observation was followed up
with a detailed analysis of receptor-specific determinants of
the apparent R–E association. To that end, a carboxyl-
terminally truncated mutant receptor, 51YAST, was generat-
ed. While equal in length (346 amino acids) to mouse sst2B
receptors, it shared the extreme pentadecapeptide of its CTT
with sst2A receptors, i.e. unlike mouse sst2B receptors (see
Fig. 2). Addition of forskolin (25 mM) resulted in a 5-fold
increase in cAMP, as compared to untreated cells.89 The two89 Regarding mouse sst2B receptors, SMS 201–995 and MK-678
proved to be more effective inhibitors of AC activity than the native
receptor ligands—although the binding properties of the peptides are
virtually similar. It was therefore hypothesised that the peptides may differ
critically in their ability to induce the conformational changes required for
functional coupling of the sst2 receptor to AC. Both synthetic agonists
completely inhibited forskolin-stimulated cAMP accumulation (SMS 201–
995: EC50 = 1.1 nM; MK-678: EC50 = 0.9 nM). The native SRIF isoforms
inhibited such cAMP accumulation by a mere 60% (SRIF-14: EC50 = 5.1
nM; SRIF-28: EC50 = 4.2 nM). Receptor-mediated regulation of AC activity
was blocked by PTX (500 ng/ml) [145].murine isoforms of the sst2 receptor, i.e. sst2A and sst2B, and
51YAST bind SRIF-14 with similar high affinity, as mea-
sured by displacement of [125I]Tyr11-SRIF-14 with SRIF-14
(mouse sst2A: IC50 = 0.51 nM; mouse sst2B: IC50 = 0.62 nM;
51YAST: IC50 = 0.72 nM). Accordingly, the CTT by itself
would seem not to make a difference to high-affinity agonist
binding. But in cells expressing mouse sst2B receptors,
51YASTor mouse sst2A receptors, 100 nMSRIF-14 inhibited
forskolin-stimulated cAMP accumulation by 61%, 55%, and
33%, respectively. And, in reality, the sheer length of the
CTT, i.e. the steric bulk, may determine the extent of
successful R–E coupling. Agonist-induced desensitisation,
which ultimately relies on phosphorylation of serine and
threonine residues in the CTT, clearly divided the mouse
sst2A receptor and 51YAST from the mouse sst2B receptor,
probably due to the number of potential phosphorylation sites
(see below). Native receptor isoforms thus exhibit a similar
binding affinity with regard to SRIF-14, but the mouse sst2B
receptor has an advantage over the longer splice variant as
regards functional coupling to AC and is much more resistant
to agonist-induced reduction in high-affinity binding than the
sst2A receptor [145]. The tentative conclusion emerging from
this evidence might be that, although ICL-III contains the
primary determinants of GP specificity [200], the CTT could
very well be a codeterminant in so far as it modulates the
efficiency of R–GP coupling. As it happens, a variety of
receptors mediating inhibition of AC activity [e.g. D2 (dopa-
mine), alpha2 (EN), A1 (purine), M2 (acetylcholine)] are one
and all characterised by a short CTT [201].90
Partly imitating the work of Strnad et al. [197], Hersh-
berger et al. [202] had CHO-K1 cells stably transfected with
rat sst1 or rat sst2 receptors. In either bioassay, the inves-
tigators found forskolin-stimulated cAMP accumulation to be
inhibited by approximately 35%, having added SRIF-14 or
SRIF-28, with ED50 values in the nanomolar range. The
ability of PTX to block inhibitory signals implied GP
transduction. At the same time, Garcia and Myers [188]
reported the rat sst2 receptor to mediate inhibition of cAMP
accumulation in both GH3 cells, which express the sst2
receptor on an endogenous basis, and transfected HEK-293
cells. In CHO-DG44 cells stably transfected with human sst2
receptors—but lacking endogenous Gi-alpha-1—SRIF-14
failed to inhibit forskolin-stimulated cAMP accumulation.90 But there are observations that tend to pull in the opposite direction.
Stably expressed in CHO-K1 cells, mutant sst5 receptors derived from WT
human receptors were thus found to show a progressive loss of functional
coupling to AC in proportion to their respective degrees of CTT truncation.
In fact, the shortest mutant receptor (Delta318) failed to mediate any
inhibition at all [159]. And, what is more, inhibitory signals mediated by rat
sst2A and sst2B receptors, including inhibition of cAMP accumulation, are
equally susceptible to agonist-induced desensitisation [85].
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functionally couple to AC. Inhibition by SRIF-14 took place
in a dose-dependent and PTX-sensitive manner [203]. A
study by Schoeffter et al. [204] supported these conclusions.
In CHO cells transfected with human sst2 receptors, a variety
of SRIF analogues and short synthetic peptides potently
inhibited forskolin-stimulated cAMP accumulation. In
CHO-K1 cells stably transfected with either rat sst2A or rat
sst2B receptors, SRIF induced dose-dependent inhibition of
forskolin-stimulated cAMP accumulation (rat sst2A: pIC50 =
10.5; rat sst2B: pIC50 = 10.4). However, inhibition seemed to
be in inverse proportion to SRIF concentration, as gradually
raised by Schindler et al. [85], resulting in bell-shaped dose–
response curves. PTX blocked but the inhibitory component
of the cellular response to SRIF, with a net increase in cAMP
being left over. In RINm5F cells, the sst2-selective non-
peptide SRIF analogue L-054,522 potently inhibited cAMP
accumulation stimulated by GLP-1 [24]. The same SRIF
analogue inhibited cAMP accumulation in U343 cells,91
which express sst2A receptors [205]. Another sst2-selective
nonpeptide SRIF analogue, i.e. L-779,976, inhibited forsko-
lin-stimulated cAMP accumulation and chloride secretion in
rat colocytes, proving 10 times more potent than SMS 201–
995 [206].
The mouse sst3 receptor, as characterised by Yasuda et al.
[88], was the first receptor subtype definitively shown to
associate with AC. It coupled to some PTX-sensitive GP
subform and mediated SRIF-induced inhibition of cAMP
accumulation stimulated by either forskolin or dopamine
acting on D1 receptors. Similar results were obtained by
Yamada et al. [79], investigating the human homologue. In
COS-1 cells coexpressing human D1 and sst3 receptors, SRIF
inhibited dopamine-stimulated cAMP accumulation by 25–
30% in a dose-dependent manner. In HEK-293 cells tran-
siently expressing the mouse sst3 receptor, which requires the
presence of Gi-alpha-1 to functionally couple to AC, SRIF
completely reversed the effect of forskolin on cAMP accu-
mulation. GTP-gamma-S greatly reduced high-affinity bind-
ing of [125I]MK-678 to SRIF receptors in HEK-293 plasma
membranes [198]. In CHO-DG44 cells stably transfected91 U343 cells derive from a human glioma.
92 Chimeric Gi-alpha subunits were produced by Law et al. [207] to
determine the functional domains of Gi-alpha-1 responsible for this coupling.
One chimera (Gi-alpha-2/Gi-alpha-1), constructed from the amino-terminal two
thirds of Gi-alpha-2 ligated to the carboxyl-terminal third of Gi-alpha-1, was
found to possess the properties required for coupling of sst3 receptors to
AC. A similar Gi-alpha-2/Gi-alpha-3 chimera did not succeed in this respect. It
was concluded by Law et al. that the carboxyl-terminal third of Gi-alpha-1
must interact with sst3 receptors. This may be true. But, strictly speaking, it
may be that all of the Gi-alpha subunits tested interact with sst3 receptors but
that only the carboxyl-terminal third of Gi-alpha-1 effectively interacts with
AC, providing the molecular basis of R-E coupling. Either conclusion is
equally valid on the basis of the present evidence. It should be borne in
mind that receptor subtypes other than the sst3 receptor are coupled to AC
[562]. Selectivity of the individual GP—or, indeed, lack of it—works both
forwards and backwards in signal transduction, i.e. applying to effector
systems and receptor subtypes, respectively.with mouse sst3 receptors and Gi-alpha-2 or Gi-alpha-3 while
lacking Gi-alpha-1, SRIF failed to inhibit cAMP accumulation.
By contrast, SRIF did inhibit forskolin-stimulated cAMP
accumulation in cells stably coexpressing sst3 receptors and
Gi-alpha-1. Hence, Gi-alpha-1 would appear to selectively cou-
ple sst3 receptors to AC [207].
92 In CCL-39 cells stably
transfected with the fish sst3 receptor, SRIF potently
inhibited forskolin-stimulated cAMP accumulation, trans-
duction being PTX-sensitive [89].
In transiently transfected COS-7 cells, high-affinity bind-
ing of agonists to human sst4 receptors was significantly
reduced by GTP and PTX added separately. Apparently,
Demchyshyn et al. [93] had succeeded in demonstrating R-
GP coupling. But quite discrepant results were reported by
Raynor et al. [208] at almost the same time. In CHO-K1 and
COS-1 cells expressing rat sst5 receptors (‘‘SSTR4’’) and
human sst4 receptors (‘‘SSTR5’’), respectively, high-affinity
binding of analogues to only rat sst5 receptors was reduced
by pretreatment of cells with GTP analogues, Na+, and PTX.
Furthermore, rat sst5 receptors were able to mediate inhibi-
tion of AC activity. Rat sst5 receptors—but not human sst4
receptors, according to these investigators—are thus shown
to couple to some GP. In CHO-K1 cells stably expressing rat
sst5 receptors, SRIF-14 and SRIF-28 maximally inhibited
forskolin-stimulated cAMP accumulation by 63% and 68%,
respectively, with potencies of 50 and 1 nM. The ability of
sst5 receptors to mediate inhibition of cAMP accumulation
had previously been reported by O’Carroll et al. [97]. In
CHO-K1 cells, PTX blocked regulation by native receptor
ligands of AC activity. In COS-1 cells transiently expressing
the sst4 receptor, SRIF did not affect forskolin-stimulated
cAMP accumulation, consistent with a lack of effect of
guanyl 5V-yl imidodiphosphate (GMP-PNP), Na+, and PTX
on agonist binding to this receptor subtype. Similar negative
results, regarding the effect on AC, were obtained with
CHO-DG44 cells stably expressing sst4 receptors [208]. A
month later, things were turned upside down again. Kaup-
mann et al. [187] not only confirmed the initial findings
published by Demchyshyn et al. but also characterised one of
the signalling pathways operated by sst4 receptors. Human
sst1–4 receptors had been stably expressed in HEK-293 cells.
In cells expressing any of the receptor subtypes, agonist
binding was accompanied by inhibition of forskolin-stimu-
lated cAMP accumulation. The conclusion seemed to be the
following: given the appropriate cellular environment, all
four receptor subtypes (sst1–4) can functionally couple to
AC. Also Bito et al., with CHO-K1 cells stably expressing
the rat sst4 receptor, were capable of reconstituting functional
coupling between this receptor subtype and AC [209].
As mentioned in the above, O’Carroll et al. [97] were
first to clone the rat homologue of the sst5 receptor—which
they termed ‘‘SSTR4’’. In membranes prepared from COS-7
cells transfected with the rAP6-26 cDNA clone, cor-
responding to rat sst5 receptors, high-affinity binding of
[125I]Tyr11-SRIF-14 was significantly reduced by Na+ and
GTP, implying R–GP coupling. This conclusion was cor-
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of forskolin-stimulated cAMP accumulation. Similar results
were obtained with regard to the human homologue. GTP,
GTP gamma-S, Na+, or PTX added to membranes prepared
from transiently transfected COS-7 cells significantly re-
duced high-affinity binding of the radioligand [125I]Leu8-D-
Trp22-Tyr25-SRIF-28 to human sst5 receptors. This evidence
alone indicated receptor coupling to some PTX-sensitive
GP. Both SRIF-14 and SRIF-28, interacting with human sst5
receptors, could be shown to inhibit forskolin-stimulated
cAMP accumulation in a dose-dependent manner [96].
However, there appeared to be some dissimilarity at the
pharmacological level between the species. Similar to the rat
sst5 receptor, the human homologue of this receptor subtype
mediated inhibition of forskolin-stimulated cAMP accumu-
lation when activated by SRIF. But SMS 201–995 failed to
evoke a similar response when added to cells expressing
human sst5 receptors. By contrast, cAMP accumulation was
potently inhibited by the cyclic octapeptide in cells express-
ing the rat homologue [210]. In HEK cells expressing the
mouse sst5 receptor, SRIF-14 and SRIF-28 inhibited for-
skolin-stimulated cAMP accumulation with comparable
ED50 values [98].
Stably expressed in CCL-39 cells, each of the human
receptor subtypes mediated inhibition of forskolin-stimulat-
ed cAMP accumulation without exception. However, SRIF-
28 turned out to be a consistently, if only slightly, more
potent inhibitor than SRIF-14 and CST at all receptors
[211].
In summary, the SRIF receptors cloned so far are all
functionally coupled to AC.93 Functional elimination of
individual GP subforms by either antisera or antisense
oligonucleotides/plasmids has helped identify the PTX-sen-
sitive Gi-alpha-1, Gi-alpha-2, and Gi-alpha-3 as virtually equipo-
tent intermediaries in the transduction pathway of cAMP
accumulation.
3.2.3. Regulation of calcium channels
It is customary to distinguish between voltage- and
ligand-gated ion channels. Without anything being implied
about their specific chemical nature, ligands may be of
either the external or internal type. As distinct from recep-
tors such as the nicotinic, which forms an integrated R–E
pentamer, with acetylcholine as external ligand, the STMS
receptors, including the muscarinic, depend on the GP for
functional coupling, channel-gating ligands thus deriving93 The consensus of two reviews published in 1995 is that each of the
receptor subtypes cloned to date may associate with AC, if more or less
efficiently [381,498]. Apparently, it took a while for Reisine et al. [563] to
fully adopt this view. Hence, in one review, they tended to insist that only
sst2, sst3, and sst5 receptors—together forming a receptor subclass on
structural and pharmacological grounds—couple to PTX-sensitive GP
subforms and mediate the inhibition of AC activity by SRIF. Then, in other
publications of the same year (1995), the R–E association concerned is
recognised without reservation [192,395,564] (cf. Table 1).from the cytosol. Inward Ca2 + currents through voltage-
gated Ca2 + channels couple changes in the membrane
potential to various Ca2 +-dependent cellular processes,
e.g. exocytosis. Neurotransmitters and hormones interact
with GPC receptors, modulating the intracellular Ca2 +
balance in neuronal, endocrine, and neuroendocrine cells
[212]. In some bioassays, SRIF evidently inhibits secretory
activity by decreasing intracellular Ca2 +. This, in turn, is
achieved by either opening K+ channels, thereby indirectly
inhibiting Ca2 + currents, or closing voltage-gated Ca2 +
channels. In either case, internal-ligand gating is intrinsic
to transduction of the inhibitory signal [10,213,214]. Hence,
the difficulty in maintaining the sharp distinction between
voltage- and ligand-gated ion channels. The truth is that
channels may be subject to combined voltage-ligand gating.
In the case of regulation mediated by GPC receptors, the
ligand is some GP or second messenger.
On the basis of characteristics such as large in conduc-
tance, neuronal in distribution or transient in duration of
opening, voltage-gated Ca2 + channels have been divided
into the following classes: (1) L-type channels sensitive to
any dihydropyridine (DHP), i.e. amlodipine, felodipine,
isradipine, nicardipine, nifedipine, nimodipine, nisoldipine,
and nitrendipine, and cadmium (Cd2 +), being slowly inac-
tivating;94 (2) N-type channels sensitive to omega-cono-
toxin (OCT) GVIA; and (3) T-type channels sensitive to
mibefradil and nickel (Ni2 +), being rapidly inactivating.95
SRIF has been found to regulate not only L-type and N-
type but also T-type Ca2 + currents [215].
Expanding on the early work by Scho¨nbrunn et al.
[216,217], Reisine et al. [218]—concluding from their
own observations from AtT-20 cells—reported that SRIF
seemed quite capable of inhibiting inward Ca2 + currents via
both cAMP-dependent and-independent pathways. This
study was succeeded by another on a different pituitary
strain. Whole-cell clamp experiments were thus conducted
on GH3 cells to investigate the regulation of voltage-
dependent Ca2 + currents by hormonal stimulators and
inhibitors of pituitary secretion. The resting membrane
potential was approximately  40 millivolt (mV), interrup-
ted by spontaneous action potentials that faded only during
L–R interaction at the cell surface. The hypothalamic
secretagogue LHRF depolarised the plasma membrane to
approximately  10 mV. By contrast, hyperpolarisation to
approximately  60 mV was induced by SRIF. Under95 Low voltage-activated (LVA) T-type Ca2 + currents are stimulated by
angiotensin II (AT1 receptor), ATP, endothelin-1, and isoproterenol while
inhibited by angiotensin II (AT2 receptor), atrial natriuretic peptide (ANP),
and SRIF. As a group, if somewhat heterogenous, T-type Ca2 + channels are
characterised by small conductance [ < 10 pS, similar Ca2 + and Ba2 +
permeabilities, slow deactivation, and a voltage-dependent inactivation rate.
Less specific properties include activation at low voltages, rapid
inactivation, and blockade by Ni2 + [565].
94 Though belonging to the dihydropyridines, Bay K-8644, which is
extensively used by the experimental designs presented below, actually
functions as an activator of Ca2 + channels.
97 There is the well-known temptation to identify the GP with G-alpha,
which always confers some degree of regulatory specificity on the activated
receptor. The Go subforms expressed by GH3 cells represent entirely
different subunit constellations. Illustrating the notion of transductional
convergence, these GP subforms thus discriminate between two different-
ligand receptors, i.e. they couple specifically to a receptor each, but couple
to the same effector.
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fast inactivating Ca2 + currents. Only the former responded
to receptor activation; LHRF stimulated whereas SRIF
inhibited slowly inactivating currents. Intracellularly applied
cAMP failed to imitate the effect of LHRF, which—contrary
to VIP—rather appeared to inhibit than stimulate AC
activity in GH3 cells. PTX blocked stimulatory as well as
inhibitory receptor-mediated effects on inward currents.
Two PTX-sensitive GP subforms were identified, i.e. Gi
and Go. Rosenthal et al. [219] concluded that LHRF and
SRIF would appear to regulate voltage-dependent Ca2 +
currents via cAMP-independent pathways involving some
PTX-sensitive GP. These results were supported by Yatani
et al. [220,221] who found that SRIF inhibits secretion from
GH3 cells by a complex transduction mechanism involving
a PTX-sensitive step but partly bypassing the regulation of
cAMP accumulation. The secretory response to both cAMP
analogues and K+ depolarisation was thus inhibited. SRIF
was found to induce a membrane hyperpolarisation similar
to that generated by acetylcholine in cardiac pacemaking
cells, leading to a decrease in intracellular Ca2 +. And when
acting on muscarinic cholinoceptors, acetylcholine did in
fact induce the same effects in GH3 cells as SRIF. In rat
somatotrophs, Chen et al. [215] identified both L-type and
T-type Ca2 + currents, the former being triggered at  30
mV (from a holding potential of  40 mV), the latter at
 50 mV (from a holding potential of  70 mV). Regula-
tion of these different-type Ca2 + currents by SRIF could be
shown to be equally PTX-sensitive (100 ng/ml, 10 h). Using
GH3 cells stably transfected with the rat mu-opioid receptor,
Piros et al. [222] found that [D-Ala2,Me-Phe4,Gly-o15]en-
kephalin (DAMGO) inhibited L-type (nimodipine-sensitive)
Ca2 + currents by 23.8F 1.0% (1 AM DAMGO). By com-
parison, endogenous SRIF receptors mediated 22.9F 2.5%
inhibition of similar currents (1 AM SRIF). Inhibition of
Ca2 + currents induced by either DAMGO or SRIF could be
seen to be PTX-sensitive and dose-dependent.
Using the antisense technique (AST), Kleuss et al. [223]
resolved the transduction mechanisms responsible for nega-
tive regulation of voltage-dependent Ca2 + currents. By intra-
nuclear injection of antisense oligonucleotides, individual GP
subforms endogenous to GH3 cells may thus be functionally
eliminated.96 Their work made it possible to identify the GP
subforms belonging to the bipartite Go subfamily, both of
them transducing an inhibitory signal, though coupled to
different-ligand receptors, a muscarinic cholinoceptor and a96 The AST used by Kleuss et al., despite their own terminology,
should not be confused with the knockout (KO) technique (KOT) proper. In
this review, that term will be strictly reserved for the generation and study
of receptor-deficient mutant mice, i.e. so-called ’’KO mice’’. The KOT has
been instrumental in characterising the physiological part played by
individual receptor subtypes (see below). The use of antisense oligonucleo-
tides results in functional elimination of genes or genoneutralisation.
Similarly, immunoneutralisation results from the use of specific antisera
functionally eliminating regulatory peptides, etc.SRIF receptor, respectively: Go-alpha-1 and Go-alpha-2.
97 Apart
from Go-alpha-2 and Gbeta-1, the Ggamma-3 subform is required
for functional coupling of the activated SRIF receptor to L-
type Ca2 + channels. By comparison, a heterotrimeric com-
plex assembled from Go-alpha-1, Gbeta-3, and Ggamma-4
selectively couples the muscarinic cholinoceptor (M4) to
those same channels [162,224,225].98 In ovine somato-
trophs, both antibodies raised against Go-alpha and anti-
sense oligonucleotides specific for Go-alpha (ASm) blocked
inhibition of Ca2 + currents by SRIF (10 or 100 nM).
Both antibodies against Gi-alpha-1, Gi-alpha-2 or Gi-alpha-3
and antisense nucleotides specific for Gi-alpha-3 failed to
imitate this blockade of SRIF action. Finally, antisense
oligonucleotides specific for Go-alpha-2, unlike those spe-
cific for Go-alpha-1, blocked SRIF action [10,226].
Another study was published by Yassin et al. [227],
characterising GH3 cells stably expressing the neuronal class
E (alpha-E1) Ca2 + channel. Addition of SRIF or carbachol
resulted in a slower alpha-E1 activation and a decreased
current amplitude. Both effects were PTX-sensitive and
voltage-dependent for either agent. Dialysis of the cell
interior with GTP-gamma-S imitated the action of the
externally applied agents. It thus appeared that alpha-E1
channels are modulated by some PTX-sensitive GP—not via
the PTX-resistant pathway earlier observed in alpha-A1-
expressing GH3 cells. In primary rat somatotrophs, the
respective effects of the two hypothalamic regulators SRF
and SRIF on L-type Ca2 + currents were investigated by the
perforated-patch clamp technique. SRIF was found to inhibit
SRF-stimulated Ca2 +-like currents [using barium (Ba2 +) as
charge carrier/tracer]. However, these currents never de-
creased below control in response to SRIF. Interestingly,
withdrawal of SRIF increased L-type Ca2 +-like currents by
26.8%. A similar ‘‘rebound’’ effect could not be demonstrat-
ed in cells treated overnight with PTX (100 ng/ml). Thus,
withdrawal of SRIF apparently facilitates the activity of L-
type Ca2 + channels via some PTX-sensitive GP [228].99
Pancreatic B cells isolated from obese hyperglycemic
mice provided a system for studying the effects of galanin99 It was noted that a specific inhibitor of PK-A, H-89 (1 AM)
reversibly curtailed the increase in L-type Ca2 +-like currents to control. A
even higher concentrations (10 AM), H-89 inhibited currents by more than
40%, compared to control values [228].
98 Four different—but largely similar—beta-polypeptide sequences
and five gamma cDNAs have been identified so far. Because of the
relatively pronounced sequence heterogeneity of the gamma subunits,
functional differences of the G-beta-gamma complexes have been attributed
to the gamma subunits. The mRNA of Ggamma-2, Ggamma-3, and Ggamma-4,
respectively, is expressed in GH3 cells (Ggamma-1 is only found in retina).
Similar to Gi, identified Go subforms have been consistently sensitive to
PTX [162,224,225].,
t
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intracellular Ca2 +. Glucose-stimulated insulin secretion
was inhibited by either agent in proportion to membrane
repolarisation and decreasing intracellular Ca2 +. Upon ad-
dition of galanin (16 nM) or SRIF (400 nM), Ca2 + levels
described an initial nadir followed by a prolonged rise,
finally reaching a new steady state. The slowly increasing
Ca2 + was sensitive to a blocker of voltage-gated Ca2 +
channels, i.e. D-600 (50 AM). With intracellular Ca2 + raised
by 25 mM K+, both galanin and SRIF still inhibited insulin
secretion. Oscillations in intracellular Ca2 + were induced by
adding 5 mM Ca2 + to a cell suspension incubated in the
presence of 20 mM glucose and any of the agents galanin,
SRIF or the alpha-2-adrenergic agonist clonidine (10 nM).
PTX blocked the effects of galanin, SRIF, and clonidine on
intracellular Ca2 +. Nilsson et al. [229] concluded that
putative mechanisms involved in inhibition would be the
following: (1) repolarisation-induced decrease in intracellu-
lar Ca2 +; (2) decreased sensitivity of the secretory machinery
to Ca2 +; and (3) direct interference with the exocytotic
process. Other studies on B cells showed a similar tendency.
In permeabilised HIT-T15 cells,
100 SRIF inhibited Ca2 +-
induced insulin secretion. However, PTX added prior to
permeabilisation abolished the transduction of inhibitory
signals. Hence, it appeared that SRIF interferes with exocy-
tosis downstream from the synthesis of soluble intracellular
messengers [230]. In HIT cells, Hsu et al. [231] used the
whole-cell patch-clamp technique (PCT) to investigate the
signalling pathways operated by SRIF receptors during
inhibition of secretory activity. With an observable effect
in the picomolar range (from 10 pM to 1 AM), SRIF was
found to decrease Ca2 + currents, intracellular Ca2 +, and
basal insulin secretion in a dose-dependent manner. The rise
in intracellular Ca2 + and insulin secretion induced by either
depolarisation with K+ (15 mM) or activation of Ca2 +
channels with Bay K-8644 (1 AM) was curtailed by SRIF
in a dose-dependent manner over the same range as
above.101 In the presence of glucose, SRIF also curtailed
the rise in intracellular Ca2 + induced by IBMX (1 mM). In
HIT cells, SRIF (100 nM) did not interfere with outward K+
currents through KATP channels (see below). Pretreatment of
these cells with PTX (100 ng/ml) overnight abolished the
inhibitory effect of SRIF on Ca2 + currents, intracellular
Ca2 +, and insulin secretion. Thus, Ca2 + influx through
voltage-gated Ca2 + channels is inhibited via some PTX-
sensitive GP. In RINm5F cells, which display voltage-
dependent DHP-sensitive (but according to Birnbaumer et
al., not OCT-sensitive; however, cf. Ref. [232]) Ca2 + cur-
rents, SRIF inhibited Ca2 + currents by 20% (compared to
50% by EN acting on alpha-2 receptors). Receptor-mediated100 HIT-T15 cells derive from a SV40-transformed strain of hamster B
cells.
101 SRIF displayed the following IC50 values: 8.6 pM (K
+-stimulated
secretion), 83 pM (Bay K-8644-stimulated secretion), 0.1 nM (K+-induced
rise in intracellular Ca2 +), and 0.29 nM (Bay K-8644-induced rise in
intracellular Ca2 +) [231].inhibition of Ca2 + currents was insensitive to intracellularly
applied cAMP. However, it was abolished by both the
intracellularly applied GDP analogue guanosine 5V-O-(2-
thiodiphosphate) (GDP-beta-S) and PTX. By contrast, gal-
anin decreased Ca2 + currents in a PTX-resistant manner by
40%. PTX-sensitive GP subforms expressed by RINm5F
cells include Gi-alpha-1, Gi-alpha-2, Go-alpha-2, and another
unidentified Go-alpha subform, probably Go-alpha-1 [233].
SRIF contributes to the regulation of amylase secretion
from isolated pancreatic acini by inhibiting cAMP accumu-
lation. But similar to elsewhere, there are other inhibitory
signalling pathways operated by SRIF receptors in the
exocrine pancreas. A study by Ohnishi et al. [234] proved
this point. Isolated rat pancreatic acini were incubated with
1 AM Ca2 + ionophore A23187 and 1 mM 8Br-cAMP. In a
dose-dependent manner, SRIF subsequently inhibited the
secretory response evoked by the two stimulatory agents
combined. Maximal inhibition was achieved at 0.1 AM,
corresponding to a decrease in the secretory response of
approximately 30%. In electrically permeabilised acini,
rising levels of free Ca2 + boosted amylase secretion, an
effect potentiated by cAMP; the dose–response curve for
Ca2 +-induced secretion was shifted leftwards by cAMP, and
the peak value of secretion was elevated. Conversely, SRIF
inhibited the effect of cAMP on Ca2 +-induced amylase
secretion by shifting the dose–response curve to the right.
PTX added to acini completely abolished SRIF-induced
inhibition of amylase secretion stimulated by A23187 and
8Br-cAMP. It would appear from this that SRIF inhibits the
secretory response to cAMP and Ca2 + by decreasing the
Ca2 + sensitivity of exocytosis.
In C cells of the strain rMTC 44-2,102Scheru¨bl et al.
[235] reported the Ca2 +-induced rise in intracellular Ca2 +
and calcitonin secretion to be potently inhibited by SRIF or
SMS 201–995. Inhibitory signals were blocked by PTX.
Under voltage-clamp conditions, C cells exhibited slowly
inactivating Ca2 +-channel currents. Incubation with 100 nM
SRIF reversibly decreased Ca2 + currents by approximately
30%. The Ca2 + current and its inhibition by SRIF were not
affected by intracellularly applied cAMP. Whereas PTX had
no effect on control Ca2 + currents, it evidently blocked their
inhibition by SRIF. Thus, SRIF is able to inhibit Ca2 +-
stimulated calcitonin secretion by decreasing voltage-de-
pendent Ca2 + currents and intracellular Ca2 +. These SRIF
actions are dependent on PTX-sensitive GP transduction,
though completely independent of shifts in cAMP balance.
In another C-cell strain, i.e. rMTC 6–23, the effect of SMS
201–995 on intracellular Ca2 + was investigated by Zink et
al. Increasing extracellular Ca2 + led to a sudden rise in
intracellular Ca2 +; this effect was reversed by the specific
Ca2 + chelator ethylene glycol bis(beta-aminoethyl ether)-
N,N,NV,NV-tetraacetate (EGTA) and a Ca2 + antagonist such
as verapamil. NEN induced a similar rise in intracellular102 rMTC 44-2 cells derive from a rat medullary thyroid carcinoma,
secretion comprising calcitonin.
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Also SMS 201–995 was able to inhibit the effect of NEN.
However, PTX blocked inhibition by SMS 201–995 [236].
The thyroid Ca2 + channels were further characterised by
Raue et al. [237]. Extracellular Ca2 + regulates calcitonin
secretion by Ca2 + influx through DHP-sensitive voltage-
gated Ca2 + channels. Calcitonin secretion may also be
stimulated via a cAMP-dependent pathway operated by
glucagon or SRF receptors. Glucagon-stimulated cAMP
accumulation is inhibited by SRIF in a PTX-sensitive
manner. SRIF inhibits both cAMP- and Ca2 +-dependent
calcitonin secretion. Furthermore, SRIF cAMP-indepen-
dently but PTX-sensitively inhibits voltage-dependent
Ca2 + currents, thereby decreasing intracellular Ca2 +.
Applying the whole-cell configuration of the PCT, elec-
trophysiological experiments were performed on three dif-
ferent neuroendocrine strains: pituitary GH3, thyroid rMTC
44-2, and carcinoid BON cells. In rMTC 44-2 cells, SMS
201–995 curtailed the increase in cAMP induced by either
glucagon or SRF, and the calcitonin secretion consequently
decreased. In carcinoid BON cells, SMS 201–995 (0.1 M)
reversibly inhibited inward currents through voltage-gated
Ca2 + channels by approximately 25%, similar results being
obtained in rMTC 44-2 and GH3 cells. The inhibitory effect
on Ca2 + influx was found to be independent of cAMP levels,
suggesting two parallel pathways of signal transduction, but
the effect was blocked by PTX. Participation of PTX-
sensitive Go subforms in the coupling of the activated
receptor to voltage-gated Ca2 + channels in GH3 cells was
further corroborated by intranuclear injections of antisense
oligonucleotides, thereby ‘‘knocking out’’ individual GP
subunits selectively. sst3 receptors are presumed to be
responsible for interfering with cAMP accumulation via Gi
[88]. Other receptor subtypes supposedly couple to voltage-
gated Ca2 + channels via Go-alpha, in particular Go-alpha-2,
leaving out of account the possibility that one and the same
receptor subtype may couple to several effector systems in
different cell lines or, indeed, in one and the same cell [238].
In GH3, rMTC 44-2, and RIN-1056E cells,
103 the PCT
revealed spontaneous electrical activity (generation of action
potentials) as well as voltage-dependent Ca2 + currents. The
latter were negatively regulated by SRIF [239].
Golard and Siegelbaum [240] characterised receptor-
mediated regulation of voltage-dependent Ca2 + currents in
chicks. Thus, in chick sympathetic neurones subjected to
whole-cell voltage-clamp techniques, both NEN and SRIF
inhibited OCT-sensitive N-type Ca2 + currents in a voltage-
dependent manner. PTX effectively blocked this inhibition.
Replacing GTP in the patch pipette with GTP-gamma-S
resulted in irreversible inhibition, consistent with PTX-
sensitive GP transduction. Inhibition by NEN and SRIF
proved to be nonadditive. Signals transmitted by either
agent may therefore seem to converge at common sites103 RIN-1056E cells derive from a pancreatic tumour, secretion
comprising CCK.midway in transduction, if not as far downstream as the
effector itself. The inhibitory response to repeated applica-
tions of either agent desensitised, with little evidence of
cross-desensitisation. By inhibiting varying proportions of
L-type and N-type Ca2 + currents, SRIF continues to regu-
late secretion of acetylcholine in chick neurones at different
stages of maturation [241].
According to Toth et al. [242], activation of SRIF recep-
tors endogenous to HEK-293 cells or kappa-opioid recep-
tors—only expressed upon transfection—led to inhibition of
Ca2 + currents in alpha-B1-expressing cells. Ca2 + currents in
alpha-B1-expressing cells shared the properties of N-type
currents. Inhibition could be blocked with PTX. By contrast,
no inhibition could be demonstrated in cells expressing
alpha-E1 channels. Ca2 + currents in these cells exhibited a
novel profile resembling that of the ‘‘R-type’’ current.
With IC50 values of 1 AM, 5.5 AM, and 4 nM, respec-
tively, the transmitters [Met5]enkephalin, NEN, and SRIF
inhibited voltage-dependent, OCT-sensitive Ca2 + currents
in guinea-pig submucous neurones. These PTX-sensitive
actions could be imitated by GTP-gamma S. By contrast,
Ca2 + currents responded to neither Bay K 8644 (0.1–10
AM) nor nifedipine (1 AM). Surprenant et al. [243] have
characterised N-type Ca2 + channels.
In NG 108-15 cells, the four transmitters bradykinin, leu-
enkephalin, NEN, and SRIF inhibit N-type Ca2 + currents.
With the exception of the cellular response to bradykinin,
receptor-mediated inhibition is PTX-sensitive. By stable
expression of a mutant, PTX-resistant alpha subunit of
GoA, which specifically preserved functional coupling of
leu-enkephalin receptors and adrenoceptors, Taussig et al.
[244] demonstrated at least three coexistent transduction
pathways converging at a common effector. Sustained
exposure of NG 108-15 cells to SRIF resulted in receptor
desensitisation with regard to inhibition of both cAMP
accumulation and N-type Ca2 + currents [245].
In isolated neurones derived from the rat nucleus tractus
solitarius, SRIF inhibited both N-type and P/Q-type Ca2 +
currents in a PTX-sensitive manner. So did baclofen and
DAMGO, activating GABAB and mu-opioid receptors,
respectively. An antiserum directed against the amino-termi-
nal region of Go-alpha (GC/2) attenuated the cellular response
to SRIF without interfering with inhibition of Ca2 + currents
induced by baclofen or DAMGO [246]. In sympathetic
neurones derived from the male rat major pelvic ganglion,
both SRIF and EN (alpha2 adrenoceptor) inhibited N-type
Ca2 + currents in a PTX-sensitive manner. Zhu and Yakel
[247] reported that this receptor-mediated inhibition could be
significantly decreased by inhibiting the Ca2 +/calmodulin-
regulated protein phosphatase calcineurin. Inhibition of
voltage-dependent Ca2 + currents by GTP-gamma-S closely
paralleled the respective actions of EN and SRIF. Similarly, it
was reversed by calcineurin. However, this phosphatase does
not interfere with inhibition of N-type Ca2 + currents when
mediated by muscarinic cholinoceptors. Unlike baclofen,
whose receptor-mediated actions would appear to be con-
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cells of the mouse neurogenesis, SRIF potently inhibited
both L-type and N-type Ca2 + currents at either extreme of
the maturation from pluripotent embryonic stem cells into
neurones proper. Inhibition, which was PTX-sensitive, could
be imitated by GTP-gamma-S [248]. In a both dose-depen-
dent and PTX-sensitive manner, SRIF, peptide YY, and
galanin inhibited L-type Ca2 + currents in histamine-secret-
ing enterochromaffin-like cells. Those currents form part of
the secretory response to PACAP [249].
3.2.4. Receptor subtypes associated with calcium channels
Partly by mechanisms operating on voltage-gated Ca2 +
channels, as reported by Iversen and Hermansen [250],
SRIF inhibits glucose-induced insulin secretion in pancre-
atic B cells. And in RINm5F cells stably transfected with the
cloned human sst2 receptor, both SRIF and SMS 201–995
inhibited high voltage-activated (HVA) Ca2 + currents.
(RINm5F cells express both endogenous L-type and N-type
Ca2 + channels.) Similar currents were inhibited by neither
SRIF nor SMS 201–995 in cells expressing human sst1
receptors [251]. With the same strain serving as a model,
Degtiar et al. [252] used microinjection of antisense oligo-
nucleotides to resolve the subunit constellation supplying
SRIF receptors with GP transduction. Oligonucleotides
were thus complementary to various subforms of each of
the three GP subunits. It appeared that only those oligonu-
cleotides aligning with the respective transcripts of Go-alpha-
2, Gbeta-1, and Ggamma-3 blocked SRIF-induced inhibition of
Ca2 + currents. Furthermore, sst2 receptors seemed to medi-
ate the electrical response to SRIF.104 In 1046–38 cells,105
Roosterman et al. [253] reported the relatively sst1-selective
SRIF analogue CH-275 to inhibit voltage-dependent Ca2 +
currents significantly, with SMS 201–995 evoking but a
modest electrical response, presumably by activation of sst2
receptors.106 In transfected GH12C1 cells
107, however, Chen
et al. [254] reported both sst1 and sst2 receptors to mediate
inhibition of Ca2 + currents in a PTX-sensitive manner.
Evidence of these R–E associations emerged from separate
tests with the peptide agonists CH-275 and MK-678, either
of which is taken to be subtype-selective.108 Setting out to104 The observation that NC 8-12, supposedly a sst2-selective SRIF
analogue, could induce functional coupling of SRIF receptors to voltage-
gated Ca2 + channels in RINm5F cells urged the investigators to conclude
that sst2 receptors must be responsible for mediating the cellular response
[252]. However, it should be noted that NC 8-12 also binds to human sst3
receptors with high affinity (IC50 = 0.09 nM) while refusing to interact with
the human sst5 receptor (IC50= > 1000 nM). Hence, NC 8–12 is but
relatively sst2-selective (IC50 = 0.024 nM). Unlike SMS 201–995, it is not a
genuine SRIF1-selective agonist either [397].
105 1046-38 cells derive from another rat insulinoma.
106 The reverse held good as regards regulation of AC activity in 1046-
38 cells. SMS 201–995 thus inhibited cAMP accumulation, with CH-275
being virtually impotent [253].
107 GH12C1 cells derive from a rat anterior pituitary tumour.
108 Similar reservations thus apply in this case. Strictly speaking, CH-
275 and MK-678 are SRIF2- and SRIF1-selective, respectively (cf. Table 2).characterise possible constellations of GP subunits respon-
sible for negative regulation of N-type Ca2 + currents by
adenosine, EN (alpha2 adrenoceptor), PG-E2 and SRIF, Jeong
and Ikeda [255] managed to reconstitute receptor-mediated
inhibition ofCa2+ currents by expressingGo-alpha-A,Go-alpha-B,
andGi-alpha-2 in rat sympathetic neurones.Gbeta-1 andGgamma-2
provided the rest of the heterotrimer. Neither Gi-alpha-1 nor
Gi-alpha-3 coupled receptor to effector. The following rank
order of coupling efficiency was observed for the SRIF
receptor: Go-alpha-B =Gi-alpha-2>Go-alpha-A. Jeong and Ikeda
made the important observation that different heterotrimeric
constellations, though with varying coupling efficiency, had
the ability to couple a series of distinct GPC receptors to the
same effector. Delmas et al. [256] approached regulation of
N-type Ca2 + currents in dissociated rat superior cervical
sympathetic neurones from another angle. Interestingly, the
ability to interact with the effector is conferred on the G-
beta-gamma dimer released from the receptor-activated
heterotrimeric GP. The investigators found that expression
of the C-terminal domain of beta-ARK-1, which contains
the consensus motif for binding G-beta-gamma, led to a
decrease in fast, PTX-sensitive, and voltage-dependent
inhibition of Ca2 + currents by NEN or SRIF. By contrast,
slow, PTX-resistant, and voltage-independent inhibition by
angiotensin II remained intact. Overexpression of a dimer
constructed from Gbeta-1 and Ggamma-2 made it possible to
imitate the voltage-dependent inhibition of Ca2 + currents
mediated by both adrenoceptors and SRIF receptors. Sim-
ilarly, coexpression of the consensus motif and the dimeric
components Gbeta-1 and Ggamma-2 abolished inhibition of
Ca2 + currents. Findings are taken as evidence that endog-
enous G-beta-gamma dimers, rather than activated G-alpha
monomers, couple the GPC receptor functionally to the N-
type Ca2 + channel. Alternatively, however, sequestering of
G-beta-gamma with the beta-ARK-1 fragment has been so
successful as to render the G-alpha monomer, whether Gi-
or Go-alpha, incapable of interaction with the ligand-acti-
vated receptor. In GH3 cells, carbachol, galanin, and SRIF
inhibited L-type Ca2 + currents in a PTX-sensitive manner.
Pretreatment with PTX resulted in a situation where only
Go-alpha-2, applied in purified form by a patch pipette, could
reconstitute functional coupling of SRIF receptors to the
Ca2 + channels. For carbachol and galanin to regain their
ability to inhibit Ca2 + currents under similar conditions,
however, Go-alpha-1 was required. Despite this apparent GP-
subform specificity, carbachol, galanin, and SRIF all stim-
ulated incorporation of the photoreactive GTP analogue
[alpha-32P]GTP azidoanilide into both Go-alpha subforms.
By contrast, Gi-alpha subforms appeared to have no place in
functional coupling to L-type channels [232].
By the whole-cell PCT, the SRIF1-selective agonist MK-
678 was found to inhibit voltage-dependent L-type Ca2 +
currents in AtT-20 cells. This effect was blocked by PTX.
Ca2 + currents were also inhibited by other relatively sst2-
selective peptide agonists such as BIM-23,027 and NC 8–
12. The relatively sst5-selective peptide agonist BIM-23,052
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cells in a PTX-sensitive manner109. However, functional
coupling of sst2 and sst5 receptors, respectively, to Ca
2 +
channels turned out to be differentially regulated. Thus,
preexposure to BIM-23,052 curtailed the decrease in Ca2 +
currents mediated by sst5 receptors, representing an instance
of desensitisation. By contrast, sst2-mediated inhibition of
the Ca2 + current was not affected by preexposure to MK-
678 [257]. In vitro, Raynor et al. [176] demonstrated that the
native receptor ligand as well as either of the synthetic SRIF
analogues MK-678 and CGP-23,996, besides inhibiting
forskolin-stimulated cAMP accumulation by 25–30%, were
capable of inhibiting a HVA Ca2 + current in rat neocortical
neurones to a similar extent.
Regrettably, matters are not as simple as could be
desired. Activation of endogenous sst2 receptors in the strain
AR42J110 by receptor-selective analogues led to a dose-
dependent increase in intracellular Ca2 +.111 Since PI turn-
over remained constant throughout the observation period,
activation of PL-C had to be ruled out as an intermediate
step in signal transduction. When incubated in a Ca2 +-free
external buffer, however, the effect failed to appear. The
source of Ca2 + thus being extracellular, receptors would
have to activate Ca2 + channels—quite contrary to what has
been reported elsewhere [258].
In AtT-20 cells, endogenous sst2 and sst5 receptors have
been shown to be functionally coupled to L-type Ca2 +
currents in a PTX-sensitive manner. The highly sst5-selec-
tive SRIF analogue L-362,855, which is a cyclic heptapep-
tide with the pharmacological behaviour of an antagonist/
partial agonist (see below), was instrumental in this discov-
ery. Thus, it potently abolished the inhibition of Ca2 +
currents induced by the relatively sst5-selective peptide
agonist BIM-23,052 [257,259].
In isolated neuroendocrine tumour cells of the human gut,
both SRIF and SMS 201–995 inhibited L-type Ca2 + currents
in a dose-dependent manner. Thus, 100 nM of SRIF and SMS
201–995 decreased the current amplitude by 38F 19% and
35F 14%, respectively. Inhibition by dihydropyridines and
peptide transmitters could be seen to be nonadditive. An
isradipine-resistant Ca2 + current formed but a minor fraction
of the total current amplitude in cells of the origin specified.
However, this inward current also seemed rather insensitive109 Contrary to the suggestions of Tallent et al., BIM-23,052 is not sst5-
selective in the absolute sense. It binds to both mouse sst3 (IC50 = 0.42 nM)
and rat sst5 (IC50 = 0.002 nM) receptors with high affinity. However, it does
not have the high affinity for sst2 (mouse sst2: IC50 = 32 nM) receptors
characteristic of SRIF1-selective analogues, though reluctant to interact
with sst1 (human sst1: IC50 = 23 nM) and sst4 (human sst4: IC50 = 18 nM)
receptors [208,282].
110 AR42J cells derive from a rat pancreatic tumour.
111 Using receptor-specific antisera, Scho¨nbrunn et al. [508] reported
AR42J cells to express endogenous sst2 receptors, without any evidence of
the sst1 receptor. On the basis of affinity purification of the R–GP complex
with a biotinylated SRIF analogue, coprecipitation of receptor and GP with
GP-specific antisera revealed that SRIF receptors coupled to both Gi-alpha-1
and Gi-alpha-3 in this strain.to SMS 301–995. On pharmacological grounds, it had to be
concluded by Glassmeier et al. [260] that sst2 or sst5 receptors
must be involved. In rod and cone photoreceptors of the
salamander retina, L-type Ca2 + currents are differentially
regulated by SRIF. Either cell type has been found to express
sst2A receptors. But in rods, Ca
2 + currents are inhibited by
33% while stimulated by 40% in cones. Both inhibition and
stimulation is PTX-sensitive [261].
In summary, SRIF receptors are functionally coupled
to high-voltage-gated Ca2 + channels by the GP subform
Go-alpha-2, regulation being of a predominantly negative
nature. This is an instance of direct GP gating. But the
activity of Ca2 + channels is also regulated indirectly by
receptor-mediated activation of K+ channels (see below).
Either transduction pathway is blocked by PTX. Apart from
Go-alpha-2, the GP coupling SRIF receptors to Ca
2 + channels
is assembled from Gbeta-1 and Ggamma-3 in some bioassays.
Also Gbeta-3, however, has been implicated. Because SRIF
regulates the activity of different-type Ca2 + channels, it
is not surprising that, in other bioassays, a functional GP
heterotrimer assembled from Go-alpha-B, Gbeta-1, and Ggamma-2
has been reported, G-alpha being fully interchangeable with
Gi-alpha-2 and less so with Go-alpha-A. In rat insulinoma cells,
endogenous sst1 and sst2 receptors are both reported to
inhibit voltage-dependent Ca2 + currents, though with the
sst1 receptor mediating a more potent response. In AtT-20
cells, endogenous sst2 and sst5 receptors both inhibit Ca
2 +
currents. SRIF receptors with the pharmacological profile of
the sst2 subtype are also known to inhibit similar currents in
rat amygdaloid neurones. Different-type voltage dependent
Ca2 + currents are regulated by SRIF, including the follow-
ing: (1) L type; (2) N-type; and (3) T-type currents.
3.2.5. Regulation of potassium channels
The GP is a key transducer in receptor-mediated regula-
tion of the activity or opening probability of ion channels.
However, pathways of GP transduction may be divided into
those of the indirect and direct type according to the site of
action. Hence, the former type refers to intermediate-step
synthesis of second messengers, the latter to interaction of
activated G-alpha with structural elements of the channel
itself. The GP may thus act as internal ligand at the effector
(for the distinction between external and internal ligands,
see above).
In most cells, the electrical response to SRIF is compos-
ite. SRIF usually induces hyperpolarisation of the plasma
membrane [7,214]. But this state merely represents the net
balance of currents across the phospholipid bilayer. In recent
years, the SRIF-stimulated K+ current, which accounts for
hyperpolarisation and secondary inhibition of voltage-de-
pendent Ca2 + currents, has been resolved into multiple
components with individual properties [262]. Voltage-gated
K+ channels found to be operated by SRIF receptors are
divided into the following classes: (1) delayed rectifier K+
(DRK) channels opened by depolarisation and sensitive to
tetraethylammonium (TEA) and 4-aminopyridine (4-AP);
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polarisation and sensitive to Ca2 + and Ba2 +; and (3) Ca2 +-
activated K+ (BK) channels opened by depolarisation. But
there is also evidence that SRIF regulates the following
voltage-dependent K+ currents: (1) A-type K+ (AK) currents
triggered by depolarisation and blocked by 4-AP; and (2)
M-type K+ (MK) currents triggered by depolarisation and
blocked by muscarinic cholinoceptor agonists.112 Finally,
reflecting on their observations from CA1 pyramidal neuro-
nes of rat hippocampus,113 Schweitzer et al. [263] have
proposed the existence of voltage-independent, outward
leak K+ (LK) currents which are, however, progressively
sensitive to increasing levels of extracellular Ba2 +, complete
blockade being achieved at 2 mM. By contrast, extracellular
Cs+ (2 mM) completely failed to block outward LK cur-
rents, though attenuating the inward component. Unlike MK
currents, which predominate at the slightly depolarised
membrane, LK currents are stimulated at the resting mem-
brane potential, being responsible for hyperpolarisation
under these conditions. Standard bioassays used to study
the details of signal transduction normally present some
endogenous effector diversity. Apart from the IRK currents
of somatotrophs [264] and corticotrophs [265], at least three
types of voltage-dependent K+ currents have thus been
identified in pituitary cells: (1) transient outward, 4-AP-
sensitive K+ current (IA; AK); (2) slowly inactivating, TEA-
sensitive outward K+ current (IK; DRK); and (3) Ca
2 +-
activated K+ current (IK(Ca); BK) [214,266]. For the present,
IRK channels are divided into four subfamilies, including
the GP-gated IRK (GIRK) channels operated by GPC
receptors: (1) IRK subfamily (IRK1-3/Kir1.1-1.3); (2)
GIRK subfamily (GIRK1-4/Kir3.1-3.4); (3) ATP-dependent
Kir subfamily (ROMK1/Kir1.1, K(AB)-2/Kir4.1); and (4)
ATP-sensitive Kir subfamily (uKATP-1/Kir6.1, BIR/Kir6.2)
[267]. Apart from SRIF receptors and muscarinic cholino-
ceptors, AtT-20 cells express the endogenous GIRK chan-
nels Kir3.1 and Kir3.2 [268]. A growing number of GPC
receptors are known to operate voltage-gated K+ channels
sharing the functional characteristics of the GIRK subfam-
ily. Apart from muscarinic cholinoceptors (M2) and adreno-
ceptors (alpha2), adenosine (A1), dopamine (D2), GABA
(GABAB), 5-hydroxytryptamine/serotonin (5-HT1), opioid
(delta- and mu-opioid), and SRIF receptors are functionally
coupled to GIRK channels [269].
One example of direct GP gating is provided by the atrial
muscarinic K+ channel, an IRK channel with a slope112 Schweitzer et al. [300] have suggested that receptor-mediated
inhibition of MK currents depends on various components of the PI
cascade. Both muscarinic cholinoceptor agonists and angiotensin II seem
capable of such negative regulation, inhibitory signals being PTX-resistant
[566].
113 For the purposes of analysis, any contribution to hyperpolarisation
made by MK currents in CA1 pyramidal neurones could be subtracted by
using the compound MK-886 (see below), which specifically blocks the
transduction pathway of MK currents [263,302].conductance of 40 pS and a mean open lifetime of 1.4
milliseconds (ms) at potentials between  40 and  100
mV. Another is the muscarinic acetylcholine- or SRIF-gated
K+ channel present in the plasma membrane of GH3 cells.
Inwardly rectifying and with a slope conductance of 55 pS,
this particular K+ channel has been characterised in several
patch-clamp studies by Yatani et al. [220]. It has thus
emerged that both SRIF and acetylcholine, when applied
to the extracellular face of the patch, are fully capable of
activating the 55-pS K+ channel in the absence of a second-
messenger cascade reaction. Activation is tantamount to an
increase in the opening probability of the K+ channel.
Following excision of the patch, the activity of the ligand-
gated channel varies with GTP levels. The opening proba-
bility of the K+ channel is potently decreased by pretreat-
ment of the intracellular face of the patch with PTX and
the electron acceptor nicotinamide adenine dinucleotide
(NAD+). Full channel activity is restored in a GTP-depen-
dent manner by adding a nonactivated PTX-sensitive GP
purified from human erythrocytes. This GP is referred to by
the investigators as Gk. The 55-pS K
+ channel is also
susceptible of ligand-independent activation by GTP-gam-
ma-S or Mg2 +/GTP-gamma-S-activated Gk. Similar to the
G-alpha of Gi (for a systematic classification of Gk, see
below), Gk-alpha is ADP-ribosylated by PTX, and the heter-
otrimer dissociates upon activation by Mg2 +/GTP-gamma-
S. When activated by GTP-gamma-S, the G-alpha of Gk acts
directly on the muscarinic 40-pS K+ channel in atrial cells.
In comparison, Gs-alpha from human erythrocytes acts di-
rectly on two distinct voltage-gated Ca2 + channels, one in
cardiac muscle and the other in skeletal-muscle T tubules
[221]. Activation of atrial K+ channels takes place at
subpicomolar concentrations of Gk in adult guinea pig,
neonatal rat, and chick embryo. A monoclonal antibody
raised against Gk-alpha has been shown to inhibit the activa-
tion of the 40-pS K+ channels [270]. Piros et al. [271]
reported both SRIF and the selective delta-opioid receptor
agonist D-Pen2-D-Pen2-enkephalin to stimulate Ba2 +-sensi-
tive, TEA-resistant IRK currents in GH3 cells stably trans-
fected with delta-opioid and mu-opioid receptors, thereby
indirectly inhibiting voltage-dependent Ca2 + currents and
PL secretion (D-Pen2-D-Pen2-enkephalin: IC50 = 4 nM). Un-
like the synthetic opioid, SRIF also activated IRK channels
in control GH3 cells and GH3 cells stably expressing but the
mu-opioid receptor. Other known pituitary K+ currents such
as DRK, BK, and AK currents failed to show any sign of
regulation by opioids.
KATP channels play a key role in cellular metabolism.
External ligands gating these channels in pancreatic B cells
include the antidiabetic sulfonylureas. ATP, which abounds
in parallel with postprandial glucose oxidation, acts on the
K+ channel as an internal ligand. But either type of ligand
decreases the opening probability of the same K+ channel,
leading to depolarisation of the plasma membrane, activa-
tion of voltage-gated Ca2 + channels, and endocrine degran-
ulation in turn. In RINm5F cells, Fosset et al. [272] showed
114 Purified from V. cholerae, CTX stimulates the activity of AC by
inhibiting the GTPase activity of Gs. The 87-kDa protein is a hexamer
consisting of an A subunit and five B subunits. The A subunit consists of an
A1 peptide linked by a disulfide bridge to an A2 peptide. The 23-kDa A1
chain covalently modifies Gs, catalysing the transfer of an ADP-ribose unit
from NAD+to a specific arginine side chain of the alpha subunit of Gs. This
irreversible ADP ribosylation of Gs blocks its capacity to hydrolyse bound
GTP to GDP—the GP is consequently locked in the active form [160].
L.N. Møller et al. / Biochimica et Biophysica Acta 1616 (2003) 1–8430the ability of SRIF to stimulate K+-like outward currents in
a dose-dependent manner, with an EC50 of 0.7 nM [using
rubidium (86Rb+) as charge carrier/tracer]. The sulfonylurea
glibenclamide, which specifically inactivates KATP chan-
nels, completely reversed these outward currents. Further-
more, activation of K+ channels by SRIF was found to be
PTX-sensitive. Functional coupling of SRIF receptors to
KATP channels would imply an inherent potential to antag-
onise stimulatory signals transduced by depolarisation and
Ca2 + currents. At high levels (2 mM) of intracellular ATP,
SRIF maintains its ability to activate KATP channels in
insulinoma cells. It seems as if SRIF renders the channels
resistant to inactivation by ATP [273]. By some ill-defined
transduction mechanism, receptor-mediated regulation of
KATP currents has been reported to depend on cAMP. But
in HIT-T15 cells, which endogenously express the GP
subforms Gi-alpha-1, Gi-alpha-2, and Gi-alpha-3, apart from three
Go subforms, 8Br-cAMP attenuated the antisecretory re-
sponse to both EN and SRIF. Inhibition of insulin secretion
by these transmitters is nonadditive, implying common sites
of action or bottlenecks in the transduction pathway.
Accounting for one component of the cellular response,
they both inhibit glipizide-stimulated insulin secretion non-
competitively and in a PTX-sensitive manner. Hence, KATP
channels must bind the sulfonylurea glipizide and endoge-
nous transducers at different epitopes. Unlike EN, SRIF is
totally dependent on PTX-sensitive GP transduction for any
of its actions [274]. A study by Sakuta [275] puts KATP
currents into a broader physiological perspective. Apart
from imidazolines and sulfonylureas, GLP-1 [7–36] stim-
ulates secretory activity by indirectly inhibiting KATP cur-
rents in B cells. Endosulphine, an endogenous KATP
antagonist, also stimulates insulin secretion. By contrast,
openers of KATP channels comprise a number of chemically
diverse compounds known to inhibit the secretion of GH in
the pituitary and GABA in the substantia nigra. Incidental-
ly, the very receptor subtype associated with K+ channels,
i.e. the sst2 receptor, has been located in either of these
particular anatomical regions [83,276–281]. Based on
observations with anterior pituitaries from adult male rats,
Raynor et al. [282] go as far as to imply that pharmaco-
logical potency in treating secretory activity of somato-
trophs varies with the expression of sst2 receptors
specifically. In pancreatic B cells, both galanin and SRIF
inhibit insulin secretion by GP-dependent signal transduc-
tion, the cascade reaction including internal-ligand gating of
KATP channels. In vascular smooth muscle cells, acetylcho-
line and histamine stimulate the release of endothelium-
derived hyperpolarising factor, which is capable of activat-
ing KATP channels [270,275]. The KATP agonist diazoxide,
also known from antihypertensive therapy, and SMS 201–
995 are used to treat the neonatal disorder persistent hyper-
insulinemic hypoglycemia of infancy. This condition results
from mutations in the subunits that polymerise to form the
KATP channel of B cells. In the absence of operational KATP
channels, spontaneous electrical activity at the plasmamembrane causes hypersecretion. A positive response to
therapy relies, however, on a different-type K+ channel
rather than restoration of KATP currents [283]. Perhaps this
channel is identical to the sulfonylurea-insensitive, low-
conductance K+ channel previously identified by Rorsman
et al. [284] in B cells. They found that EN inhibited
electrical activity and insulin secretion by GP-dependent
activation of this channel. In glucagon-secreting alpha cells
of mouse PIL, Yoshimoto et al. [285] reported SRIF to
induce hyperpolarisation by stimulation of GIRK currents.
Unlike the well-characterised KATP currents of neighbour-
ing beta cells, which do share the sensitivity to PTX, SRIF-
stimulated IRK currents never showed any response to
tolbutamide. The RT-PCR combined with immunohisto-
chemistry (IHC) suggested transduction by Kir3.2c and
Kir3.4. Nevertheless, Suzuki et al. [286] have actually
demonstrated the expression of Kir6.2, belonging to the
subfamily of KATP channels, in alpha, beta, and delta cells
of mouse PIL, secreting glucagon, insulin, and SRIF,
respectively. However, Kir6.2 has not been found in exo-
crine acinar cells.
In neurones of the guinea-pig plexus submucosus and rat
nucleus locus coeruleus, North et al. [269] demonstrated the
ability of delta-opioid and mu-opioid receptors, respective-
ly, to mediate stimulation of IRK currents, with resultant
membrane hyperpolarisation. Neither PK-A nor PK-C
appeared to be involved in signal transduction. However,
there was evidence that GTP-gamma-S might have a part to
play. In the guinea-pig ileocecal plexus submucosus, SRIF
hyperpolarised more than 90% of the neurones, with
maximal effect occurring at a SRIF concentration of 30
nM, corresponding to a membrane potential of 30–35 mV.
Under voltage clamp at  60 mV, SRIF stimulated outward
currents reaching a maximum of 350–700 pA. The hyper-
polarisation or outward current reversed polarity at a
membrane potential (about  90 mV in control solutions)
that changed according to the logarithm of the external K+
concentration. SRIF-stimulated currents showed inward
rectification. So when inward rectification of the resting
membrane was blocked by extracellular cesium (Cs+) or
Rb+, the inward rectification of the SRIF-stimulated cur-
rents also disappeared. Although alpha2 adrenoceptors and
delta-opioid receptors could mediate a similar cellular
response, neither adrenergic nor opioid antagonists inter-
fered with SRIF regulation of IRK currents. Hyperpolarisa-
tion (or outward current) was insensitive to forskolin,
cholera toxin (CTX),114 sodium fluoride, phorbol esters,
115 Another activator of BK channels is ANP whose actions,
similar to those of SRIF, are largely inhibitory. In contradistinction to
SRIF, however, ANP widely depends on GPC receptors functionally
coupled to guanylyl cyclase (GC) for its cellular response. And this
receptor-mediated regulation of cGMP accumulation is entirely positive,
unlike the regulation of the second messenger cAMP. In GH4C1 cells,
White et al. [567] reported ANP to stimulate BK currents by signals
extending to some phosphatase. However, the electrical response to
ANP is preceded by rapid activation of both GC and cGMP-dependent
protein kinase. The latter, in turn, might be responsible for activating
the phosphatase. In pancreatic acini, SRIF has been reported to activate
GC [568].
116 The cells used, as indicated, do not appear to express endogenous
GIRK channels. So Ruiz-Velasco [296] and Ikeda used intranuclear
microinjection of cDNA corresponding to members of the GIRK subfamily.
The whole-cell PCT served to map functional coupling of endogenous GPC
receptors to those GIRK channels. Injection of cDNA encoding individual
GIRK subunits did not suffice to evoke anything like the large-scale
adrenoceptor-mediated response observed after expression of either
GIRK1-2 or GIRK1-4. While the cellular response to epinephrine could
be abolished by PTX, it took CTX to interfere with VIP-induced
stimulation of GIRK currents, rather unexpectedly suggesting transduction
by Gs. In fact, as compared to untreated neurones, PTX potentiated the
cellular response to VIP.
117 By comparison, angiotensin II inhibits MK currents in rat
sympathetic (superior cervical ganglion) neurones, probably in a PTX-
resistant manner similar to muscarinic cholinoceptor agonists [566].
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phate (ATP-gamma-S). With regard to the IRK currents,
GTP-gamma-S imitated SRIF action to some extent, driving
the membrane potential towards the K+ equilibrium poten-
tial [287]. In AtT-20 cells, SRIF stimulates IRK currents in
a PTX-sensitive manner. However, Cs+ decreased K+ con-
ductance ( gk). A decrease in corticotropin secretion paral-
leled receptor-mediated stimulation of IRK currents. This
antisecretory response could be abolished by Cs+ [288]. In
neurones of the rat locus coeruleus, from a holding poten-
tial of  60 mV, both CST and SRIF potently stimulated
IRK currents (CST: pEC50 = 6.62; SRIF: pEC50 = 6.93),
with a display of almost perfect cross-desensitisation fol-
lowing sustained exposure to high levels of either agonist.
The electrical response to CST would seem to be mediated
entirely by SRIF receptors. Thus, CST evidently refused to
interact with mu-opioid receptors. Naloxone (10 AM) failed
to interfere with CST action (300 nM–10 AM). Mu-opioid
receptors, however, could be activated by met-enkephalin
during a period of receptor desensitisation induced by high
levels of CST (3 AM), with resultant stimulation of IRK
currents [289].
Setting something of a puzzle, Dichter et al. [290]
reported that SRIF-14 would seem to stimulate voltage-
dependent K+ currents while SRIF-28 tended to inhibit
those same currents in neurones of the mammalian CNS.
The investigators recognised, however, that both receptor
ligands inhibited voltage-dependent Ca2 + currents. And
either of the effectors investigated seemed to depend on
GP transduction for activation by SRIF. Apparently, Kur-
enny et al. [291] succeeded in demonstrating differential
regulation of the membrane potential by the native receptor
ligands SRIF-14 and SRIF-28. In C cells of a bullfrog
sympathetic ganglion, where muscarinic cholinoceptors
mediate hyperpolarisation, SRIF-28 thus reasserted an in-
hibitory profile by activating IRK channels, with SRIF-14
reduced to relative inactivity. In B cells, by contrast, SRIF-
14 proved to be a much more potent inhibitor of voltage-
dependent, non-inactivating MK currents than SRIF-28.
The B-cell response to muscarinic-cholinoceptor activation
is stimulatory.
White et al. [292–294] reported SRIF, in parallel with
inhibition of cAMP accumulation, to stimulate the activity
of large-conductance BK channels in rat pituitary tumour
cells. Such signal transduction, which soon turned out to
be rather complex, involving much more than simple
channel gating by the receptor-activated GP, could be
blocked by inhibitors of either PL-A2 or 5-lipoxygenase
(5-LO). Lipoxygenase metabolites of arachidonic acid
(AA) would seem to play the part of second messengers
transducing stimulatory signals onwards from some PTX-
sensitive GP to a phosphoserine/threonine phosphatase
(PSTP) regulating the activity of BK channels. Bypassing
the proximal site of PL-A2, exogenous AA imitated SRIF
action by stimulating BK currents via dephosphorylation.
As could be predicted, the electrical response to AA wasblocked by inhibitors of lipoxygenase only—not by inhib-
itors of PL-A2.
115
In hippocampal CA3 neurones, adenosine, GABAB, se-
rotonin, and SRIF receptors mediated stimulation of Ba2 +-
sensitive GIRK currents (SRIF: EC50 = 75 nM). Under
specified conditions, functional coupling to GIRK channels
seemed to display synergism. At saturating concentrations of
agonists, combined application of baclofen and 2-chloroa-
denosine, serotonin, or SRIF thus resulted in a subadditive
cellular response. At subsaturating concentrations, however,
baclofen combined with 2-chloroadenosine evoked a supra-
additive response [295]. In adult rat sympathetic neurones
derived from the superior cervical ganglion, the transmitters
adenosine, NEN, PG-E2, SRIF, and VIP activated exogenous
GIRK channels [296].116
In rat somatotrophs, SRIF reversibly stimulated TEA-
sensitive DRK and TEA-resistant but 4-AP-sensitive AK
currents by 75% and 45%, respectively. With DRK currents
being characterised by a threshold of  20 mV, transient
outward AK currents could be triggered at  40 mV (from a
holding potential of 80 mV) by Chen et al. [266].
Moore et al. [297] reported both native SRIF isoforms to
stimulate time- and voltage-dependent, non-inactivating, and
outward MK currents in CA1 pyramidal neurones of the
hippocampus.117 Slowly triggered by depolarisation, MK
currents persist at slightly depolarised membranes. By con-
trast, both muscarine and carbachol inhibited these neuronal
currents. Being resistant to TEA, 4-AP, and Cs+, MK
currents could be inhibited by Ba2 + (1 mM) and carbachol
(50 AM), with reversal of SRIF-induced hyperpolarisation
[298]. Also low-dosage, ethanol (22–44 mM) inhibits MK
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the transduction pathways of both BK and MK currents. In
hippocampal neurones, Schweitzer et al. [300] thus found
that the electrical response to SRIF could be abolished by
two known inhibitors of PL-A2, i.e. quinacrine and 4-
bromophenacyl bromide, while imitated equipotently by
AA and leukotriene C4.118 Furthermore, actions of both
SRIF and AA are blocked by an inhibitor of lipoxygenase,
i.e. nordihydroguaiaretic acid, being insensitive to the cyclo-
oxygenase inhibitor indomethacin. While the prostaglandins
PG-E2, PG-F2alpha, and PG-I2 could be seen to have no part
in signal transduction, the specific 5-LO inhibitors 5,6-
methanoleukotriene A4 methylester and 5,6-dehydroarachi-
donic acid both abolished the electrical response to either
SRIF or AA.119 However, Schweitzer et al. [301] noticed
that, with the M-type component of the total K+ current
specifically eliminated by lipoxygenase inhibitors, an out-
ward current stimulated by either SRIF or AA remained.
Lammers et al. [302] showed that regulation of hippocampal
MK currents by SRIF could be blocked by the compound
MK-886 (0.25–1 AM) which is a specific inhibitor of 5-LO-
activating protein (FLAP).120
Tallent and Siggins [303] argued that intracellularly
applied Cs+ blocked regulation of postsynaptic K+ currents
by SRIF in rat CA1 pyramidal neurones. However, Cs+
evidently failed to restore EPS potentials attenuated by
SRIF. Contrary to inhibitory postsynaptic (IPS) poten-
tials,121 which proved altogether resistant to SRIF at high
doses (5 AM), EPS potentials should respond to SRIF
according to its negative regulation of glutamate-stimulated
currents.122 Having thus deprived postsynaptic K+ currents
of any contribution to SRIF-induced attenuation of EPS
potentials, Tallent and Siggins found that extracellular Ba+
blocked attenuation of these potentials by SRIF. This could
be evidence of presynaptic K+ currents contributing to SRIF
action. It should be noted that MK currents are not Cs+-
sensitive [298]. Therefore, it might be premature to rule out
any postsynaptic contribution on their part to SRIF-induced
attenuation of EPS potentials.118 However, leukotriene B4 is significantly less potent with regard to
MK currents than AA [301].
119 By contrast, SRIF actions were resistant to the 12-lipoxygenase (12-
LO) inhibitor baicalein. Accordingly, 12-hydroperoxyeicosatetraenoic acid,
i.e. a 12-LO metabolite of AA, failed to imitate SRIF action [301].
120 FLAP is an 18-kDa integral membrane protein required for
activation of 5-LO. Similar to 5-LO, it has been found by Lammers et al.
[302] to be expressed in various regions throughout rat brain, including
brainstem, cerebellum, hippocampus, hypothalamus, primary olfactory
cortex, superficial neocortex, and thalamus. Highest levels, however, are
expressed in cerebellum and hippocampus. In the latter, FLAP is
colocalised with 5-LO in CA1 pyramidal neurones.
121 IPS potentials were generated via GABAA or GABAB receptors
[303].
122 Stimulation of these composite cationic currents, which give rise to
EPS potentials, is mediated by AMPA/kainate and N-methyl-D-aspartate
(NMDA) receptors (see below).3.2.6. Receptor subtypes associated with potassium
channels
In a bioassay consisting of cultured rat neocortical
neurones, Raynor et al. [176] first reported SRIF and
MK-678 to stimulate DRK currents by as much as 25–
30%. However, those K+ currents did not respond to even
high concentrations of CGP-23,996. In fact, MK-678 could
be seen specifically to increase DRK currents in such cells
where CGP-23,996 proved incapable of similar action. In a
later study by the same investigators, SRIF1 receptors—
pharmacologically characterised by high affinity for SMS
201–995—were found to couple to some GP, mediating the
stimulatory effect of SRIF on DRK currents in brain
neurones. In comparison, SRIF2 receptors did not even
appear to be efficiently coupled to any GP [304]. This
was indeed evidence that receptors might associate with K+
channels. Granted the existence of five distinct receptor
subtypes, however, it became urgent to narrow down the
possible candidates. At concentrations of 100–500 nM,
SRIF has recently been reported to stimulate DRK currents
in both rod and cone photoreceptors of the salamander
retina. These cells have been shown to express endogenous
sst2A receptors. The electrical response to SRIF was abol-
ished by PTX and substantially attenuated by GDP-beta-S
[261].
According to Bell and Reisine [168], the G-alpha of the
Gk heterotrimer characterised by Yatani et al. [220] is
identical to Gi-alpha-3. By an immunoprecipitation tech-
nique, this particular GP subform was originally found to
couple to SRIF receptors in the strain AtT-20 and rat brain
[163,164]. Later, in HEK-293 cells transiently transfected
with mouse sst2 receptors, antiserum directed against Gi-
alpha-3 specifically immunoprecipitated a R–GP complex
[198]. It may thus be concluded that the sst2 receptor plays
a part in regulation of K+ currents (cf. Table 1). In ovine
somatotrophs studied with whole-cell recording by Chen
[10,305], antibodies raised against Gi-alpha or Gi-alpha-3
specifically attenuated the electrical response to locally
applied SRIF (10 or 100 nM), which amounted to an
increase in K+ currents of up to 150% of control. Anti-
bodies against Go-alpha, Gi-alpha-1 or Gi-alpha-2 failed to
interfere with K+ currents regulated by SRIF, and so did
heat-inactivated (60 jC for 10 min) Gi-alpha. By compari-
son, Kozasa et al. [306] presented Gi-alpha-2 as the subform
likely to be responsible for functional coupling of musca-
rinic cholinoceptors to GIRK channels in AtT-20 cells. In
this bioassay, also SRIF is known to stimulate K+ currents
in a PTX-sensitive manner. The truth is that both Gi-alpha-2
and Gi-alpha-3 transduce SRIF-induced activation of IRK
channels. In a pair of human GH-secreting adenomas,
where IRK currents are stimulated by SRIF, Bito et al.
[209] found Gi-alpha-1, Gi-alpha-2, and Gi-alpha-3 to be
expressed along with Go. Following microinjection of
GP-specific antisera directed against the carboxyl terminus
of either Gi-alpha-3 or Gi-alpha-1/Gi-alpha-2, they could report
that antiserum specific for Gi-alpha-3 alone attenuated the
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al. investigated the respective transduction pathways of
IRK currents in locus-coeruleus neurones of newborn rats
and AtT-20 cells. In rat neurones, the GP-specific antise-
rum anti-Gi-1/Gi-2, but neither of the antisera anti-Gi-3 and
anti-Go/Gi-3, blocked SRIF-induced stimulation of IRK
currents. Consistent results were obtained with antisense
and sense oligonucleotides. Using microinjection in rat
neurones, Bito et al. [209] showed that antisense oligonu-
cleotides specific for Gi-alpha-2, unlike sense oligonucleo-
tides, attenuated the electrical reponse to SRIF. Neither
antisense nor sense oligonucleotides specific for Gi-alpha-1,
Gi-alpha-3 or Go-alpha could interfere with activation of IRK
channels by SRIF. However, though functionally coupled
to IRK channels, SRIF receptors entered complex forma-
tion with a different GP subform in AtT-20 cells. In these
mouse endocrine cells, as opposed to rat neurones, anti-Gi-
3, but not anti-Gi-1/Gi-2, blocked SRIF-induced stimula-
tion of IRK currents.
In rat cortical oligodendrocytes, SRIF (3 AM) inhibited
IRK currents by 58F 33%. Subsequent RT-PCR analysis
argued that rat sst1 receptors alone could be responsible for
the rapid blockade ( < 1 s) observed. It is indeed an
interesting notion that a single receptor subtype should
mediate inhibition of K+ currents, with the rest of the
receptor family engaged in stimulation of such currents
[307].
In Xenopus oocytes, Kreienkamp et al. [308] had rat
sst2–5 receptors functionally coupled to GIRK1 channels,
using the native receptor ligands SRIF-14 and SRIF-28.
While rat sst1 receptors defied functional coupling to the
effector in question, activation of sst2 receptors resulted in
the most potent regulation of K+ currents. By comparison,
human D3 receptors are known to operate GIRK2 channels
[268].
In summary, SRIF regulates different-type voltage-de-
pendent K+ currents, including the following: (1) DRK; (2)
IRK; (3) BK; (4) AK; and (5) MK currents. Furthermore,
there is evidence that SRIF also regulates single-type
voltage-independent K+ currents: LK currents. It should
be noted that KATP channels are also inwardly rectifying
[274,309]. To integrate the transduction pathway of GIRK
currents, either Gi-alpha-2 or Gi-alpha-3, also known to interact
with AC, is required for an internal ligand. With GP gating
being intrinsic to transduction terminating at GIRK chan-
nels, their activity is regulated in the simplest manner
possible with GPC receptors. SRIF tends to decrease the
electrical excitability of the cell by its effects on K+
channels. Receptor-mediated activation of K+ channels thus
results in hyperpolarisation of the plasma membrane, which
is thereby rendered refractory to the propagation of spon-
taneous action potentials. In consequence, intracellular
Ca2 + is decreased due to inhibition of the normal depolar-
isation-induced inward Ca2 + currents through voltage-gated
Ca2 + channels. The receptor subtypes sst2–5, but not sst1,
activate GIRK channels in Xenopus oocytes, with function-al coupling by the sst2 receptor being the most efficient. If
functionally coupled at all, the sst1 receptor seems be
unique in so far as it mediates inhibition rather than
stimulation of IRK currents.
3.2.7. Regulation of a sodium-proton antiporter
Awell-known function of PK-C is to activate some SPA
by phosphorylation. Na+ is allowed to enter the cell in
exchange for H+. A rising intracellular pH may thus
contribute integrally to the process of metabolic arousal
set off by the PI cascade. This transduction pathway is GP-
dependent (see above). Though inconclusive with regard to
the mechanics of R–E coupling, Barber et al. [310] were
the first to publish a study on the antagonistic effects of EN
and SRIF on intracellular pH. In enteric endocrine cells,
accumulation of cAMP is stimulated and inhibited by
activation of beta-adrenoceptors and SRIF receptors, re-
spectively. But in parallel with these shifts in cAMP
balance, which certainly presuppose GP transduction, the
GPC receptors concerned revealed an ability to regulate
Na+–H+ exchange. But SPA activity turned out to be
entirely independent of cAMP levels. Interacting with beta2
adrenoceptors, EN thus induced intracellular alkalinisation.
By contrast, activation of SRIF receptors was accompanied
by acidification. Changes in intracellular pH induced by EN
were dependent on extracellular Na+ and blocked by the
K+-sparing diuretic amiloride, which inhibits Na+–H+ ex-
change. Intracellular pH was equally insensitive to forsko-
lin, DB-cAMP, and 8Br-cAMP, which potentiate the AC
cascade at different steps in signal transduction. Prolonging
the lifetime of activated Gs, CTX decreased EC50 for EN-
stimulated cAMP accumulation (leftward shift of the dose–
response curve), but it did not affect alkalinisation mediated
by beta2 adrenoceptors. Correspondingly, PTX completely
blocked the inhibition of cAMP accumulation induced by
SRIF while unable to affect the inhibition of Na+–H+
exchange. Observations lent themselves to the notion of
parallel but strictly collateral and self-sufficient transduction
mechanisms. Regulation of SPA activity would seem to
involve some GP resistant to bacterial toxins, if indeed any
such intermediaries at all.
In a subsequent study, Ganz et al. [311] could add a
number of GPC receptors to those regulating SPA activity.
Also prostaglandin-E1 and PTH receptors may thus mediate
intracellular alkalinisation by stimulating Na+-dependent,
amiloride-sensitive Na+–H+ exchange. By contrast, dopa-
mine shares the ability of SRIF to inhibit SPA activity, with
D2 receptors heading a transduction pathway of intracellu-
lar acidification. Stimulation of Na+–H+ exchange mediat-
ed by any of the relevant receptors—beta-adrenergic,
prostaglandin-E1, and PTH—was independent of both
cAMP levels and the CTX-sensitive Gs. Correspondingly,
inhibition of SPA activity mediated by D2 receptors was
independent of the PTX-sensitive Gi. How intracellular
acidification plays a part in the pathway of apoptosis is
described in a recently published report by Thangaraju et
L.N. Møller et al. / Biochimica et Biophysica Acta 1616 (2003) 1–8434al. [312]. It emerges that receptor-mediated apoptosis is
equally dependent on acidification and dephosphorylation.
But there may also be such a thing as purely acidification-
induced, SRIF-independent apoptosis. Lowering of intra-
cellular pH to approximately 6.5 by proton-ionophore
clamping or inhibition of proton transport across the
plasma membrane (SPA, H+-ATPase) is thus followed by
activation of some PTP and apoptosis. When intracellular
pH is raised by clamping, receptor-mediated apoptosis is
completely abolished. However, SRIF retains its ability to
regulate PTP activity under these conditions. And irrespec-
tive of intracellular pH, apoptosis also becomes impossible
in the absence of a functionally intact PTP. So neither a pH
near the optimum of 6.5 nor an active PTP is itself
sufficient to induce apoptosis. Although the activity of
the PTP might appear to be somehow regulated by intra-
cellular pH, since dephosphorylation-dependent apoptosis
may well take place in the absence of SRIF, receptor-
mediated activation of PTP is actually rather insensitive to
pH changes. SRIF may induce intracellular acidification
and dephosphorylation by regulating SPA (and, possibly,
H+-ATPase) and PTP activity, respectively, but for apopto-
sis to occur, those two effects must form an integratedTable 1
Mechanisms of signal transduction receptor–effector associationsresponse. Two separate effector systems, usually thought of
in terms of parallel transduction pathways, may thus act in
concert.
3.2.8. Receptor subtypes associated with the sodium–
proton antiporter
For the purposes of detailed comparison, Hou et al.
[193] had human sst1 receptors and mouse sst2 receptors
expressed either stably in Ltk cells or transiently in HEK-
293 cells. Subtype-specific signalling pathways emerged.
High-affinity binding of the radioligand [125I]Tyr11-SRIF-
14 was reduced with similar efficacy by GTP-gamma-S in
membranes exposing either receptor subtype at their surface
(IC50 ~3 mM). PTX (100 ng/ml, 18 h) reduced agonist
binding to 63F 8% of control for human sst1 receptors—
but to 17F 4% for mouse sst2 receptors. Thus, human sst1
receptors as well as mouse sst2 receptors couple to some
GP in Ltkcells, and mouse sst2 receptors—but apparently
not human sst1 receptors—may couple exclusively to PTX-
sensitive GP subforms. When activated by SRIF-14 in
Ltkcells, either receptor subtype mediated inhibition of
forskolin-stimulated cAMP accumulation by a PTX-sensi-
tive pathway. SRIF also proved capable of lowering intra-
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a difference to SPA activity. In agreement with earlier
reports, this particular effect was shown to be resistant to
PTX treatment. A set of chimeric receptor variants were
produced to identify the sequence characteristics responsi-
ble for functional coupling of human sst1 receptors to the
SPA. Data argued that the ability of sst1 receptors to
interfere with Na+–H+ exchange requires molecular deter-
minants outside ICL-III.
Results obtained with microphysiometry argue that reg-
ulation of SPA activity may turn out to be more complex
than originally suspected. Smalley et al. [313] thus reported
that SRIF and L-362,855 lowered extracellular pH [mea-
sured by an increase in extracellular-acidification rate
(EAR)] in a bioassay using CHO-K1 cells transfected with
human sst4 receptors. With pEC50 values of 9.6 and 8.0,
respectively, SRIF and L-362,855 thus induced a dose-
dependent increase in EAR. Interestingly, PTX blocked the
pH response to either agent. N-ethylisopropyl amiloride (10Notes to Table 1:
Receptor subtypes Effectors
sst1 (i) AC
(ii) Ca2+ channe
(iii) K+ channels
(iv) SPA
(v) PTP
(vi) PL-C
(vii) MAPK kina
(viii) AMPA/kaina
sst2 (i) AC
(ii) Ca2+ channe
(iii) K+ channels
(iv) SPA
(v) PTP
(vi) PL-C
(vii) MAPK kina
(viii) AMPA/kaina
sst3 (i) AC
(ii) Ca2+ channe
(iii) K+ channels
(iv) SPA
(v) PTP
(vi) PL-C
(vii) MAPK kina
(viii) AMPA/kaina
sst4 (i) AC
(ii) Ca2+ channe
(iii) K+ channels
(iv) SPA
(v) PTP
(vi) PL-C
(vii) MAPK kina
(viii) AMPA/kaina
sst5 (i) AC
(ii) Ca2+ channe
(iii) K+ channels
(iv) SPA
(v) PTP
(vi) PL-C
(vii) MAPK kina
(viii) AMPA/kainaAM) also inhibited extracellular acidification. However,
inhibitors of PK-C (Go-6976), MAPK (PD-98059), TK
(genistein), or PTP (sodium orthovanadate) failed to inter-
fere with the pH response. It was concluded by Smalley et al.
that sst4 receptors would seem to mediate activation of some
SPA, signals being transduced by Gi/Go. That SRIF should
really stimulate Na+–H+ exchange in a PTX-sensitive man-
ner constitutes an interesting piece of information, and as it
must be said to conflict with the general tendency of reports
on sst1 receptors, it invites speculation on possible transduc-
tion mechanisms (cf. Table 1). In CHO-K1 cells stably
transfected with either rat sst2A or sst2B receptors, SRIF
induced a dose-dependent increase in EAR (rat sst2A:
pEC50 = 9.0; rat sst2B: pEC50 = 9.9). PTX treatment, howev-
er, caused a rightward shift of dose–response curves for
SRIF (rat sst2A: pEC50 = 8.3; rat sst2B: pEC50 = 8.4) [85].
Using a microphysiometer (Cytosensor), which measures
EAR in real time, Chen and Tashjian [314] identified
distinct transduction pathways operated by either sst1 orReferences
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ls [253,254]
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[193,314]
[319,328]
[194,341,346]
se [350]
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nil
[334,335]
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se [352]
te nil
[187,209,211,341]
ls nil
[308]
[313]
[335]
[341]
se [209,353,364,366,367]
te nil
[96–98,208,210,211,341]
ls [257]
[308]
nil
[337]
[341,347]
se [365]
te nil
124 SRIF receptors are not the only GPC receptors to be associated with
some PTP. Angiotensin II stimulates PTP activity by interaction with AT2
receptors. Receptor activation thus results in dephosphorylation of tyrosine
residues. Dephosphorylation of a synthetic substrate, para-nitrophenyl
phosphate, is selectively inhibited by the PTP inhibitor sodium orthova-
nadate, not by the PSTP inhibitors. Contrary to PTP activation mediated by
SRIF and dopamine receptors, however, the PTP operated by AT2 is not
affected by the guanyl nucleotides GTP-gamma-S and GDP-beta-S.
Removal of the GP by lectin-affinity chromatography does not result in
decreased PTP activity either [569]. As regards the integration of external
stimuli, mitotic regulation by SRIF has several aspects. Rodriguez-Martin et
al. [568] reported the participation of some PTP in signal transduction.
Gastrectomy in rats was found to result in both pancreatic growth and a
higher density of SRIF receptors (146% of control). Furthermore, SRIF
increased GC activity 2-fold in pancreatic acinar membranes. However,
pancreatic SRIF-like immunoreactivity decreased to 55% of control.
Similarly, PTP activity dropped to 74% of control. Numbers of SRIF
receptors, GC activity, SRIF-like immunoreactivity, and PTP activity were
corrected by addition of proglumide (20 mg/kg, IP), i.e. a gastrin/CCK-
receptor antagonist. The investigators concluded that upregulation of SRIF
receptors might constitute a cellular response to mitogenic activity induced
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123 In control/WT F4C1 cells,
which express no SRIF receptors, basal EAR remained the
same in the presence of SRIF. In cells transfected with sst1
receptors, by contrast, SRIF induced a dose-dependent
decrease in EAR. In F4C1 cells expressing sst2 receptors,
SRIF evoked a bidirectional EAR response, i.e. a rapid
increase followed by a decrease below basal. The relatively
subtype-selective SRIF analogues CH-275 and MK-678,
activating sst1 and sst2 receptors, respectively, further
corroborated these observations. While abolishing the de-
crease in EAR mediated by both sst1 and sst2 receptors,
PTX imposed but partial blockade on the increase in EAR
mediated by sst2 receptors. Methylisobutyl amiloride, an
inhibitor of the ubiquitous SPA NHE1, offered but modest
attenuation of the pH response to SRIF. However, removal
of extracellular Na+ nearly blocked the EAR response to
SRIF.
In summary, SRIF receptors may be functionally coupled
to some SPA, although transduction evidently takes place
along different pathways. So far, classical PTX-resistant
SPA activation has been observed with sst1 receptors alone,
taking place in carcinoma cells of the colon. However, sst4
receptors have appeared to be coupled in a PTX-sensitive
manner by Gi/Go to some SPA.
3.2.9. Regulation of a phosphotyrosine phosphatase
When activated by ligand binding, the tetrameric insulin
receptor (340 kDa) assumes the functional properties of a
TK, catalysing the phosphorylation of tyrosine residues in
target proteins. Forming part of the enzymatic induction
itself, the cytosolic TK domains of insulin and IGF-1
receptors undergo autophosphorylation upon ligand binding.
Also the monomeric EGF receptor (175 kDa) has evolved a
TK function. Indeed, many cellular and viral oncogenes
encode TK isozymes, including the c and v forms of src,
yes, fgr, fes, abl, ros, and erb-B. Activation of the integrated
R-E TK by an external ligand plays a major part in mitogenic
signal transduction [315]. Fitting in with the general pattern
of antisecretory and antiproliferative actions, it would un-
doubtedly testify to the omnipotence of this regulatory
peptide for SRIF to be able to interfere with phosphoryla-
tion-dependent transduction. As it happens, the evidence that
SRIF regulates PTP activity is overwhelming.124 In conflu-
ent AR42J cells, Tahiri-Jouti et al. [316] reported SMS 201–
995 to induce a rapid but transient increase in the activity of
some PTP. The enzymatic response evoked by the SRIF
analogue was dose-dependent, with half-maximal and max-
imal activation occurring at concentrations of 6 pM and 0.1
nM, respectively. 32P-labelled poly [Glu, Tyr] served as the
substrate of dephosphorylation. PTP activity was inhibited
by orthovanadate, Zn2 +, and the catalytic product poly [Glu,
Tyr] itself. Conversely, it was stimulated by EDTA and the123 F4C1 cells derive from a rat anterior pituitary tumour.reducing agent dithiothreitol. Applying gel-filtration chro-
matography (GFC) to solubilised plasma membranes, the
investigators observed a peak of catalytic activity at a relative
MW of 70,000. Comparable results were obtained by incu-
bating rat pancreatic acinar membranes with SMS 201–995
or lanreotide (BIM-23,014). Colas et al. [317] found PTP
activity to be stimulated in a dose-dependent manner, half-
maximal activation occurring at concentrations of 7 and 37
pM and maximal activation at 0.1 and 0.1–1 nM for SMS
201–995 and BIM-23,014, respectively. Similar to other
PTP isozymes, the enzyme concerned had its activity neg-
atively regulated by Zn2 +, Mn2 +, Mg2 +, and orthovanadate
while activated by dithiothreitol. Additionally, activity was
inhibited by soybean trypsin inhibitor but stimulated by
trypsin.
Purified rat pancreatic acinar plasma membranes were
prelabelled with SRIF-28 and solubilised by means of a
detergent (CHAPS). Subsequently, immobilised antibodies
raised against the amino-terminal part of SRIF-28 (anti-[S28
(1–14)]) were applied during immuno-affinity chromatog-
raphy to single out L–R complexes.125 By sodium dodecyl
sulfate (SDS) gel electrophoresis (GE) applied to the affin-
ity-purified material, a band representing a molecular mass
of 87 kDa could be generated, by the investigators identified
as the SRIF receptor.126 Purified SRIF-receptor preparations
were found to display PTP activity, with significant dephos-
phorylation of a pair of phosphotyrosine substrates: the
phosphorylated EGF (32P-EGF) receptor and 32P-poly
[Glu, Tyr]. Another protein of 66 kDa was identified in
the immuno-affinity eluate by means of polyclonal anti-
bodies raised against Src homology 2-containing PTP-1125 The linear half of the native octacosapeptide is not involved in
receptor recognition.
126 As compared to GFC, GE is characterised by higher-resolution
MW estimates.
by pancreatic growth factors such as CCK.
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noprecipitated by anti-SHPTP-1 antibodies from both prela-
belled and untreated pancreatic membranes. Accordingly, a
66-kDa PTP appears to interact directly with SRIF receptors
at the level of the plasma membrane. At any rate, there is
evidence of molecular interaction strong enough to cause
copurification; the 68-kDa SHPTP-1 has the potential to
participate in intermolecular, direct protein–protein interac-
tions, forming functional heteropolymers with membrane
proteins [318]; a rabbit polyclonal antibody was raised
against a synthetic peptide corresponding to 15 amino acids
of the carboxyl region common to human and rat SHPTP-1
isozymes, the object being to ascertain whether PTP activity
in the immuno-affinity eluate represented the workings of a
structurally related enzyme. Catalytic activity was stimulat-
ed by dithiothreitol and inhibited by orthovanadate, a
common feature of known PTP isozymes. Rat pancreatic
acinar cells highly express sst2 mRNA [319], and essential
pharmacological characteristics are shared by sst2 receptors
and the pancreatic SRIF receptors of the rat. In mouse NIH-
3T3 fibroblasts expressing the sst2 receptor, SRIF activates a
membrane-bound PTP [319–321].
In MCF-7 cells,128 SMS 201–995 induced translocation
of soluble SHPTP-1 to the plasma membrane rather than
directly stimulating the activity of the membrane-bound
enzyme. Srikant and Shen [322] found the cellular response
to SMS 201–995, including translocation and antiprolifer-
ative actions, to be dependent on GP transduction and
inhibited by orthovanadate. Using the same strain as a
model, Thangaraju et al. [312] reported SRIF to induce
apoptosis. This cellular response is paralleled, if not indi-
rectly caused by induction of the WT tumour-suppressor
protein p53, Bax, and an acidic endonuclease with a pH128 MCF-7 cells derive from a human breast adenocarcinoma.
127 SHPTP-1 is also known as PTP1C, hemopoietic cell phosphatase
(HCP), PTPN6, and SHP-1 [570]. SHPTP-1 is expressed primarily by
hemopoietic cells. In contrast with another PTP, i.e. CD45, which is
required for stimulatory signalling via several lymphoid receptors, SHPTP-
1 has been shown to play an inhibitory part in the receptor-mediated
signalling of immunocompetent cells [571]. In a study published by
Brumell et al. [570], the human isozyme was found to be localised
predominantly to the cytosol in unstimulated neutrophils. Following
induction with neutrophil agonists such as phorbol ester, chemotactic
peptide or opsonised zymosan, which decreased PTP activity by 30–60%,
a fraction of the enzyme redistributed to the cytoskeleton. Inhibition of its
catalytic activity paralleled agonist-induced phosphorylation of serine
residues in SHPTP-1. Either effect was blocked by incubating the cell
preparations with bisindolylmaleimide I, a potent and specific inhibitor of
PK-C. Proving this point, immunoprecipitated SHPTP-1 was efficiently
phosphorylated in vitro by purified PK-C. In mpl-transfected 32D cells,
megakaryocyte growth and development factor [MGDF, thrombopoietin
(TPO), c-mpl ligand] induced phosphorylation of tyrosine residues in mpl,
JAK2, SHC, SHPTP-1, and SHPTP-2 (Syp, PTP1D) [572]. In non-
hemopoietic HeLa cells, which derive from a human cervical carcinoma,
plentiful expression of SHPTP-1 resulted in decreased net phosphorylation
of tyrosine residues in the EGF receptor. By dephosphorylating this
monomeric TK, SHPTP-1 evidently opposed receptor inactivation. In
return, the EGF receptor could be seen to recruit SHPTP-1 by
phosphorylation [573]. c-mpl is one of the cytokine receptors.optimum of 6.5. Cytotoxic signals mediated by SRIF recep-
tors are transduced by SHPTP-1, but they are equally
dependent on a low intracellular pH of 6.5. Thangaraju et
al. showed that clamping of intracellular pH at 7.25 by the
proton ionophore nigericin abolished SRIF-induced apopto-
sis, apparently without affecting the induction of SHPTP-1,
p53, and Bax. On the other hand, apoptosis could be induced
by simply clamping intracellular pH at 6.5, intracellular pH
values of 6.0 and 6.7 marking the lower and upper limit of
induction, respectively. Similar to receptor-mediated signal-
ling, this purely acidification-induced apoptosis involved
translocation of SHPTP 1, and the inactive mutant enzyme
SHPTP 1C455S blocked the pathway of apoptosis. Inhibit-
ing the activity of either the SPA or H+ ATPase thus sufficed
to induce apoptosis, with intracellular pH values of 6.55 and
6.65, respectively. With regard to intracellular pH and
apoptosis, the response to SRIF equalled that of combined
SPA and H+-ATPase inhibition. To amplify the inhibitory
response to SRIF, SHPTP-1 must be recruited to the mem-
brane at an early stage in signalling. Membrane-bound
SHPTP-1 functions upstream in receptor-mediated cytotoxic
signal transduction involving intracellular acidification and
apoptosis. The anti-apoptotic protein Bcl-2 acts downstream
from SHPTP-1 and p53 to block SRIF-induced acidification,
but once intracellular acidification is established, Bcl-2 is
unable to interfere with apoptosis. Thus, overexpression of
Bcl-2 in MCF-7 cells led to blockade of SRIF-induced
apoptosis upstream from intracellular acidification due to
inhibition of p53-dependent induction of Bax, raising of the
resting intracellular pH, and curtailment of the SRIF-induced
decrease in intracellular pH. However, Bcl-2 was quite
unable to prevent apoptosis triggered by direct acidification.
Also Fas ligation results in acidification-dependent apopto-
sis, with SHPTP-1 as part of the transduction pathway [323].
Opposite effects of SRIF on the growth pattern of cancer
cells may to some extent depend on the variable expression
of PTP isozymes. Douziech et al. [63] demonstrated this
point in two separate strains, i.e. PANC-1 and MIA PaCa-
2.129 While SRIF-14 and SMS 201–995 inhibited both
basal and EGF-stimulated cell proliferation in a PANC-1
culture, a positive growth response to either of these agents
could be observed in MIA PaCa-2 cells. And, correspond-
ingly, whereas both total PTP and, in particular, specific
SHPTP-1 activity increased in response to SRIF and SMS
201–995, when these agents were added to PANC-1 cells,
total PTP activity increased but slightly in MIA PaCa-2
cells, specific SHPTP-1 activity not being detectable at all.
The absence of SHPTP-1 in the MIA PaCa-2 strain could be
confirmed by WB.
Initial hints that SRIF might regulate PTP activity,
mingled with allusions to ‘‘a cytosolic receptor for somato-
statin’’, can appear rather cryptic, especially when consid-129 Both PANC-1 and MIA PaCa-2 cells derive from an undiffer-
entiated human pancreatic adenocarcinoma.
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ever, Hierowski et al. [324] reported SRIF to induce
dephosphorylation of phosphotyrosine residues in a mem-
brane-bound protein. EGF receptors, by contrast, mediated
phosphorylation of the same target substrate. Most sugges-
tively, vanadate could be seen to interfere with SRIF action.
Using the same strain, Liebow et al. [325] went on to prove
that growth inhibition closely paralleled PTP activity as
stimulated by a selection of SRIF analogues. So the most
potent activator of PTP must, by implication, be the most
potent inhibitor of malignant cell growth. The following
rank order of potency could be obtained in MIA PaCa-2
cells: vapreotide (RC-160)>RC-121>SRIF-14>SMS 201–
995. Both RC-160 and SMS 201–995 exhibit high affinity
for human sst2 receptors [319]. But MIA PaCa-2 cells
express but endogenous sst4 receptors [94]. Besides, as
demonstrated by Douziech et al. [63], SHPTP-1 is not
expressed by the MIA PaCa-2 strain either. So it seems as
if the receptor subtype sst4 must be solely responsible for
mediating stimulatory signals to an effector that is not
identical with the single PTP isozyme known to be operated
by SRIF receptors. However, the evidence of PTP activity in
MIA PaCa-2 cells is quite substantial. Reporting on obser-
vations made with the same strain, Pan et al. [326] could
thus confirm functional coupling between SRIF receptors
and some PTP, adding the part played by some PTX-
sensitive GP in this transduction pathway.
In cells derived from human nonfunctioning pituitary
adenomas, the vast majority (90%) of which express one or
more subtypes of the SRIF receptor, both SRIF and BIM-
23,014 inhibited cell proliferation (measured as [3H]Thd
uptake) stimulated by an activator of PK-C, i.e. phorbol 12-
myristate 13-acetate (PMA). Vanadate blocked this cellular
response. In the one adenoma tested, Florio et al. [327]
found SRIF to positively induce dephosphorylation. In
parallel with stimulation of PTP activity, SRIF and BIM-
23,014 potently inhibited voltage-dependent Ca2 + currents.
3.2.10. Receptor subtypes associated with the phosphotyr-
osine phosphatase
In COS-7 and NIH-3T3 cells transfected with either
human sst1 or sst2 receptors, the effect of RC-160 and
SMS 201–995 on PTP activity was investigated. Both
analogues induced a rapid increase in PTP activity (RC-
160: EC50 = 2 pM; SMS 201–995: EC50 = 6 pM) in sst2-
expressing cells. Neither analogue reacts very well with the
sst1 receptor, and only RC-160 could stimulate PTP activity
in cells expressing this receptor subtype. The activity of AC
was not inhibited in any of the cultures expressing sst1 or
sst2 receptors. PTP was stimulated by the two analogues in
proportion to their respective receptor affinities [319]. CHO-
K1 cells were stably transfected with either rat sst1 or sst2
receptors. In both systems, cAMP accumulation was
inhibited by functional receptor coupling to AC. Further-
more, rat sst1 receptors were found to mediate stimulation of
PTP activity (EC50 = 70 nM) in a PTX-sensitive manner[328]. In CHO cells expressing either sst2 or sst5 receptors,
RC-160 inhibited proliferation induced by fetal bovine
serum (FBS) (sst2: EC50 = 53 pM; sst5: EC50 = 150 pM).
However, there was no antiproliferative effect in FBS-treated
cells expressing sst1, sst3, or sst4 receptors. In sst2-expressing
cells, orthovanadate reversed the antiproliferative effect of
RC-160. Only in these cells did RC-160 inhibit insulin-
induced proliferation and stimulate the activity of some PTP.
Activation of the PTP (EC50 = 4.6 pM) as well as inhibition
of cell proliferation (EC50 = 53 pM) and competitive binding
(IC50 = 170 pM) occurred at similar levels of the analogue.
In sst5-expressing cells, by contrast, the transduction path-
way of dephosphorylation was not involved in the antipro-
liferative effect of RC-160. Inhibitors of neither PTP nor
PSTP attenuated the cellular response to RC-160. In sst5-
expressing cells, RC-160 inhibited CCK-stimulated intra-
cellular Ca2 + mobilisation at doses (EC50 = 0.35 nM) similar
to those required to inhibit CCK-induced cell proliferation
(EC50 = 1.1 nM) and SRIF-14 binding (IC50 = 21 nM). RC-
160 had no effect on basal or carbachol-stimulated Ca2 +
levels in cells expressing sst1 – 4 receptors [329]. The
unspliced sst2A receptor was expressed in COS-7 and
NIH-3T3 cells. A number of stable SRIF analogues, i.e.
RC-160, SMS 201–995, and BIM-23,014, displaying high
affinity for this particular receptor subtype, were found to
stimulate the activity of a membrane-bound PTP. Interest-
ingly, the analogues stimulated catalytic activity and
inhibited cell proliferation in proportion to their respective
affinities for sst2 receptors. Conditions being equal, none of
the analogues affected cell proliferation in sst1-expressing
cells [321].
A completely unsuspected mechanism of antiprolifera-
tive action was reported by Rauly et al. [330]. In the absence
of exogenous ligands, expression of sst2 receptors in NIH-
3T3 cells apparently leads to inhibition of cell growth. As
demonstrated by the RT-PCR, expression of sst2 receptors
stimulates the expression of prepro-SRIF mRNA. Following
posttranslational modification, there is a production of
immunoreactive SRIF-like peptide that corresponds pre-
dominantly to SRIF-14. In this setting, antisera directed
against SRIF can be shown to reverse sst2-mediated inhibi-
tion of cell proliferation. Expression of sst2 receptors in
NIH-3T3 cells is associated with constitutive activation of
SHPTP-1, resulting from enhanced expression of the pro-
tein. Orthovanadate or antisense oligonucleotides specific
for SHPTP-1 decrease the sst2-mediated inhibition of cell
proliferation. Apart from confirming the functional coupling
of sst2 receptors to some PTP, these results provide evidence
for a negative autocrine loop. So far, however, the results
await further confirmation.
In CHO cells expressing both the sst2 receptor and
SHPTP-1, Lopez et al. [331] construed R–E coprecipitation
as evidence of direct protein–protein interaction on a consti-
tutive basis. Activation of the sst2 receptor, however, resulted
in rapid uncoupling from SHPTP-1, accompanied by an
increase in catalytic activity. In control cells, SHPTP-1
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but transient dephosphorylation of phosphotyrosine residues.
PTX blocked SRIF-induced stimulation of SHPTP-1 activity.
Gi-alpha-3 was specifically immuno-precipitated by antisera
directed against the sst2 receptor or SHPTP-1. SRIF induced
rapid uncoupling of Gi-alpha-3 from the sst2 receptor. Hence,
Gi-alpha-3 may form part of the R–E complex. SRIF inhibited
proliferation of cells coexpressing the sst2 receptor and
SHPTP-1. No such effect was detectable in cells expressing
the catalytically inactive C453S mutant SHPTP-1. It appears
that SHPTP-1, which is thus activated by the sst2 receptor in
CHO cells, leading to inhibition of insulin-induced cell
proliferation, plays a part in negatively modulating insulin-
induced mitogenic signals by direct interaction with the
insulin receptor. The mechanism signifies a sort of self-
limiting, negative feedback. Hence, SRIF inhibits insulin-
induced mitogenic signals really by potentiating dephosphor-
ylation by SHPTP 1. Activation of the insulin receptor leads
to a rapid but transient increase in tyrosine phosphorylation of
the receptor itself, its substrates IRS-1 and Shc, and SHPTP-
1. Insulin-induced phosphorylation is responsible for in-
creased SHPTP-1 activity. Concurrently, SHPTP-1 is induced
to interact with the insulin receptor. Phosphorylation of TK
substrates is reversed in this manner. Combined addition of
insulin and RC-160 results in a higher and faster increase in
SHPTP-1 interaction with the insulin receptor. This is
reflected in proportional inhibition of phosphorylation of this
receptor and its substrates, IRS-1 and Shc. RC-160 also
induces a higher and more sustained increase in SHPTP-1
activity. And RC-160 completely abolishes the effect of
insulin on SHPTP-1 phosphorylation. In CHO cells coex-
pressing the sst2 receptor and a catalytically inactive mutant
SHPTP-1, insulin as well as RC-160 failed to stimulate
SHPTP-1 activity. Overexpression of the mutant SHPTP-1
thus resulted in a breakdown of normal mechanisms of
negative feedback, i.e. termination of mitogenic signal trans-
duction by dephosphorylation of the insulin receptor did not
take place, inhibition by RC-160 of insulin-induced insulin-
receptor phosphorylation decreased, and modulation of cell
proliferation by insulin and RC-160 was abolished [332].130
A membrane-bound form of the Raf-1 serine kinase has
been shown to be inactivated by some PTP in NIH-3T3 cells
stably transfected with v-Ras. Regulation of PTP activity, in
turn, is dependent on PTX-sensitive GP transduction [333].
In NIH-3T3 cells transiently expressing the human sst3
receptor, while stably transfected with Ha-Ras, SRIF stim-
ulated PTP activity in parallel with inactivation of the
constitutively active Raf-1 [334].
In NIH-3T3 cells stably transfected with Ha-Ras (G12V),
transient expression of each receptor subtype was put to the130 Using RC-160 and CHO cells expressing the sst2 receptor, Lopez et
al. [502] disclosed yet another aspect of SRIF-induced inhibition of cell
proliferation. They found that SHPTP-1, when activated by the liganded
receptor, in turn activates the neuronal nitric oxide synthase (nNOS) by
dephosphorylation. The nitric oxide (NO) released in this way finally
activates guanylyl cyclase.test for the individual ability to mediate activation of some
PTP. SRIF-14 in combination with GMP-PNP stimulated
catalytic activity in sst2-, sst3-, and sst4-expressing cells.
This effect was sensitive to PTX. Neither the receptor ligand
nor GMP-PNP alone stimulated PTP activity. A combina-
tion of SRIF and GDP was equally impotent. Coexpression
of the sst2 receptor and a catalytically inactive Cys-to-Ser
mutant SHPTP-2 abolished the response to SRIF and GMP-
PNP [335].
Antiproliferative actions of SRIF comprise both growth
inhibition and apoptosis, either of which can be shown to
result partly from translocation of soluble SHPTP-1 to the
plasma membrane [121]. The tumour-suppressor protein p53
and the proto-oncogene product c-Myc regulate the growth-
phase succession of the cell cycle. Whereas p53-induced G1
arrest requires induction of p21, i.e. an inhibitor of cyclin-
dependent kinases, apoptosis requires induction of Bax. c-
Myc, however, is capable of blocking p53-induced G1 arrest
by interfering with p21-induced inhibition of cyclin-depen-
dent kinases. None of the human receptor subtypes but sst3,
when stably expressed in CHO-K1 cells, mediated signals for
apoptosis. Dephosphorylation-dependent conformational
changes in WT p53 and induction of Bax form part of this
cellular response to SRIF. Apoptosis does not require G1
arrest and is not dependent on c-Myc [336]. Induction of the
retinoblastoma protein Rb and arrest of the G1 phase of the
cell cycle form part of the cellular response to SRIF-trans-
mitted cytostatic signals. In CHO-K1 cells, signals mediated
by the human sst5 receptor was found to depend on both GP
transduction and PTP activity. When added directly to the
plasma membranes, however, SMS 201–995 proved incapa-
ble of stimulating PTP activity. Such activity would thus
seem to require translocation of a soluble enzyme to the level
of the plasma membrane [337]. Molecular determinants of
functional effector coupling reside for a large part in the CTT.
Apparently, they span from particular amino acid motifs to
the mere length of the CTT. The latter has recently been
illustrated by Hukovic et al. [159] in the case of GP-
dependent regulation of AC activity. According to length, a
series of carboxyl-terminally truncated human sst5-receptor
mutants failed progressively to mediate signals for growth
inhibition. This effect was closely paralleled by decreasing
PTP translocation, low levels of the hypophosphorylated
form of Rb, and unsustained G1 arrest [337]. Similar to
inhibition of cAMP accumulation, dephosphorylation of
phosphotyrosine residues mediated by SRIF receptors varies
in proportion to the length of the CTT. It should be noted,
however, that length is more than bulk. A longer CTT may
either obstruct GP coupling [145] or help stabilise interaction
with the GP heterotrimer, but it may also contain positive bits
of information in terms of conserved motifs (cf. Table 1).
Pages et al. [338] provided the first evidence that sst2-
mediated cell-cycle arrest depends on upregulation of the
cyclin-dependent kinase inhibitor p27 (Kip1). Activated
SHPTP-1 maintains high levels of this inhibitor. In CHO
cells transfected with sst2 receptors, RC-160 induced G1 cell-
132 It appeared that the secretory response to cAMP-dependen
secretagogues, i.e. PG-E2 and CTX, was inhibited in a dose-dependen
manner by both SRIF and clonidine, transduction converging at the site o
AC. While PG-E2 induced a rapid and sustained increase in short-circui
currents (Isc) across the HT29-19A monolayers, compatible with stimulated
Cl secretion, the application of SRIF (0.1 AM) to the basolateral bathing
medium at the peak of the secretory response resulted in 60–70% inhibition
of Isc. In comparison, the Isc response evoked by CTX was only inhibited
by 45–50%. Inhibition correlated with a decrease in cAMP, being blocked
by PTX at a concentration that brought about ADP ribosylation of a 41-kDa
Gi [180].
133 From a systematic viewpoint, there are several possibilities
Without exception, the GP subforms known to couple to SRIF receptors
are susceptible to ADP ribosylation by PTX. So even though PTX may
block inhibition by SRIF, completely restoring the secretion of Cl, it takes
a separate analysis to determine if it is the same GP subform that is
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part of an antiproliferative response to which p21 (Cip1/
Waf1) did not contribute. However, p27 (Kip1) occupies a
site in this transduction pathway. Activation of sst2 receptors
had the following consequences: (1) decrease in p27 (Kip1)-
cdk2 association; (2) inhibition of insulin-induced cyclin E-
cdk2 kinase activity; and (3) high levels of hypophosphory-
lated Rb. With a catalytically inactive mutant SHPTP-1
expressed in CHO cells, by contrast, entry into cell cycle
and down-regulation of p27 (Kip1) took place, irrespective of
receptor activation. Likewise, the mutant, by default, im-
posed blockade on the following cellular processes: (1)
regulation of p27 (Kip1) expression by insulin and RC-160;
(2) p27 (Kip1)-cdk2 association; (3) cyclin E-cdk2 kinase
activity; and (4) phosphorylation of Rb. A catalytically
inactive mutant such as SHP-1C455S blocked SRIF-induced
apoptosis by preventing recruitment of WT SHPTP-1 to the
membrane [323]. More recently, Held-Feindt et al. [205]
reported receptor-mediated activation of PTP, especially
SHPTP-2, by the sst2-selective nonpeptide SRIF analogue
L-054,522 in U343 cells. Secondary dephosphorylation of
EGF and PDGF receptors, tantamount to receptor inactiva-
tion, was observed, forming part of the antiproliferative
cellular response.
In summary, SRIF receptors are functionally coupled to
different-substrate phosphatases, including the following: (1)
PTP; (2) PSTP; and (3) calcineurin. With widely different
substrate specificities, these enzymes are integrated into dis-
tinct transduction pathways, the common denominator being
PTX-sensitive activation by SRIF receptors. Although hu-
man receptor subtypes are all capable of coupling function-
ally to some PTP, the individual steps in signal transduction
are still unknown. However, Gi-alpha-3 has been implicated
due to coprecipitation with the sst2 receptor and SHPTP-1. It
is uncertain whether regulation of PTP activity takes place by
direct GP interaction or is more circumstantial. The complex-
ity of intracellular signalling is brought out by the fact that
PSTP may regulate Ca2 + and K+ currents across the plasma
membrane by dephosphorylation of channel proteins.
3.2.11. Regulation of the phosphoinositide cascade
Reports on this transduction pathway have not been quite
consistent. In isolated canine parietal cells, both of the
native SRIF isoforms dose-dependently inhibited gastric-
acid secretion stimulated by secretagogues that activate both
AC and PL-C. The inhibitory transduction mechanisms
involved were partly sensitive to PTX [339].
In HT29-19A cells, Warhurst et al. [180] investigated
transduction pathways accounting for the antisecretory
response to SRIF and clonidine.131Without specification131 The secretion regulated by SRIF and clonidine concerns outward
Cl currents. The basolateral Na+–K+ATPase maintains the electro
chemical gradient driving Cl into the enterocyte from the bloodstream
Cl thus travels across the plasma membrane by symport with Na+
Subsequently, Cl is secreted to the lumen.
responsible for functional coupling of SRIF receptors to both AC and othe
effectors. Once dissociated from the receptor-activated GP, the same G
alpha could distribute itself among various target effectors. Or it might be
that, originating from the same GP heterotrimer, G-beta-gamma engages
some other enzyme or ligand-gated ion channel while G-alpha covers AC
Alternatively, inhibitory signals diverge at the site of the receptor itself
with activation of different GP subforms.-
.
.of the individual receptor subtypes involved, they found
evidence of multiple-path transduction originating from
SRIF receptors and terminating at a number of effectors.
Both SRIF receptors and alpha2 adrenoceptors mediated
inhibition of cAMP accumulation.132 An indication of
further sites of action distal to AC sprang from the
observation that SRIF and clonidine retained their ability
to inhibit secretory activity in the presence of DB-cAMP.
However, SRIF (1 AM) added at the peak of the response
evoked by DB-cAMP curtailed the increase in Isc by
merely 30–35%. That SRIF-induced inhibition should be
both PTX-sensitive and, to some extent, cAMP-indepen-
dent hinted at GP transduction downstream from cAMP
accumulation.133 Both SRIF and clonidine proved to be
potent inhibitors of Ca2 +-dependent secretion. Carbachol
(200 AM) induced but a modest increase in Isc (6–7 AA).
When added prior to carbachol-induced stimulation, SRIF
(1 AM) and clonidine (10 AM) inhibited the maximal Isc
response by 65–70%. Similar to receptor-mediated regula-
tion of AC activity by SRIF and clonidine, inhibition of
Ca2 +-dependent secretion could be blocked by PTX. Apart
from the electrical response, carbachol also induced a 3-
fold but transient increase in IP3. In turn, IP3 accumulation
led to a rapid increase in Ca2 + levels. Added to the
bioassay before the secretagogue, SRIF (1 AM) failed to
inhibit carbachol-stimulated IP3 accumulation to any sig-
nificant extent. Neither SRIF nor clonidine had any effect
on basal intracellular Ca2 +. When interfering with the
secretory response to Ca2 +-dependent secretagogues such
as carbachol, SRIF (and clonidine) would thus appear to
depend on PTX-sensitive GP transduction downstream
from both PI turnover and Ca2 + mobilisation. To define
the true sites of GP-dependent regulation, the increase in
Isc (due to Cl secretion) induced by thapsigargin and 4-
alpha-phorbol 12,13-dibutyrate (PDB), respectively, wast
t
f
t
.
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-
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136 It is indeed an astonishing line of thought that the same GP subform
should be capable of regulating the activity of different effector systems
according to the activating receptor subtype. One way to account for such a
bidirectional selectivity, i.e. downstream as well as upstream in signal
transduction, might probably be to endow various subforms of beta and
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increase in Isc (1.5F 0.1 AA/cm2 [n = 9]) across HT29-19A
monolayers. Ruling out an independent part for Ca2 +
mobilisation, SRIF (1 AM) added at the peak of this
response had no significant inhibitory effect. However, as
little as 20 nM PDB induced a larger increase in Isc
[5.1F 0.4 AA/cm2 (n = 7)]. Application of SRIF to the
basolateral surface led to a rapid decrease in Isc by
31.5F 2.5% (n = 5). By concurrent addition of thapsigargin
and PDB, synergism became evident [12.7F 1.2 AA/cm2
(n = 10)]. Under these conditions of combined stimulation,
the inhibition by SRIF amounted to 29.0F 6% (n= 5). At
least in HT29-19A cells, therefore, activation of PK-C—
rather than mobilisation of Ca2 +—could represent the
decisive step in stimulatory signal transduction though there
is clearly a synergistic cooperation between the enzymatic
amplifier and third messenger in question. If the ability of
SRIF to inhibit the secretory response evoked by a Ca2 +-
dependent secretagogue such as carbachol depends, at least
in part, on regulation of PK-C activity or any of its
substrates, it may open up new alleys of speculation.
Despite the obvious difference in substrate specificity, some
kind of enzymatic antagonism might be established within
the framework of a putative PTP. Alternatively, the opposite
effects on intracellular pH brought about by PK-C and
hitherto unidentified transducers of SRIF receptor-mediated
signalling may point to the SPA as the true site where
transduction pathways converge (see above).
3.2.12. Receptor subtypes associated with the phosphoino-
sitide cascade
In COS-7 cells transfected with the human sst2 receptor,
Tomura et al. [340] found receptor-mediated signals to
diverge along separate transduction pathways. Not only did
SRIF inhibit forskolin-stimulated cAMP accumulation
(EC50 ~ 100 pM). It also stimulated accumulation of the
second messenger IP3. While completely disinhibiting AC
activity, PTX (100 ng/ml, 18 h) imposed but partial blockade
on the other component of the cellular response, i.e. SRIF-
stimulated PL-C activity, IP3 accumulation, and Ca
2 + mobi-
lisation. In COS-7 cells expressing human sst1 receptors, by
contrast, regulation of either cascade must be characterised
as rather inefficient. SRIF at concentrations of up to 100 nM
thus failed to evoke any detectable response.135 The findings
of Tomura et al. were extended in a subsequent study. In
COS-7 cells transfected with the cDNA of human sst3, sst4,
or sst5 receptors, receptor activation led to a substantial
increase in intracellular Ca2 +. Meanwhile, extracellular135 COS-7 cells express endogenous P2-purinoceptors. Both SRIF and
ATP induce transient rises in Ca2 + levels by mobilising Ca2 + predom-
inantly from intracellular stores. Signalling by ATP is PTX-resistant. As
could be verified with EGTA, extracellular Ca2 + has little part in rising
Ca2 + levels [340].
134 Thapsigargin raises intracellular Ca2 + by depletion of intracellular
stores, and PDB activates PK-C without significantly increasing PI
turnover.Ca2 + was kept down by EGTA. All receptor subtypes, i.e.
including human sst1 and sst2 receptors, were capable of
mediating the activation of PL-C. While consistently inhib-
iting the activity of PL-C, PTX proved to be relatively more
efficient at lower doses of SRIF. Differential coupling
efficiency with regard to PL-C was reported for the various
human receptor subtypes, with the following rank order
of potency after receptor activation by 1 AM SRIF:
sst5>sst2>sst3>sst4Hsst1. Functional coupling of human
sst3, sst4, and sst5 receptors to AC was reconstituted, for-
skolin-stimulated cAMP accumulation being inhibited in a
PTX-sensitive manner. But at increasing doses of SRIF
(above 10 nM), inhibitory signals mediated by the human
sst5 receptor gradually decreased in potency. And, interest-
ingly, this particular receptor subtype furthermore revealed
an apparent potential to activate AC in cells pretreated with
PTX [341]. It might be hypothesised that human sst1–5
receptors preferentially couple to the PTX-sensitive Gi-alpha/
Go-alpha at lower doses of SRIF. But human sst2, sst3, and sst5
receptors may also couple to the PTX-resistant Gq-alpha to
activate PL-C at higher doses. Several AC isozymes (type
I–VI) have been identified, varying in their individual Ca2 +/
calmodulin sensitivity [342]. Type II, V, and VI have been
shown to be activated by receptors functionally coupled to
PL-C via activation of PK-C and Ca2 + mobilisation [343].
In CHO cells stably expressing human sst1 receptors
(CHO-SR1), SRIF-14 dose-dependently inhibited forsko-
lin-stimulated cAMP accumulation (ED50 = 1.0 nM). In
addition, SRIF-14 stimulated IP3 accumulation in a dose-
dependent manner (ED50 = 40 nM). Either effect was
blocked by PTX. Also carbachol stimulates PIP2 hydrolysis
in CHO cells, and the respective effects of carbachol and
SRIF are additive. Carbachol-stimulated IP3 accumulation,
however, is not affected by PTX. While the Gi subforms
Gi-alpha-2 and Gi-alpha-3 are both endogenous to CHO cells,
Gi-alpha-1 is not. Antiserum (EC/2) directed against Gi-alpha-3
blocked inhibition of cAMP accumulation by SRIF-antise-
rum (AS/7) directed against Gi-alpha-1/Gi-alpha-2 did not [194].
Other investigators had originally assigned this particular Gi
subform, i.e. Gi-alpha-3, to the transduction pathway of K
+
currents, transducing positive regulation mediated by sst2
receptors [168,220].136 Although the SRIF-induced stimula-gamma subunits with the ability to bind Gi-alpha-3 interchangeably,
conferring differential functionality: when binding one dimer of G-beta-
gamma subforms, Gi-alpha-3 would specifically interact with sst2 receptors,
regulating K+ currents, and when binding another, it would interact with
sst1 receptors and subsequently inactivate AC. However, this is not at all
how it works elsewhere; actually, the GP seems to come as a package,
assembled from invariant subunits (cf Go). If not put down to cell-specific
expression, it also remains to be clarified how an activated alpha subunit,
dissociated from the G-beta-gamma dimer, should be able to distinguish
between alternative effector systems.
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cloned Gq subforms display target sites for ADP ribosyla-
tion. Kubota et al. [194] therefore proposed that the G-beta-
gamma dimer derived from the activated GP might activate
PL-C. This model would imply two parallel signalling
pathways, the activated GP alone—rather than the recep-
tor—providing the site of transductional divergence. This
hypothesis has subsequently been confirmed byMurthy et al.
[344]. In smooth-muscle cells of the intestine, endogenous
sst3 receptors were coupled to Gi alpha-1 and a Go-alpha; but
whereas G-alpha inactivated AC in each case, the G-beta-
gamma dimer of either GP subform specifically activated the
isozyme PL-C-beta-3 (cf. Table 1).
In confluent monolayers of SH-SY5Y cells,137 neither
NP-Y (30–100 nM) nor SRIF (100 nM) could increase
intracellular Ca2 + in the absence of carbachol. But when
applied in combination with carbachol (1 or 100 AM), both
NP-Y (300 pM–1 AM) and SRIF (300 pM–1 AM) added
significantly to the rise in intracellular Ca2 + resulting from
activation of muscarinic cholinoceptors. In the presence of 1
AM carbachol, SRIF thus raised intracellular Ca2 + with a
pEC50 of 8.24. However, atropine (1 AM) or PTX (200 ng/
ml, 16 h) abolished the rise in intracellular Ca2 + induced by
NP-Y or SRIF. By contrast, the cellular response to carba-
chol showed but little sign of PTX sensitivity. An activator
of Ca2 + channels, maitotoxin (2 ng/ml), raised intracellular
Ca2 + without any positive contributions from NP-Yor SRIF
being recorded subsequently. Both these compounds, when
combined with carbachol, preserved the ability to raise
intracellular Ca2 + in a nominally Ca2 + free external buffer.
Thapsigargin (100 nM), however, blocked Ca2 + mobilisa-
tion stimulated by NP-Y or SRIF. Connor et al. [345] tested
a series of SRIF analogues for their ability to raise intracel-
lular Ca2 +, with the following rank of potency coming out:
BIM-23,027> or = SRIFHL-362,855HBIM-23,056. The
investigators considered this compelling evidence that the
SRIF receptor involved (in activation of PL-C) must be sst2.
In F4C1 cells, exogenous sst2 receptors, when activated
by MK-678, mediated stimulation of PL-C and Ca2 +
mobilisation. This cellular response proved but partially
PTX-sensitive. Activation of sst1 receptors, also the result
of transfection, by the relatively subtype-selective SRIF
analogue CH-275 failed to evoke a similar response in the
bioassay used [254].
Similar to the mu-opioid receptor, Lee et al. [346] reported
functional coupling between delta-opioid receptors and PL-C
to be dependent on coexpression of the PTX-sensitive G16 in
COS-7 cells. In this particular bioassay, where delta-opioid
receptors could be seen to be expressed at higher levels than
kappa-opioid and mu-opioid receptors, though all exoge-
nous, Lee et al. found activation of PL-C increasingly weak
when mediated by kappa-opioid and mu-opioid receptors.
Activation of adenosine (A1) receptors, alpha2 and beta2
adrenoceptors, C5a, dopamine (D1 and D2), formyl-peptide,138 CCL-39 cells are lung fibroblasts derived from the Chinese
hamster.137 SH-SY5Y cells derive from a human neuroblastoma.LH, and SRIF (sst1 and sst2) receptors resulted in stimulation
of PL-C activity, with maximal stimulations ranging from
1.5- to almost 17-fold.
Siehler and Hoyer [347] investigated the ability of indi-
vidual receptor subtypes to regulate the activity of PL-C in
stably transfected CCL-39 cells.138 SRIF-14 (10 AM) stim-
ulated [3H]IP3 accumulation by 200% and 1070% in CCL-39
cells expressing human sst3 and sst5 receptors, respectively.
Similarly, intracellular Ca2 + rose by 1600% and 2790%
during activation of sst3 and sst5 receptors, respectively.
PTX (100 ng/ml) imposed but partial blockade on SRIF-
stimulated IP3 accumulation, i.e. 30% and 15%, respectively.
Human sst1, sst2, and sst4 receptors, however, mediated but
weak or no stimulation of PL-C activity (Emax = 114%,
122%, and 102%, respectively). Siehler and Hoyer found
that, in CLL-29 cells, most SRIF analogues tested behaved
as full agonists at human sst3 receptors (Emax = 218–267%),
and agonist-induced PI turnover correlated well with radio-
ligand binding, [35S]GTP-gamma-S binding, and inhibition
of cAMP accumulation. At sst5 receptors, by contrast, Emax
reflected L–R interactions varying from nearly full agonism
(MK-678, CST-17, SRIF-28), compared to receptor activa-
tion by SRIF-14, to very low partial agonism (SMS 201-995,
BIM-23,052), and the agonist-induced PI turnover correlated
rather poorly with radioligand binding, [35S]GTP-gamma-S
binding, or inhibition of cAMP accumulation.
In Epstein–Barr virus-immortalised B lymphoblasts, by
the RT-PCR found to express the receptor subtype sst2A
solely, Rosskopf et al. [348] observed SRIF-induced stim-
ulation of IP3 accumulation.
In summary, SRIF receptors may activate either of the
phospholipases PL-A2 and PL-C. The former has been found
to release AA in hippocampal neurones while the latter is
responsible for IP3 accumulation in various bioassays, in-
cluding astrocytes and smooth muscle cells of the intestine.
In transfected CHO-K1 cells, the sst4 receptor mediates
stimulation of PL-A2 activity in a PTX-sensitive manner.
Working downstream in signal transduction, PL-A2 has been
reported to occupy a site in the MAPK cascade (see below).
Both sst2A and sst5 receptors stimulate IP3 accumulation in
transfected COS-7 and F4C1 cells. However, the sst5 receptor
can apparently also mediate the opposite effect on PL-C,
inhibiting IP3-induced Ca
2 + mobilisation in transfected
CHO-K1 cells. In fact, all known receptor subtypes may
be functionally coupled to PL-C. It is thought that SRIF
regulates the activity of PL-C, with dimeric G-beta-gamma
(released from Gi-alpha-1 or Go-alpha) rather than monomeric
Gq-alpha transducing the receptor-mediated signals.
3.2.13. Regulation of the mitogen-activated protein-kinase
cascade
It took a while before investigators, having consistently
reported on positive regulation of MAPK activity by SRIF,
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finding, of course, represented something of a puzzle. The
well-known position of the cascade reaction in mitogenic
signal transduction harmonised little with the notion of
SRIF as the ubiquitous inhibitor of cell proliferation. How-
ever, rather more agreeable results eventually came out in a
report published by Cattaneo et al. [349]. The human strains
SY5Y and H-69139 provided the major bioassays. It was
shown that BIM-23,014, reasserting the antiproliferative
potential of SRIF, could potently inhibit [3H]Thd incorpo-
ration in both SY5Y and H-69 cells. The relative activity of
MAPK reflected this cellular response. In SY5Y cells, BIM-
23,014 (1 nM) completely inhibited MAPK activity stimu-
lated by FBS (20%), IGF-1 (100 ng/ml), or carbachol (1
mM). Under similar conditions, BIM-23,014 also inhibited
FBS-stimulated MAPK activity in H-69 cells. When treating
either SY5Y or H-69 with BIM 23,014, there was a
concomitant, though strictly collateral, decrease in cAMP.
In other words, cAMP had no part in mitogenic signal
transduction, and the observed shift in cAMP balance could
not be causally linked to growth inhibition. In fact, 8Br-
cAMP (1 mM) inhibited incorporation of [3H]Thd stimu-
lated by FBS (10%) (SY5Y and H-69 cells) or IGF-1 (100
ng/ml) (SY5Y cells). Furthermore, forskolin (50 AM) com-
pletely inhibited MAPK activity stimulated by FBS (20%)
in both H-69 and SY5Y cells. Intracellular Ca2 + and pH
were not affected by the SRIF analogue.
In PANC-1 cells, SRIF-14 and SMS 201-995, while
activating SHPTP-1, inhibited the activity of a membrane-
bound TK and p42-MAPK in parallel with inhibition of
basal and EGF-stimulated cell proliferation. In MIA PaCa-2
cells, by contrast, both SRIF-14 and SMS 201–995 stimu-
lated the activity of a membrane-bound TK but did not
modify the p42-MAPK and p44-MAPK, which are consti-
tutively active in the strain concerned. The activity of p38-
MAPK was also not affected [63].
3.2.14. Receptor subtypes associated with the mitogen-
activated protein-kinase cascade
In CHO-K1 cells stably transfected with the sst1 recep-
tor, SRIF inhibited cell proliferation stimulated by fibro-
blast-growth factor (FGF) while capable of both
stimulating MAPK activity and potentiating FGF-stimulat-
ed activity of this enzyme. sst1-mediated activation of
MAPK, which boosted expression of the cyclin-dependent
kinase inhibitor p21 (Cip1/Waf1), is sensitive to PTX and
evidently depends on the small GP Ras,140 phosphatidyl
inositol 3-kinase (PI3K), the serine/threonine kinase Raf-1,
and SHPTP-2 [350]. PI3K is known to be a negative
regulator of cellular differentiation [351].
In MIN-6 cells,141 there is an endogenous expression of
the sst3 receptor solely. SRIF, whose antiproliferative140 Compare the findings of Mori et al. [357] in the above.
141 MIN-6 cells derive from a mouse insulinoma.
139 H-69 cells derive from a human small-cell lung carcinoma.actions were evident, significantly inhibited c-fos ex-
pression stimulated by FBS. However, the cellular response
to SRIF turned out to be biphasic. SRIF (100 nM) thus
transiently increased c-fos expression levels to 282F 4.7%
before decreasing them to 27F 7.6% of basal (as set by
10% FBS). In parallel, MAPK activity first increased to
656F 91.2% and then decreased to 39F13.3% of basal. In
contrast with the late-phase response, the early-phase re-
sponse was resistant to PTX treatment [352].
High levels of both PAF and sst4 receptors are present
in rat hippocampus. Functional coupling of these recep-
tors to sites in the MAPK cascade, including PL-A2, has
been a consistent finding in CHO cells [353]. Early
reports claimed SRIF receptors to play a regulatory part
with regard to PL-A2 in striatal astrocytes, stimulating
enzymatic activity. From this evidence alone, SRIF might
be able to regulate AA release, feeding the biosynthetic
transduction pathways of cyclo- and lipoxygenases [354].
Before then, SRIF had been shown to participate in
regulation of membrane conductance in rat hippocampal
neurones [355]. As the rat sst4 receptor has been shown
to be the predominant receptor subtype in the hippocam-
pus [95,276,356], it was stably expressed in CHO-K1
cells by Bito et al. [209] in order to study the exact
mechanisms of signal transduction. It became clear that
sst4 receptors are associated with multiple parallel signal-
ling pathways, mediating the following effects: (1) inhi-
bition of cAMP accumulation; (2) stimulation of AA
release; and (3) activation of the MAPK cascade. AA
release typically forms part of metabolic events including
an increase in intracellular Ca2 +. Nevertheless, stimulation
of neither IP3 accumulation nor Ca
2 + mobilisation was
mediated by sst4 receptors, ruling out the participation of
PL-C. MAPK-dependent phosphorylation of myelin-basic
protein (MBP) proved to be dose-dependently stimulated
via ligand-activated sst4 receptors. Similarly, phosphory-
lation of a kinase-deficient recombinant MAPK by
MAPK kinase was stimulated by SRIF. Release of AA
thus appears to result from at least five consecutive steps
in signal transduction: (1) receptor activates GP; (2) GP
activates MAPK kinase; (3) MAPK kinase activates
MAPK; (4) MAPK activates PL-A2; and (5) PL-A2
hydrolyses triacylglycerol (TAG) to form AA and DAG.
Apart from cAMP accumulation being disinhibited, AA
release as well as activation of MAPK and MAPK kinase,
respectively, were found to be abolished by PTX. This is
the reason why some GP—by analogy with receptor-
mediated regulation of AC activity and various ion
currents—is proposed to be operative in the cascade
reaction. Even so, regulation of MAPK-kinase activity
at a site distal to the GP could be more complex than
indicated. Functional coupling of sst4 receptors to the
separate effector systems characterised displayed compa-
rable ED50 values, being in the nanomolar order. Accord-
ing to Mori et al. [357], activation of the MAPK cascade
mediated by either PAF or SRIF receptors did not appear
142 In U343 cells, according to Held-Feindt et al. [205], sst2A-receptors
mediated inhibition of ERK 1 and 2 by dephosphorylation.
143 Similar to AMPA/kainate receptors, the NMDA receptor, which is
abundant in hippocampus, is a cation receptor. In other respects, however, i
differs from AMPA/kainate receptors: (1) functional integrity, including
sensitivity to glutamate, depends on binding of glycine; and (2) at the
resting membrane potential, the channel is blocked by Mg2 +, this cationic
blockade being lifted by partial depolarisation of the postsynaptic
membrane alone.
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unlike the SRIF receptor, is but partially sensitive to PTX.
The observation that sst4 receptors may activate MAPK
kinase/MAPK via a PTX-sensitive GP was the first to
support a direct association of a SRIF receptor with a
phosphorylation cascade proper. Implications are potentially
manifold. Finding a SRIF receptor at the head of a mitogenic
signalling pathway may have been somewhat unsuspected,
considering the overall antiproliferative actions of SRIF;
thus, MAPK has been shown to relate intimately to the
products of oncogenes [358,359]. On the other hand, AA and
its metabolites have been shown to take part in the regulation
of ion-channel activity in such a way as to fit in with the
general characterisation of SRIF action [360]. Different-type
K+ currents, including Sk, DRK, BK, muscarinic K+, and
MK currents, are modulated by those soluble agents. Acti-
vation of PL-A2 might partly account for the PTX-sensitive
and cAMP-independent regulation of some K+ currents
mediated by SRIF receptors [294,300,361–363]. In CHO-
K1 cells copiously expressing the rat hippocampal receptor
subtype sst4, the mechanisms of AA release came under
closer scrutiny, following the initial reports by Bito et al.
[209]. Rat sst4 receptors mediated activation of MAPK and
furthermore induced phosphorylation of the 85-kDa cytosol-
ic PL-A2 via PTX-sensitive pathways. At similar IC50
values, both effects could be blocked by wortmannin. AA
release from these cells was strongly stimulated by a com-
bination of SRIF-14 and Ca2 + ionophore [364].
Cordelier et al. [365] reported that, in CHO-K1 cells
expressing endogenous CCK receptors and stably trans-
fected with the human sst5 receptor, proliferation and
activation of MAPK both depended on signals transduced
via the stimulatory pathway of GC. Inhibitors of the soluble
GC, cGMP-dependent kinases, and MAPK kinase, i.e. LY-
83583, KT-5823, and PD-98059, respectively, each blocked
mitogenic signals mediated by CCK receptors. Such signals
were also sensitive to PTX. The increase in cGMP induced
by CCK could be virtually abolished by LY-83583. KT-
5823 inhibited CCK-induced phosphorylation and activa-
tion of p42-MAPK. RC-160, which did not potentiate the
antiproliferative actions of LY-83583 or KT-5823, inhibited
both CCK-stimulated cGMP accumulation and the activity
of p42-MAPK (cf. Table 1).
In a bioassay comprising CHO-K1 cells transfected with
human sst4 receptors, SRIF induced phosphorylation of
extracellular signal-regulated kinase (ERK) 1 (p42) and 2
(p44). Such modification formed part of a general prolifer-
ative response to SRIF, paralleling activation of MAPK. In
the acute phase of ERK phosphorylation, culminating 10
min after SRIF application, the cellular response could be
blocked by PTX and attenuated by either the Src inhibitor
PP1 or the beta-gamma-sequestrant transducin, while resis-
tant to the MEK1 inhibitor PD-98059. After 4 h, phosphor-
ylation was sensitive to both PTX and transducin, resistant
to PP1, and abolished by PD-98059. Inhibition of PK-C led
to a total blockade of the proliferative response evoked bySRIF. Expression of Ras (N17) made virtually no difference
to SRIF-stimulated cell proliferation as such. However, it
did attenuate acute-phase phosphorylation of ERK. Prolif-
erative signals were specifically and consistently blocked by
PD-98059 [366].142
Smalley et al. [367] reported that both SRIF and L-
362,855, when interacting with human sst4 receptors
expressed in CHO-K1 cells, transiently stimulated the
activity of p42/p44-MAPK. Receptor desensitisation, with
lack of regulatory coupling to effector, could be induced by
sustained exposure to SRIF only. A selective PI3K inhibitor,
i.e. LY-249,002, blocked both SRIF-induced phosphoryla-
tion of MAPK and the concomitant increase in EAR.
However, PD-98059 blocked receptor-mediated activation
of MAPK alone, not the pH response to SRIF.
In summary, SRIF receptors with the pharmacological
profile of SRIF1 receptors mediate inhibition of MAPK
activity, sst2, sst3, and sst5 receptors being functionally
coupled to this effector in SY5Y, NIH-3T3 (also mouse
insulinoma), and transfected CHO-K1 cells, respectively.
By contrast, receptor subtypes corresponding to the phar-
macological receptor subclass represented by SRIF2 recep-
tors, i.e. sst1 and sst4 receptors, mediate activation of MAPK
in transfected CHO-K1 cells. Although the transduction
pathway is blocked by PTX, individual GP subforms
involved have not yet been identified.
3.2.15. Regulation of (R,S)-alpha-amino-3-hydroxy-5-meth-
yl-4-isoxazole propionic acid/kainate receptors
Glutamate and aspartate are excitatory amino acids.
AMPA/kainate receptors are cation channels.143 When
liganded by glutamate, they are activated, with both Na+
and K+ currents being stimulated. Due to the high electro-
chemical Na+ gradient, however, Na+ currents predominate,
resulting in depolarisation of the postsynaptic membrane.
Under patch-clamp conditions, Viollet et al. [368] reported
SRIF-14 to modulate the glutamate sensitivity of mouse
hypothalamic neurones with either stimulatory or inhibitory
actions, the former being imitated by CH-275, the latter by
SMS 201–995. In a subsequent study, the investigators
confirmed their initial observations, finding that SRIF either
potentiated or attenuated the electrical response to gluta-
mate, peak currents being stimulated by 30% and inhibited
by 49%, respectively. In terms of changes in mean current
amplitude during receptor activation, neither of the synthetict
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PTX blocked regulation of glutamate-stimulated currents by
SMS 201–995 alone, restoring the EPS potentials of hypo-
thalamic neurones. By contrast, receptor-mediated actions
of CH-275 thus turned out to be insensitive to PTX.
Modulation by the endogenous ligand itself, which activates
every receptor subtype equipotently, varied similarly in
response to PTX [369]. In CA1 pyramidal neurones of rat
hippocampus, SRIF reversibly attenuated EPS potentials
generated via AMPA/kainate receptors (IC50 = 22 nM;
Emax = 100 nM). Sensitivity of SRIF action to the alkylating
agent N-ethylmaleimide suggested transduction by either Gi
or Go subforms [303].
3.2.16. Receptor subtypes associated with (R,S)-alpha-
amino-3-hydroxy-5-methyl-4-isoxazole propionic acid/kai-
nate receptors
Based on the relative subtype selectivities of CH-275
and SMS 201–995, having also investigated the subtype-
specific expression pattern of SRIF receptors in mouse
hypothalamic neurones [368], Lanneau et al. [369] allowed
themselves to conclude that the mouse sst1 receptor
mediates the PTX-resistant increase in sensitivity to gluta-
mate while the mouse sst2 receptor is responsible for
mediating the PTX-sensitive decrease in sensitivity to
glutamate.
In summary, two receptor subtypes have so far been
associated with AMPA/kainate receptors. However, sst1
and sst2 receptors evidently mediate opposite effects on
neuronal sensitivity to glutamate. Physiological implications
of signalling via this transduction pathway await further
investigation.4. Pharmacology of somatostatin receptors
The need to distinguish between more receptor subtypes
was first brought into focus by the observation of differen-
tial binding of the synthetic SRIF analogues CGP-23,996
and MK-678 in rat brain. Binding sites with high affinity for
the cyclic hexapeptide, as stated in the above, were to be
referred to as SRIF1 receptors [181]. Albeit with varying
affinities, [125I]CGP-23,996 labels several receptor subtypes
in rat brain [192]. Furthermore, SRIF1 and SRIF2 receptors
are not straightforwardly identical to sst2 and sst1 receptors,
respectively, as indicated by some investigators [168,304].
The truth is that cloned sst1 and sst2 receptors rather
constitute prominent members of the pharmacological re-
ceptor subclasses represented by SRIF2 and SRIF1 recep-
tors, respectively. And the original categories, of course, are
inadequate in so far as they neglect the results of recombi-
nant technology. They cannot fully capture the individual
properties of presently five cloned receptor subtypes. At the
time, however, the distinction between SRIF1 and SRIF2
receptors was useful for laying down guidelines for future
investigations.Similar reservations apply to studies of signalling path-
ways and pharmacological properties of particular receptor
subtypes: to a great extent, results vary with the cellular
model systems (bioassays) used in each case. So as with the
functional coupling of receptor to effector, reports on the
relative binding affinities of both native receptor ligands and
synthetic analogues tend to conflict.
4.1. Biological characterisation of endogenous
somatostatin
In acknowledgment of the native peptide heterogeneity, it
soon became a topic whether the two SRIF isoforms, with
seemingly distinct patterns of expression, were specifically
adapted for acting via particular routes or interacting with
particular receptor subtypes [370]. For instance, it was
hypothesised that SRIF-14 might preferentially serve as a
paracrine transmitter in places like the gastric antrum,
modulating the metabolism of neighbouring G cells and
parietal cells [371]. In a similar vein, SRIF-28 would be
better suited to resist the degradation by proteases of the
bloodstream, acting long-distance and evoking a systemic
response. Before anything definite was suspected about
receptor diversity and ligand specificity, all sorts of spec-
ulations were nourished by observations from rat neocortical
neurones. Both peptide isoforms were found to inhibit Ca2 +
currents. But as to the regulation of K+ currents, not only did
one study show lack of cross-desensitisation to SRIF-14 and
SRIF-28; apparently, in another study, the two peptides also
induced opposite effects on K+ currents [362,372,373]. As a
rule, it is hard to make sense of such transmitter-specific
transduction originating from the same receptors. In theory,
of course, receptor ligands may induce different conforma-
tional changes, according to their individual structure.
However, closer scrutiny of data may reveal competing
sources of confusion. Irrespective of length, reduction of
the disulfide bridge and consequent linearisation of either
SRIF isoform result in a loss of binding and biological
activity [374]. Endogenous ligands at SRIF receptors, in-
cluding rat CST-14 and human CST-17, display comparable
high binding affinities. Unlike the majority of presently
available synthetic analogues, they bind well to all receptor
subtypes without exception, behaving as full agonists [75].
A determinant of high-affinity binding appears to be a
stretch of amino acids, i.e. Phe7-Trp8-Lys9-Thr10, which is
shared by the native receptor ligands and a number of
synthetic SRIF analogues, including the cyclic hexapeptide
L-363,301, the two cyclic octapeptides SMS 201-995 and
L-362,823, the cyclic decapeptide CGP-23,996 and the five
CGP-23,996-like cyclopeptides SA, II, IV, V, and L-
362,862, and the two linear peptides BIM-23,052 and
BIM-23,068. The residues of this central tetrapeptide form
a beta bend (BB). Stabilisation of this secondary-structure
element has been thought to be essential to the bioactivity of
peptide analogues. Cyclic or bicyclic constraints such as
may be introduced by a disulfide (cystine) bridge or/and an
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(see below). But synthesising a reliable bioactive analogue
for experimental as well as therapeutic purposes is not
merely a question of attaining the appropriate stereometry.
The endogenous peptides are extremely short-lived. Half-
lives of SRIF-14 and SRIF-28 are reported to be 1.1–3.0
and 1.9–2.5 min, respectively, upon intravenous infusion
[375]. Modification of key residues in the primary structure
is therefore required to ensure the relevant properties,
exemplified by a classical compound like SMS 201–995.
Four structural elements are alleged to confer the desired
combination of metabolic stability and high specificity: (1)
the amino terminal D-phenylalanine; (2) the carboxyl-termi-
nal amino-alcohol threoninol; (3) the D-tryptophan; and (4)
the disulfide bridge [376]. The D-phenylalanine recurs in the
three octapeptides RC-160, BIM-23,034, and NC4-28B and
the five linear peptides BIM-23,052, BIM-23,056, BIM-
23,058, BIM-23,066, and BIM-23,068; the D-tryptophan in
the three hexapeptides BIM-23,027, MK-678, and L-
363,301, the heptapeptide BIM-23,030, the six octapeptides
RC-160, BIM-23,034, BIM-23,014, BIM-23,042, NC4-
28B, L-362,823, the seven CGP-23,996-like peptides SA,
II, III, IV, V, L-362,855, and L-362,862, and the five linear
peptides BIM-23,052, BIM-23,056, BIM-23,058, BIM-
23,066, and BIM-23,068; and the disulfide bridge in the
heptapeptide BIM-23,030 and the six octapeptides RC-160,
BIM-23,034, BIM-23,014, BIM-23,042, NC4-28B, and
L-362,823.144
With regard to the larger isoform SRIF-28 (Ser-Ala-Asn-
Ser-Asn-Pro-Ala-Met-Ala-Pro-Arg-Glu-Arg-Lys-Ala-Gly-
c[Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys]),
early reports offered some evidence of B-cell and brain
selectivity of action. In vivo, SRIF-28 was found to be
apparently 380 times as potent as SRIF-14 (Ala1-Gly2-
c[Cys3-Lys4-Asn5-Phe6-Phe7-Trp8-Lys9-Thr10-Phe11-Thr12-
Ser13-Cys14]) to inhibit arginine-stimulated insulin secre-144 The tetrahedral array of four different groups about the alpha
carbon atom (C-1) confers optical activity on amino acids. The two mirror
image forms are referred to as the L isomer and the D isomer, and they form
an enantiomeric pair. A molecule that is not congruent with its mirror image
is chiral. A chiral molecule has handedness and hence is optically active. A
molecule with n asymmetrical centres and no plane of symmetry has 2n
stereoisomeric forms. Biologically isolated alpha-amino acids normally
have the L configuration, i.e. they belong to the same stereochemical series
With the exception of the simplest amino acid glycine, which has a single
hydrogen atom for a side chain, all alpha-amino acids have at least one
asymmetrical carbon atom, i.e. the beta-carbon atom (C-2). The alpha
carboxyl group of one amino acid is joined to the alpha-amino group o
another amino acid by an amide bond. During the formation of such amide
bonds, the asymmetrical carbon atom of the substituted methylen group is
preserved, with the potential for enantiomerism thus being passed on to
peptides. The insertion of D isomers, as opposed to native amino acids in
the L configuration, into the synthetic peptides is a simple but ingenious
device. SMS 201–995 has a half-life in plasma of approximately 90 min
However, inversion of the chirality not only provides relative protection
against the in vivo degradation by proteases. It may also result in dramatic
changes of peptide action. This has been clearly illustrated during the
synthesis of receptor antagonists (see below). 145 Notice special SRIF numbering!-
-
.
-
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.tion.145 However, SRIF-28 was only three times as potent as
SRIF-14 to inhibit arginine-stimulated glucagon secretion
[377]. GRP acts within the brain to produce a prompt and
sustained hyperglycemia, hyperglucagonemia, and relative
or absolute hypoinsulinemia. When applied intracisternally,
as opposed to systemically, SRIF decreases this hypergly-
cemia and hyperglucagonemia [378,379]. It turned out that
SRIF-28 was 10 times as potent as SRIF-14 to inhibit
bombesin-induced hyperglycemia in the CNS [377]. Other
reports lend support to these observations. In a membrane
preparation derived from a hamster insulinoma, the equilib-
rium dissociation constant (KD) for SRIF-28 (1 nM) was
found to be more than five times lower than that for SRIF-
14 [380]. However, the most striking results in support of a
‘‘SRIF-28-selective’’ receptor subtype, judged by the direct
evidence of inhibition studies rather than physiological
parameters, were published by O’Carroll et al. [97]. Binding
competition quickly sketched out a unique pharmacological
profile for the cloned rat sst5 receptor. In COS-7 cells
expressing rAP6-26 cDNA, SRIF-28 proved to be the most
potent competitor of radioligand binding, displaying an
almost 30-fold higher affinity than SRIF-14. Exposure of
membrane preparations to GTP or Na+ lowered binding
affinity of the radioligand [125I]Tyr11-SRIF-14 itself. But
evidence to the contrary has also emerged. CHO cells stably
transfected with either sst1 or sst2 receptors were found to
exhibit an apparently higher affinity for SRIF-14 than SRIF-
28 [77]. In COS-1 cells transiently expressing rat sst4
receptors, binding affinity appeared to be higher for the
SRIF-14 isoform than SRIF-28 [95]. Matters are summed up
in reviews published by Patel et al. [121,381]. Human sst1–4
receptors do show a slightly higher degree of affinity for
SRIF-14 than SRIF-28. Conversely, human sst5 receptors
are indeed SRIF 28-selective. On the basis of structural
similarity and pharmacological reactivity to octapeptide and
hexapeptide SRIF analogues, human sst2, sst3, and sst5
receptors form a subclass of SRIF receptors. Another
receptor subclass includes the remaining receptor subtypes,
i.e. human sst1 and sst4 receptors, which both react poorly
with the analogues in question.
When synthesising SRIF analogues, i.e. agonists as well
as antagonists, preservation of the core residues D-Trp8-Lys9
has been thought to be an absolute prerequisite for full
receptor recognition and bioactivity. By contrast, the wing
residues of the central tetrapeptide, i.e. D-Phe7 and Thr10,
may undergo minor substitution, e.g. with tyrosine and
serine/valine, respectively, without significant lowering of
binding affinity [382–384]. The motif concerned forms part
of the BB, which is usually stabilised by cyclisation of the
peptide backbone (amide bond), a disulfide bridge or both
constraints concurrently [384,385]. In the paragraphs below,
Raynor et al. [282] have described the binding properties of
an entire series of selective linear analogues which contain
aromatic residues in place of the native structural motif of a
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the conformation of the BB through hydrophobic interac-
tions of the aromatic side chains. In most of these analogues,
residues in position 5 are D-isomers, with position 6 being
taken up by a residue in the L-configuration.
Structure–activity studies performed by Nutt et al. [384]
showed the key role of the Lys9 amino group in high-affinity
binding of the cyclic hexapeptide L-363,301. An evident
loss of activity thus resulted from substitution of this residue
with ornithine, arginine, histidine or p-amino phenylalanine.
According to topographic models of cyclic SRIF analogues,
the central BB-forming portion is responsible for receptor
recognition [386]. It is notable that neither SRIF-14 nor
CST-14 shows any preferential conformation in solution
when represented by circular dichroism and nuclear mag-
netic resonance [387].
An entirely novel approach to the fabrication of SRIF
analogues is marked by the work of the Merck Research
Group. In combinatorial libraries constructed on the basis of
molecular modelling of standard peptide analogues, the first
generation of nonpeptide analogues with high specificity for
each of the receptor subtypes has been identified. SRIF
analogues generated along these lines represent a degree of
subtype selectivity that is unprecedented. Using such highly
subtype-selective analogues, it finally becomes realistic to
define the individual contributions of each receptor subtype
to physiological homeostasis [388,389].
4.2. Comparative assessment of somatostatin analogues
As was stated above, receptor diversity was initially sug-
gested by the observation of differential binding of synthetic
SRIF analogues. The decapeptide [125I]CGP-23,996 (c[Aha-
Lys-Asn-Phe-Phe-Trp-Lys-Thr-Tyr-Thr-Ser]) was found to
bind selectively to rat-brain SRIF receptors in a saturable
manner and with high affinity. This particular radioligand
binding was inhibited by various SRIF analogues, with
the following rank order of potency: SRIF>L-362,823
(c[Aha-[Cys-Phe-D-Trp-Lys-Thr-Cys]])>SMS 201–995 (D-
Phe-c[Cys-Phe-D-Trp-Lys-Thr-Cys]-Thr-ol)HMK-678
(c[N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe]) = L-363,301 (c[Pro-
Phe-D-Trp-Lys-Thr-Phe]). However, [125I]MK-678 labelled
rat-brain SRIF receptors which were not detected by low
nanomolar concentrations of [125I]CGP-23,996. Binding of
[125I]MK-678 to brain membranes was also saturable and of
high affinity. SRIF-14, SRIF-28, D-Trp8-SRIF-14, SMS 201-
995, L-362,823, and MK-678 displayed similar potencies to
inhibit this binding. These preliminary results highlighted
the existence of at least two receptor subtypes with distinct
pharmacological profiles [181]. A later report by Raynor and
Reisine [304] maintained that locomotor activity resulting
from the application of MK-678 to the nucleus accumbens
must be selectively mediated by SRIF1 receptors. The
binding properties of MK-678 were further characterised
by He et al. High-affinity binding of [125I]MK-678 to
solubilised rat-brain SRIF receptors reached equilibrium by90 min (at 25 jC) and dissociated from the receptor with a
t1=2 of 60 min [150].
The initial findings of Raynor et al. [183] were elaborat-
ed in later reports. The radioligand [125I]Tyr11-SRIF-14 has
virtually indistinguishable affinities for the various receptor
subtypes. Upon radioligand labelling of brain receptors,
inhibition by MK-678 was incomplete, consistent with the
highly selective binding of this analogue. Binding of
[125I]MK-678 to SRIF1 receptors was monophasically
inhibited by SRIF, the octapeptides (including SMS 201–
995), and the hexapeptides (including MK-678). By con-
trast, the smaller CGP-23,996-like analogues failed to
inhibit [125I]MK-678 binding to SRIF1 receptors. Binding
of [125I]CGP-23,996 to SRIF receptors was inhibited by
SRIF and the octapeptides with a Hill coefficient (n) of less
than 1, indicating that [125I]CGP-23,996 labels multiple
receptor subtypes. The hexapeptides and CGP-23,996-like
compounds induced only partial inhibition of [125I]CGP-
23,996 binding, which were additive, indicating selective
interactions of these compounds with the different receptor
subpopulations labelled by [125I]CGP-23,996. GTP-gamma-
S (100 AM) completely abolished specific binding of
[125I]MK-678 to SRIF1 receptors while only partially af-
fecting binding to SRIF receptors by [125I]Tyr11-SRIF-14 or
[125I]CGP-23,996. The component of [125I]CGP-23,996
labelling that was sensitive to GTP-gamma-S was equally
sensitive to inhibition by MK-678. SRIF1 receptors are
sensitive to cyclic hexapeptides such as MK-678 and to
GTP-gamma-S but insensitive to smaller CGP-23,996-like
compounds. SRIF2 receptors are sensitive to the CGP-
23,996-like compounds and can be selectively labelled by
[125I]CGP-23,996 in the presence of high concentrations of
the hexapeptides or GTP-gamma-S because, unlike the
SRIF1 receptor, SRIF2 receptors are insensitive to these
agents. In the strain GH3, binding of [
125I]MK-678 to SRIF1
receptors was saturable and of high affinity. Radioligand
binding was inhibited by SRIF analogues with the following
rank order of potency: MK-678>SRIF-14>SRIF-28>CGP-
23,996. Binding of [125I]CGP-23,996 to SRIF2 receptors
was also saturable and of high affinity. Radioligand binding
was inhibited by SRIF analogues with the following rank
order of potency: SRIF-28>SRIF-14>CGP-23,996. Appar-
ently, MK-678 refused to interact with the SRIF2 receptor at
all. SRIF1 and SRIF2 receptors are differentially regulated.
Binding of [125I]MK-678 to SRIF1 receptors was evidently
reduced by preexposure of GH3 cells to SRIF or MK-678.
By contrast, binding of [125I]CGP-23,996 to SRIF2 recep-
tors was unaffected by prior exposure to MK-678 and only
slightly reduced by preexposure to SRIF. GTP-gamma-S
abolished binding of [125I]MK-678 to SRIF1 receptors while
not interfering with the binding of [125I]CGP-23,996 to
SRIF2 receptors [184].
4.2.1. Binding of analogues to receptor subtype sst1
The first reports on the binding affinities of linear
analogues of SRIF were based partly on stable expression
146 Only recently, Stark and Mentlein [24] reported how potently L
797,591 inhibited GLP-1-stimulated insulin secretion in RINm5F cells
which, apart from traces of the receptor subtype sst3, express sst1 and sst2
receptors. With the sst2-selective nonpeptide SRIF analogue L-054,522 (see
below), a similar response was observed.
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affinity and saturable binding (KD = 1.2 nM), Raynor et al.
used the metabolically stable SRIF analogue [125I]CGP-
23,996 to label human sst1 receptors. Apart from linear
analogues, the inhibition studies performed included cyclic
penta-, hexa-, and octapeptide analogues. The human sst1
receptor showed high affinity for the native receptor ligands
SRIF-14 (IC50 = 0.1 nM) and SRIF-28 (IC50 = 0.07 nM),
low affinity for the pentapeptides (IC50 = 80 to >1000 nM),
and those of the octapeptides (e.g. DC 23–60 (D-Nal-c[Cys-
Tyr-D-Trp-Lys-Val-Cys]-Thr-OH): IC50 = 241 nM) and line-
ar peptides (e.g. BIM-23,052: IC50 = 23 nM) that bound to
the receptor subtype at all did so with low affinities. As a
group, the hexapeptides, including MK-678, refused to
interact with human sst1 receptors at concentrations as high
as 1 AM [282].
Buscail et al. [319] found that the SRIF analogues RC-
160 (D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp-NH2) and
SMS 201–995 display only low affinity for human sst1
receptors (IC50 = 0.43 and 1.5 AM, respectively). In CHO
cells stably transfected with human sst1 receptors, Kubota et
al. [194] tested the same analogues for their relative effects
at 1 AM on forskolin-stimulated cAMP accumulation, as
compared to the native agonists. The results yielded the
following rank of potency: SRIF-14 (ED50 = 1.0
nM) = SRIF-28>RC-160>SMS 201–995. With a similar
rank of potency, the various peptides stimulated IP3 accu-
mulation. In a dose-dependent manner, SRIF-14 inhibited
specific binding of the radioligand [125I]Tyr11-SRIF-14
(IC50 = 2.0 nM). Binding properties of individual receptor
ligands, applying to both native and synthetic agonists,
paralleled potency of signal transduction.
Liapakis et al. [390] claimed to have synthesised the first
sst1-selective peptide agonists, i.e. desamino acid (1,2,5) [D-
tryptophan8, N-p-isopropyl-4-aminomethyl-1-phenylalani-
ne9]SRIF (des-AA1,2,5 [D-Trp8, IAmp9]-SRIF/CH-275) and
its tyrosine analogue desamino acid (1,5) [125I, tyrosine2, D-
tryptophan8, N-p-isopropyl-4-aminomethyl-1-phenylala-
nine9]-SRIF (des-AA1,5 [125I, Tyr2, D-Trp8, IAmp9]SRIF).
CH-275 inhibited binding of the radioligand [125I]Tyr11-
SRIF-14 to human sst1 receptors with an affinity of
1.8F 0.7 nM but apparently refused to interact with the
other cloned receptor subtypes. Also des-AA1,5 [125ITyr2,
D-Trp8, IAmp9]SRIF bound selectively, potently, and satu-
rably to sst1 receptors. Binding of des-AA
1,5 [125ITyr2, D-
Trp8, IAmp9]SRIF to sst1 receptors was potently inhibited
by SRIF-14, D-Trp8-SRIF-14, des-AA1,2,5 [D-Trp8, IAmp9,
D-Ser13]SRIF, and SRIF-28. Analogues that selectively bind
to sst2 and sst5 receptors were incapable of displacing des-
AA1,5 [125ITyr2, D-Trp8, IAmp9]SRIF from sst1 receptors.
Chen et al. [391] have proposed that IAmp9 in CH-275,
similar to Lys9 in SRIF, interacts with Asp137 in the central
TMS-III of the sst1 receptor to form an ion pair. Thus,
substitution of this single residue, i.e. Asp137, with aspara-
gine led to a lower binding affinity of radiolabelled SRIF.
Similarly, both SRIF and CH-275 lost some of their abilityto induce a dose-dependent increase in EAR under these
conditions. In TMS-II, another single residue, i.e. Leu107,
also proved to be an essential determinant of high-affinity
binding of CH-275. However, substitution of Leu107 with
phenylalanine, which occupies the corresponding site in the
sst2 receptor, did not reduce specific binding of SRIF. It
would seem that the positively charged IAmp9 of CH-275
interacts with the negatively charged Asp137 in TMS-III
while the isopropyl group of IAmp9 forms a hydrophobic
interaction with Leu107 in TMS-II. When the investigators
substituted IAmp9 with Amp, the novel SRIF analogue
bound to sst1 and sst2 receptors with equal affinities,
subtype selectivity being lost. The observations on the
subtype selectivity of CH-275 have been questioned by
Patel. He finds that CH-275 rather behaves like a prototypic
agonist at SRIF2 receptors, i.e. the pharmacological receptor
subclass including both sst1 and sst4 receptors, with a
dissociation constant (Ki) of 3.2–4.3, >1000, >1000, 4.3–
874, and >1000 nM for binding to human sst1, sst2, sst3,
sst4, and sst5 receptors, respectively [390,392].
Rohrer et al. [389] reported the synthesis of a nonpeptide
SRIF analogue, i.e. L-797,591, that with outspoken selec-
tivity bound to the human sst1 receptor. They could present
Ki values of 1.4, 1875, 2240, 170, and 3600 nM for binding
of L-797,591 to human sst1, sst2, sst3, sst4, and sst5
receptors, respectively, representing 120-fold selectivity of
the sst1 receptor.
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In CCL-39 cells stably transfected with human sst1
receptors, the radioligand [125I]Tyr10-CST-14 displayed
high-affinity binding (pKD = 10.02F 0.04). Siehler et al.
[72] found the pharmacological profiles defined by iodinat-
ed CST and the other radioligand used, i.e. [125I]Leu8-D-
Trp22-Tyr25-SRIF-28, to be very similar for each of the five
human receptor subtypes. And none of these subtypes
showed any significant binding preference for somatostatins
or cortistatins (cf. Table 2).
4.2.2. Binding of analogues to receptor subtype sst2
The pharmacological properties of the cloned receptor
subtypes sst1 and sst2 were investigated in transfected CHO-
DG44 cells. Both sst1 and sst2 receptors displayed high
affinity for SRIF, being specifically labelled with the radio-
ligand [125I]Tyr11-SRIF-14 [196]. However, binding studies
with the sst1 receptor revealed an unmistakable selectivity
with regard to the same key analogues that had previously
been tested by Raynor and Reisine [181]; it bound CGP-
23,996-like compounds, not MK-678. Exposed to this par-
ticular set of analogues, sst2 receptors were found to describe
almost complementary properties, binding MK-678 with
high affinity while unable to interact with structural ana--
,
Table 2
Pharmacology of human somatostatin receptors subclass/subtype selectiv-
ities of SRIF analogues
SRIF receptors
Peptides:
CST-14
CST-17
CST-29
SRIF-14
SRIF-28
SRIF1
receptors
SRIF2
receptors
Peptides: Peptides:
MK-678
(seglitide)
CH-275
BIM-23,014
(lanreotide)
BIM-23,197
RC-160
(vapreotide)
SMS
201–995
(octreotide)
Sst1 receptors Sst2 receptors Sst3 receptors Sst4 receptors Sst5 receptors
Nonpeptides: Nonpeptides: Nonpeptides: Nonpeptides: Peptides:
L-797,591 L-054,522 L-796,778 L-803,087 BIM-23,268
L-779,976 BN-81,644 NNC
BN-81,674 26-9100
SRIF receptors Native receptor ligands References
Human sst1 – 5 CST-14 [72]
CST-17 [75]
CST-29 [392]
SRIF-14 [9,395–397]
SRIF-28 [9,395–397]
Receptor subclasses SRIF analogues References
Human SRIF1 MK-678 (seglitide) [9,395–397]
BIM-23,014 (lanreotide) [9,395–397]
BIM-23,197 [9]
RC-160 (vapreotide) [397]
SMS 201–995 (octreotide) [9,395–397]
Human SRIF2 CH-275 [390,392]
Receptor subtypes SRIF analogues References
Human sst1 L-797,591 [389]
Human sst2 L-054,522 [205,388]
L-779,976 [129,389]
Human sst3 L-796,778 [389]
BN-81,644 [429]
BN-81,674 [429]
Human sst4 L-803,087 [389]
NNC 26-9100 [400,401]
Human sst5 BIM-23,268 [9]
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duced by Hershberger et al. [202]. In CHO-K1 cells express-
ing either rat sst1 or sst2 receptors, MK-678 recognised only
the latter. Further confirmation came from Buscail et al.
[319]. In contrast with the low-affinity binding to human sst1
receptors (see above), the SRIF analogues RC-160 and SMS201–995 exhibited high affinity for human sst2 receptors
(IC50 = 0.27 and 0.19 nM, respectively).
It seems that principally two amino acids in the sst2
receptor determine high-affinity binding of SMS 201–995.
Mutational analysis thus revealed that substitution of Ser305
with phenylalanine in TMS-VII of the human sst1 receptor
heightened the affinity for SMS 201–995 nearly 100-fold.
When Gln291, located in TMS-VI, furthermore was substi-
tuted with asparagine, specific binding of SMS 201–995
virtually became comparable to that of the human sst2
receptor. Mutational analysis argues that interaction between
Lys9 of SRIF-14 and Asp122 in TMS-III of the rat sst2
receptor is essential to high-affinity binding of the endog-
enous ligand [393].
Strnad et al. [197] tested the binding properties of four
radioligands in CHO-K1 cells stably transfected with the
cloned rat sst2 receptor. [
125I]Tyr11-SRIF-14, Leu8-D-Trp22-
[125I]Tyr25-SRIF-28, and the heptapeptide c[D-Trp-Lys-Abu-
Phe-Me-Ala-[125I]Tyr] (peptide C) displayed comparable
affinities for rat sst2 receptors (KD = 133F 28, 95F 9, and
109F 36 pM, respectively). The iodinated octapeptide
BIM-23,014 (D-beta Nal-c[Cys-[125I]Tyr-D-Trp-Lys-Val-
Cys]Thr-NH2/peptide D) refused to interact quite as well,
binding affinity being approximately 10-fold lower
(KD = 950F 1 pM). Binding competition between the radio-
ligand [125I]Tyr11-SRIF-14 and either SRIF-14 or SRIF-28
proved these native agonists to be equipotent receptor li-
gands (SRIF-14: IC50 = 276F 130 pM; SRIF-28: IC50 =
250F 48 pM).
Labelling mouse sst2 receptors with the subtype-selective
radioligand [125I]MK-678 (KD = 0.23 nM), Raynor et al.
[282] compared the binding affinities of various linear and
cyclic penta-, hexa-, and octapeptide SRIF analogues in
stably transfected CHO-DG44 cells. Pentapeptides simply
refused to interact with mouse sst2 receptors. Similar to the
native receptor ligands (SRIF-14: IC50 = 0.28 nM; SRIF-28:
IC50 = 0.43 nM), however, hexapeptides (e.g. BIM-23,027:
IC50 = 0.001 nM), octapeptides (e.g. BIM-23,014: IC50 = 1.6
nM), and some of the linear peptides (BIM-23,068:
IC50 = 0.15 nM) potently inhibited radioligand binding.
Some hexa- and octapeptides bind in the picomolar range.
With IC50 values of >1000, 112, and 0.002 nM for binding
to human sst1, mouse sst2, and mouse sst3 receptors,
respectively, the cyclic octapeptide NC4-28B (D-Phe-
c[Cys-Tyr-D-Trp-Lys-Ser-Cys]-Nal-NH2) initially appeared
to be a genuinely subtype-selective receptor ligand. A
similar estimate applied to the cyclic hexapeptide BIM-
23,027 (c[N-Me-Ala-Tyr-D-Trp-Lys-Abu-Phe]), which
bound with relatively low affinity to mouse sst3 receptors
(IC50 = 2.4 nM), incapable of interaction with the human
sst1 receptor. But at the time, when these results were
published, neither sst4 nor sst5 receptors had as yet been
cloned. The truth is, of course, that none of the four SRIF
analogues SMS 201–995, MK-678, RC-160, and BIM-
23,014 are subtype-selective in an absolute sense. They
would be more precisely characterised as selective of SRIF1
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tors comprising sst2, sst3, and sst5 receptors. Thus, SMS
201-995, which is the first clinically applied compound,
binds to sst1, sst2, sst3, sst4, and sst5 receptors with Ki values
of 290–1140, 0.4–2.1, 4.4–34.5, >1000, and 5.6–32 nM,
respectively. The other analogues display similar binding
patterns. Unlike the endogenous ligands, they do not bind to
sst1 and sst4 receptors [9,394–396]. BIM-23,197 is a SRIF
analogue displaying considerable selectivity of the sst2
receptor. It binds to human sst1, sst2, sst3, sst4, and sst5
receptors with Ki values of >1000, 0.19, 26.8, >1000, and
9.8 nM, respectively. Properly speaking, however, BIM-
23,197 cuts the profile of a prototypic SRIF1 agonist, with a
well-known binding pattern of relatively high affinity for
sst2 and sst5 receptors, combined with relatively low affinity
for sst3 receptors. On that basis, it may be grouped together
with analogues such as SMS 201–995 [9]. By contrast, an
analogue such as NC-812 binds to sst2 and sst3 receptors
only, with Ki values of >1000, 0.024, 0.09, >1000, and
>1000 nM for binding human sst1, sst2, sst3, sst4, and sst5
receptors, respectively [397].
Recently, potent nonpeptide agonists selective of the sst2
receptor have been developed. These spiro[1H-indene-1,4V-
piperidine] derivatives, which represent a promising novel-
ty, are characterised in a publication by Yang et al. [398].
One nonpeptide SRIF analogue, L-054,522, binds to the
human sst2 receptor with an apparent Ki of 0.01 nM and at
least 3000-fold selectivity when estimated against the other
SRIF receptors. Based on its inhibition of forskolin-stimu-
lated cAMP accumulation in CHO-K1 cells stably trans-
fected with sst2 receptors, L-054,522 appears to be a full
agonist [388]. Another nonpeptide analogue is L-779,976,
with Ki values of 2760, 0.05, 729, 310, and 4260 nM for
binding to human sst1, sst2, sst3, sst4, and sst5 receptors,
respectively. This corresponds to as much as 6200-fold
selectivity of the sst2 receptor [389].
In CCL-39 cells stably transfected with human sst2
receptors, the radioligand [125I]Tyr10-CST-14 displayed
high-affinity binding (pKD = 9.45F 0.09) [72] (cf. Table 2).
4.2.3. Binding of analogues to receptor subtype sst3
While binding both of the native SRIF isoforms with high
affinity, mouse sst3 receptors showed quite low affinity for
MK-678 and SMS 201–995 [88]. The human sst3 receptor
was transiently expressed in COS-1 cells in order to estimate
the pharmacological properties of this receptor subtype.
Human sst3 receptors bound the radioligand [
125I]CGP-
23,996 specifically and with high affinity. Inhibition studies
revealed the following rank order of potency: SRIF-28
(IC50 = 0.2 nM) = CGP-23,996 (IC50 = 0.3 nM)>SRIF-14
(IC50 = 1.7 nM)>SMS 201–995 (IC50 = 35 nM) [79].
In COS-7 cells transiently transfected with human sst3
receptors, binding competition with the radioligand
[125I]Leu8-D-Trp22-Tyr25-SRIF-28, which displayed high-
affinity and saturable binding (KD = 210F 11 pM), resulted
in the following rank order of potency: D-Trp8-SRIF-14(Ki = 0.56F 0.10 nM)>SRIF-14 (Ki = 2.09F 0.45 nM)
>SMS 201–995 (Ki = 5.79F 1.10 nM)>SRIF-28 (Ki =
7.94F 1.26 nM). Challenging the results of Yamada et al.,
the human sst3 receptor may thus emerge as a relatively
SRIF-14-selective receptor subtype [87]. Rat and human
homologues of the sst3 receptor differ in pharmacological
profile (rat sst3: SRIF-28> or = SRIF-14HSMS 201–995)
[87,88,95].
Assessing the relative binding properties of linear SRIF
analogues, Raynor et al. [282] also exposed mouse sst3
receptors to a battery of cyclic penta-, hexa-, and octapep-
tide analogues. The inhibition studies involved transient
expression of mouse sst3 receptors in COS-1 cells and
labelling with the radioligand [125I]CGP-23,996 (KD = 0.36
nM). Members of all structural classes bound to mouse sst3
receptors, the affinities mostly ranging from low to moder-
ate. However, some linear peptides (e.g. BIM-23,056:
IC50 = 0.02 nM; BIM-23,058: IC50 = 0.04 nM; BIM-
23,052: IC50 = 0.42 nM) and one octapeptide (L-362,823:
IC50 = 0.08 nM) bound with high affinity. According to the
results obtained by Raynor et al., the linear peptide BIM-
23,056 (D-Phe-Phe-Tyr-D-Trp-Lys-Val-Phe-D-Nal-NH2)
even turned out to be clearly selective of the mouse sst3
receptor, binding to human sst1 and mouse sst2 receptors
with an IC50 of >1000 and >10,000 nM, respectively.
Mutational analysis confirmed that a particular aspartic-
acid residue, which appears in the same relative position of
all cloned SRIF receptors, determines high-affinity binding
of SRIF-14. Substitution of Asp124 in TMS-III of the rat sst3
receptor with either asparagine or glutamic acid thus
resulted in significantly lowered affinity [399].
Siehler et al. [89] began profiling the pharmacology of the
fish sst3 receptor in stably transfected CCL-39 cells. Four
radioligands tested bound to the receptor subtype with high
affinity and in a saturable manner (Leu8-D-Trp22-[125I]Tyr25-
SRIF-28: pKD = 10.47; [
125I]Tyr10-CST: pKD = 10.87;
[125I]CGP-23,996: pKD = 9.59; [
125I]Tyr3-SMS 201–995:
pKD = 9.57). Binding competition resulted in the fol-
lowing rank order of potency, regarding the fish sst3 re-
ceptor: MK-678 = SRIF-25>SRIF-14 = SRIF-28>CST-
14>BIM-23,014>RC-160 = L-361,301 = SMS 201–995>
or = BIM-23,052> or = L-362,855>CGP-23,996>BIM-
23,056>BIM-23,030 = cyclo-antagonist>SRIF-22. In strictly
pharmacological terms, the fish sst3 receptor would seem
closer to the human sst5 receptor than its human homologue.
Slightly inconsistent results were obtained by the same group
from other studies. In CCL-39 cells stably transfected with
fish sst3 receptors, SRIF and a selection of synthetic ana-
logues thus inhibited specific radioligand ([125I]Leu8-D-
Trp22-[125I]Tyr25-SRIF-28) binding with the following rank
of potency: SRIF-14 approximately SRIF-28>BIM-
23,052>SMS 201–995>BIM-23,056 [90].
With Ki values of 1255, >10,000, 24, 8650, and 1200 nM
for binding to human sst1, sst2, sst3, sst4, and sst5 receptors,
respectively, the nonpeptide SRIF analogue L-796,778 dis-
played 50-fold selectivity of the human sst3 receptor [389].
L.N. Møller et al. / Biochimica et Biophysica Acta 1616 (2003) 1–84 51In CCL-39 cells stably transfected with human sst3
receptors, the radioligand [125I]Tyr10-CST-14 displayed
high-affinity binding (pKD = 10.06F 0.11) [72] (cf. Table 2).
4.2.4. Binding of analogues to receptor subtype sst4
The rat sst4 receptor was transiently expressed in COS-1
cells to characterise the pharmacological profile of this
receptor subtype. Apparently, binding affinity was higher
for the SRIF-14 isoform than SRIF-28. A series of synthetic
SRIF analogues, i.e. SMS 201–995, IM 4-28, and MK-678,
failed to displace the radioligand from binding sites in
transfected cells [95].
A preliminary assessment of the pharmacological proper-
ties attributable to the human sst4 receptor was obtained from
binding competition taking place on membranes prepared
from COS-1 cells transiently expressing human sst4 recep-
tors. The radioligand [125I]Tyr11-SRIF-14 displayed high-
affinity and saturable binding to human sst4 receptors
(KD = 1.1F 0.1 nM). Signifying interaction with a homoge-
nous receptor population, the radioligand was displaced from
its binding site by SRIF-14 (IC50 = 1.0 nM) and SRIF-28
(IC50 = 1.1 nM) in a monophasic manner. The synthetic
analogues SMS 201–995 and RC-160 exhibited extremely
low-affinity binding to human sst4 receptors (>100 nM). A
third analogue, i.e. MK-678, failed to displace the radioligand
altogether. Thus, the wide similarity between human sst1 and
sst4 receptors at the structural level appears to extend to the
pharmacological profiles of the respective receptor subtypes;
they form a receptor subclass of their own among the SRIF
receptors. By contrast, both human and rat sst2 receptors bind
the above analogues with subnanomolar affinities [88,91].
Membranes prepared from COS-7 cells transiently express-
ing human sst4 receptors bound the radioligand [
125I]Leu8-D-
Trp22-Tyr25-SRIF-28 with high affinity and in a saturable
manner (KD = 57F 10 pM). Binding competition between
five SRIF analogues, including the native agonists, and this
radioligand resulted in the following rank order of potency: D-
Trp8-SRIF-14 (Ki = 0.32F 0.04 nM; n = 0.76)>SRIF-14
(K i = 1.09F 0.19 nM; n = 0.75)>SMS 201-995 (Ki =
1.36F 0.17 nM; n = 0.74)>SRIF-28 (Ki = 2.20F 0.24 nM;
n = 0.77)>MK-678 (Ki = 6.50F 1.60 nM; n = 0.64). Human
sst4 receptors may thus appear to be relatively SRIF-14-
selective. A considerable sequence homology notwithstand-
ing (86%), human and rat sst4 receptors have distinct phar-
macological profiles, e.g. with regard to SMS 201–995 and
MK-678 [93].
Extensive inhibition studies were performed by Raynor
et al. [282], comparing the binding properties of numerous
analogues from different structural classes. The human sst4
receptor (‘‘SSTR5’’) was transiently expressed in COS-1
cells and stably expressed in CHO-DG44 cells. Specific
labelling with the radioligand [125I]CGP-23,996 eluded
detection in both untransfected CHO-DG44 cells and vec-
tor-transfected COS-1 cells. In these cells, when transiently
expressing human sst4 receptors, high-affinity binding of the
radioligand could be observed (KD = 0.88 nM). Withoutexception, the cyclic hexapeptide analogues (i.e. BIM-
23,027, MK-678, L-363,301, and L-363,572 (c[D-Ala-D-
Phe-D-Trp-Lys-D-Thr-N-Me-D-Phe])) refused to interact
with the human sst4 receptor. The cyclic heptapeptide
BIM-23,030 (c[MPA-Tyr-D-Trp-Lys-Val-Cys]-Phe-NH2)
bound to human sst4 receptors with very low affinity
(IC50 = 360 nM). Of the octapeptide analogues, only BIM-
23,034 (D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Nal-NH2),
BIM-23,042 (D-Nal-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Nal-
NH2), and EC5-21 (D-Phe-c[Cys-Phe-D-Trp-Lys-Thr-Cys]-
Nal-NH2) bound to human sst4 receptors—but with low
affinity (IC50 = 252, 102, and 560 nM, respectively). Of
the cyclic CGP-23,996-like peptides, the heptapeptides
L-362,862 (c[Aha-Phe-p-Cl-Phe-D-Trp-Lys-Thr-Phe]) and
L-362,855 (c[Aha-Phe-Trp-D-Trp Lys-Thr-Phe]) bound to
human sst4 receptors with higher affinity than the best
octapeptides (IC50 = 44 and 63 nM, respectively). Pentapep-
tide analogues (i.e. SA (c[Aha-Phe-D-Trp-Lys-Thr(Bzl)]), II
(c[Aha-Phe-D-Trp-Lys-Thr]), III (c[Aha-Phe-D-Trp-Lys-
Ser(Bzl)]), IV (c[Ahx-Phe-D-Trp-Lys-Thr(Bzl)]), and V
(c[Aoc-Phe-D-Trp-Lys-Thr(Bzl)])) refused to interact with
sst4 receptors. L-362,862 and L-362,855 bind to mouse
sst2 (IC50 = 8.3 and 29 nM, respectively) and mouse sst3
receptors (IC50 = 24 and 30 nM, respectively) with an
affinity similar to that for human sst4 receptors but refuse
to interact properly with human sst1 receptors (IC50 = 580
and >1000 nM, respectively). Four linear peptides bound
to human sst4 receptors with lower affinity (e.g. BIM-
23,052: IC50 = 18 nM), six with low affinity (e.g. BIM-
23,050 (N-Me-D-Ala-Tyr-D-Trp-Lys-Val-Phe-NH2):
IC50 = 124 nM), and eight refused to interact with sst4
receptors altogether [208]. Indeed, both human sst1 and
human sst4 receptors bind few SRIF analogues with high
affinity.
In COS-1 cells transiently expressing human sst4 recep-
tors, SRIF-14 displayed specific binding (IC50 = 1.6 nM). A
number of SRIF analogues were tested for their relative
binding affinities, yielding the following rank of potency:
SRIF-14 = SRIF-28HRC-160HSMS 201–995 [94].
In CHO-K1 cells transfected with human sst4 receptors,
specific binding of [125I]Tyr11-SRIF-14 was inhibited by
SRIF, L-362,855, BIM-23,027, and MK-678 with pIC50
values of 8.82, 7.40, < 5.5, and < 5.5, respectively [313].
Contrary to L-362,855, the native receptor ligand SRIF has
been found consistently to desensitise human sst4 receptors
[313,367].
In pursuit of nonpeptide agonists, Liu et al. [400,401]
came up with a thiourea scaffold featuring the following
properties: (1) heteroaromatic nucleus to mimic Trp8; (2)
nonheteroaromatic nucleus to mimic Phe7; and (3) primary
amine or other basic group to mimic Lys9. The thiourea
NNC 26–9100 (thiourea 11, compound 17) formed the
structural lead. Several thioureas (11, 38, 39, 41, and 42)
and the urea 66 exhibit Ki values of less than 100 nM in
inhibition studies using [125I]Tyr11-SRIF-14 as the radio-
ligand. The thioureas 11 (Ki = 6 nM) and 41 (Ki = 16 nM)
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nonpeptide sst4 agonists known. A full agonist at the sst4
receptor, NNC 26–9100 exhibits 100-fold sst4/sst2 selectiv-
ity. NNC 26–9100 contains pyridine for a heteroaromatic
moiety, an aromatic group, and a basic imidazole group
linked together by a thiourea scaffold.
As reported by Rohrer et al. [389], the nonpeptide SRIF
analogue L-803,087 bound to the human sst4 receptor with
285-fold selectivity, representing Ki values of 199, 4720,
1280, 0.7, and 3880 nM for binding to human sst1, sst2, sst3,
sst4, and sst5 receptors, respectively.
In CCL-39 cells stably transfected with human sst4
receptors, the radioligand [125I]Tyr10-CST-14 displayed high
affinity binding (pKD = 9.67F 0.14) [72] (cf. Table 2).
4.2.5. Binding of analogues to receptor subtype sst5
In COS-1 cells transiently expressing human sst5 recep-
tors, SRIF-14 displayed specific binding (IC50 = 0.16 nM).
A number of SRIF analogues were tested for their relative
binding affinities, yielding the following rank of potency:
SRIF-28>SRIF-14HRC-160>SMS 201–995 [94].
In membranes derived from COS-7 cells transiently
transfected with human sst5 receptors, the radioligand
[125I]Leu8-D-Trp22-Tyr25-SRIF-28 showed high-affinity and
saturable binding (KD = 55F 10 pM). Addressing the
unique pharmacology of the sst5 receptor, Panetta et al.
[96] tested the individual binding properties of eight SRIF
analogues, including the native agonists. They inhibited
specific binding of the radioligand with the following
rank order of potency: Leu8-D-Trp22-Tyr25-SRIF-28
(Ki = 0.11F 0.03 nM)>SRIF-28 (Ki = 0.19F 0.03 nM)>D-
Tr p 8 - SR IF - 14 (K i = 0 . 28 F 0 . 02 nM)>SR IF - 14
(K i = 2 .24 F 0 .36 nM) = RC-160 (K i = 1 .7 F 0 .26
nM) = BIM-23,014 (D-Nal-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-
T h r - N H 2 ) ( K i = 2 . 7 6 F 0 . 3 7 n M ) > M K - 6 7 8
(Ki = 5.02F 0.80 nM)>SMS 201–995 (Ki = 14.16F 3.1
nM). Importantly, human sst5 receptors bound SRIF-28
with a 12.6-fold higher affinity than SRIF-14 (SRIF-28:
Ki = 0.19F 0.03 nM; SRIF-14: Ki = 2.24F 0.36 nM), sub-
stantiating the notion of a receptor subtype preferring SRIF-
28. Despite an amino acid sequence identity with the rat sst5
receptor of 75% (80.5%), the human sst5 homologue has a
distinct pharmacological profile, e.g. with regard to SMS
201–995 [96,210]. In CHO-K1 cells stably transfected with
either human or rat sst5 receptors, O’Carroll et al. [210]
tested a number of SRIF analogues for their ability to inhibit
specific binding of the radioligand [125I]Tyr11-SRIF-14
(human sst5: KD = 0.11 nM; rat sst5: KD = 0.09 nM). Obser-
vations verified the existence of two mammalian homo-
logues with little in common except the slight binding
preference for SRIF-28.147 Rat sst5 receptors bound cyclic147 A reflection of varying degrees of structural similarity, the mouse
sst5 receptor resembles rat more than human sst5 receptors when tested
pharmacologically [98].penta-(e.g. SA: IC50 = 42F 8 nM), hexa-(e.g. MK-678:
IC50 = 1.3F 0.25 nM), and octapeptide analogues (e.g.
SMS 201–995: IC50 = 0.20F 0.01 nM) with moderate to
high affinity. By contrast, human sst5 receptors bound the
majority of synthetic analogues with much lower affinity
(SA: IC50 = 757F 181 nM; MK-678: IC50 = 23F 7 nM;
SMS 201–995: IC50 = 32F 3.9 nM). However, the CGP-
23,996-like heptapeptide L-362,855 was bound with high
affinity by human sst5 receptors (IC50 = 0.016F 0.007 nM).
So were the native agonists SRIF-14 (human sst5: IC50 =
0.16F 0.03 nM; rat sst5: IC50 = 0.29F 0.04 nM) and SRIF-
28 (human sst5: IC50 = 0.05F 0.01 nM; rat sst5: IC50 =
0.05F 0.009 nM).
Raynor et al. [208] had rat sst5 receptors (‘‘SSTR4’’)
stably expressed in CHO-K1 cells. Specific labelling with
the radioligand [125I]CGP-23,996 (KD = 0.6 nM) did not
take place in untransfected CHO-K1 cells. The cyclic
hexapeptide analogues (i.e. BIM-23,027, MK-678, L-
363,301, and L-363,572) bound to rat sst5 receptors with
moderate (IC50 = < 10 nM) to low (IC50=>100 nM) affinity.
The cyclic heptapeptide BIM-23,030 bound to rat sst5
receptors with relatively high affinity (IC50 = 3.9 nM).
Most cyclic octapeptides [i.e. SMS 201–995, NC4-28B,
BIM-23,014, BIM-23,023 (D-Phe-c[Cys-Tyr-D-Trp-Lys-
Abu-Cys]-Thr-NH2), BIM-23,034, BIM-23,059 (D-Nal-
c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-Thr-NH2), BIM-23,060 (D-
Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-Nal-NH2), and
L-362,823] bind to rat sst5 receptors with high affinity
(IC50 = 0.57, 1.0, 0.10, 0.18, 0.19, 0.08, 0.09, and 1.2 nM,
respectively). Of the cyclic CGP-23,996-like peptides, the
heptapeptides L-362,862 and L-362,855 bound to rat sst5
receptors with high affinity (IC50 = 0.47 and 0.005 nM,
respectively). The benzyl-lacking pentapeptide II, however,
refused to interact with the rat sst5 receptor. CGP-23,996-
like peptide SA, IV, and V bound to rat sst5 receptors with
lower affinity (IC50 = 51, 34, and 50 nM, respectively),
pentapeptide III with low affinity (IC50 = 188 nM). Of the
18 linear peptides tested, four [.e. BIM-23,052 (D-Phe-Phe-
Phe-D-Trp-Lys-Thr-Phe-Thr-NH2), BIM-23,058 (D-Phe-
Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2), BIM-23,066 (D-
Phe-p-NO2-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2), and
BIM-23,068 (D-Phe-CPA-Tyr-D-Trp-Lys-Thr-Phe-Thr-
NH2)] bound to rat sst5 receptors with high affinity
(IC50 = 0.002, 1.2, 2.4, and 1.1 nM, respectively), another
four with moderate affinity [e.g. BIM-23,055 (D-Phe-Phe-
Tyr-D-Trp-Lys-Val-Phe-D-Phe-NH2): IC50 = 3.3 nM)], nine
with lower affinity [e.g. BIM-23,070 (D-Phe-Ala-Tyr-D-
Trp-Lys-Thr-Ala-Nal-NH2): IC50 = 10 nM], and one with
low affinity [i.e. BIM-23,049 (D-Nal-Ala-Tyr-D-Trp-Lys-
Val-Ala-Thr-NH2): IC50 = 146 nM]. From their observa-
tions, Raynor et al. concluded that rat sst5 receptors bind
analogues of all structural classes with moderate to high
affinity. Some compounds, including the linear analogue
BIM-23,052 and the CGP-23,996-like analogue L-
362,855, even came out as more than 100-fold selective
of the rat sst5 receptor as compared to other cloned
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receptors transiently expressed in COS-7 cells [97], these
receptors displayed higher affinity for SRIF-28 (IC50 =
0.23 nM) than for SRIF-14 (IC50 = 0.86 nM). Additionally,
SRIF-28 proved 50-fold more potent than SRIF-14 in
inhibiting forskolin-stimulated cAMP accumulation via
sst5 receptors.
Despite its high affinity for sst5 receptors, L-362,855 was
found to affect L-type Ca2 + currents in AtT-20 cells but
minimally at concentrations up to 100 nM. L-362,855 did
not interfere with inhibition of Ca2 + currents induced by
MK-678 while completely antagonising the effects of the
relatively sst5-selective peptide agonist BIM-23,052. In AtT-
20 cells, L-362,855 must act as an antagonist/partial agonist
at sst5 receptors since it can decrease Ca
2 + currents at
concentrations above 100 nM. Similarly, L-362,855 acts
as an antagonist/partial agonist in CHO cells transfected
with the cloned rat sst5 receptor: at concentrations below
100 nM, it is able to reverse the inhibition of cAMP
accumulation induced by SRIF while, at higher concentra-
tions, it can be seen to decrease cAMP itself. As little as a
single hydroxyl group at residue seven in the peptide is
required to convert the compound into a full agonist at sst5
receptors [257].
The receptor subtypes sst1–4 all bind the native isoforms
SRIF-14 and SRIF-28 with similar affinities, i.e. approxi-
mately 0.2 nM. In this respect, the sst5 receptor is an
exception, displaying 10–50-fold higher affinity for the
larger than the smaller isoform (0.2 and 5 nM, respectively).
By means of chimeric receptor constructions, Ozenberger
and Hadcock [402] revealed that a carboxyl-terminal region
comprising TMS-VI contains the determinants of the unique
pharmacological profile of the sst5 receptor. Thus, substitu-
tion of this entire region with the corresponding region of
the sst2 receptor conferred high affinity for both SRIF-14
and SRIF-28. Sequence analysis shows the existence of two
consensus residues, i.e. a conserved hydrophobic residue
(Ile282, Phe267, Leu268, and Leu270 in sst1, sst2, sst3, and sst4
receptors, respectively) and a conserved tyrosine (residues
288, 273, 274, and 276 in sst1, sst2, sst3, and sst4 receptors,
respectively), in the TMS-VI of the receptor subtypes sst1–4.
Neither of these residues is present in the sst5 receptor,
which, in their place, contains Gly259 and Phe265, respec-
tively. Substitution of Gly259 with phenylalanine, which
occurs at the analogous site in the sst2 receptor, failed to
modulate the subtype-specific binding preference for SRIF-
28. By contrast, substitution of Phe265 with tyrosine height-
ened the binding affinity for SRIF-14 nearly 20-fold, thus
putting the native receptor ligands on a par in binding
competition. SRIF-28 binds to sst1, sst2, sst3, sst4, and sst5
receptors with Ki values of 0.1–2.2, 0.2–4.1, 0.3–6.1, 0.3–
7.9, and 0.05–0.4 nM, respectively. By comparison, SRIF-
14 binds to the same receptor subtypes with Ki values of
0.1–2.26, 0.2–1.3, 0.3–1.6, 0.3–1.8, and 0.2–0.9 nM,
respectively [9,395–397]. With Ki values of 18.4, 15.1,
61.6, 16.3, and 0.37 nM for binding to human sst1, sst2, sst3,sst4, and sst5 receptors, respectively, BIM-23,268 displays
relative selectivity of the sst5 receptor [9].
In their original report on the fabrication of nonpeptide
SRIF analogues, no genuinely sst5-selective agonist had as
yet been identified. However, L-817,818 displayed double
selectivity of human sst1 and sst5 receptors, with Ki values
of 3.3 and 0.4 nM, respectively. It may seem a little
surprising to find those receptor subtypes grouped together,
considering their membership of different receptor sub-
classes, i.e. SRIF2 and SRIF1 receptors, respectively. On
the other hand, L-817,818 does not display nearly the same
degree of selectivity as the other nonpeptide analogues
characterised by Rohrer et al. Thus, Ki values for binding
of L-817,818 to human sst2, sst3, and sst4 receptors were 52,
64, and 82 nM, respectively [389].
In CCL-39 cells stably transfected with human sst5
receptors, the radioligand [125I]Tyr10-CST-14 displayed
high-affinity binding (pKD = 10.33F 0.03) [72] (cf. Table 2).
4.3. Regulation of somatostatin receptors
By manipulating selected variables on either side of the
plasma membrane, high-affinity binding of agonist to recep-
tor may be almost completely abolished. However, receptor
subtypes differ considerably in their sensitivity to these
modifications, and the observed binding requirements ex-
hibit a definite subtype-specific pattern. Raynor et al. [208]
approached this pharmacological topic methodically by
investigating the phenomenon of agonist regulation as well
as the respective effects of GTP analogues, PTX, and Na+.
4.3.1. Regulation by receptor agonists
Some receptor subtypes are seemingly regulated by
sustained exposure to agonist, one variable, displaying
desensitisation [403,404]. High-affinity binding to sst2 and
sst3 receptors is subject to this agonist regulation whereas, in
the case of sst1 receptors, it has not consistently been proved
to be so [88,196]. Thus, preexposure of cell preparations
(CHO-DG44) to SRIF, i.e. as a test of specific agonist
regulation, interfered with high-affinity binding to sst2
receptors, not sst1 receptors [196]. The splice variants of
the mouse sst2 receptor, i.e. sst2A and sst2B, bound SRIF
with similar high affinities in stably transfected CHO-K1
cells. However, the shorter isoform, i.e. sst2B, was found to
be much more resistant to agonist-induced reduction in
high-affinity binding/receptor desensitisation than the lon-
ger one [145]. As originally demonstrated in AtT-20 cells,
SRIF receptors may desensitise when continuously exposed
to agonists [405]. Unlike sst5 receptors, however, endoge-
nous sst2 receptors of AtT-20 cells have been found to be
relatively resistant to desensitisation, using functional cou-
pling to L-type Ca2 + channels as the measure of choice
[259]. Exposure of the CHO-K1 cells expressing mouse
sst2A receptors and 51YAST to SMS 201–995 (10 nM) for
1 h at 27j C led to a reduction in high-affinity binding of
[125I]Tyr11-SRIF-14 of 70–80% compared to nonexposed
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spliced isoform, i.e. sst2B, resulted in only a 30–35% loss of
radioligand binding. From this, it would appear that molec-
ular determinants of agonist-induced desensitisation reside
within the carboxyl-terminal 15 amino acids of 51YAST,
which are present in mouse sst2A receptors but not in mouse
sst2B receptors [145]. The CTT has been shown to be
important for phosphorylation-dependent receptor desensi-
tisation [81]. As it happens, the mouse sst2B receptor
contains only two potential phosphorylation sites (Ser335
and Ser337) whereas the mouse sst2A receptor and 51YAST
contain 11 (Ser333, Thr335, Ser341, Ser343, Ser348, Thr353,
Thr354, Thr356, Thr359, Thr367, and Ser368) and four (Ser333,
Thr335, Ser341, and Ser343) such sites, respectively [145].148
In CHO-K1 cells stably transfected with either rat sst2A or
sst2B receptors, both SRIF-induced increase in EAR and
inhibition of cAMP accumulation could be shown by
Schindler et al. [85] to be susceptible to agonist-induced
desensitisation, though somewhat less apparent subsequent
to PTX treatment. Preexposure of CHO-K1 cells expressing
rat sst5 receptors to SRIF led to a 45% loss of subsequent
agonist labelling of the SRIF receptor by [125I]CGP-23,996.
Similar treatment of COS-1 cells expressing human sst4
receptors reduced the subsequent specific binding of the
radioligand by 74% [208]. Hukovic et al. [159] reported that
preexposure of human sst5 receptors stably expressed in
CHO-K1 cells to agonist resulted in functional uncoupling
from AC. Under certain conditions, however, sustained
exposure to agonist seem to overcome this reduction in
binding. Upregulation may thus account for the slightly
mystifying results published by Bruno et al. [406]. In GH3
cells continuously exposed to SRIF (1 AM), specific binding
of the radioligand [125I]Tyr11-SRIF-14 was augmented to
280% and 350% of control values by 24 and 48 h,
respectively. When CHO-K1 cells had been continuously
exposed to agonist, differential upregulation of human SRIF
receptors could be observed by Hukovic et al. [407]. After
22 h, sst1 receptors were upregulated at the membrane by
110%, sst2 and sst4 receptors by 26% and 22%, respectively,
whereas sst3 and sst5 receptors showed little change. Ago-
nist-induced recruitment of sst1 receptors to the membrane
was confirmed by immunocytochemistry with antibodies
raised against the sst1 receptor. Subtype selectivity with
regard to internalisation and upregulation turned out to be
inversely related.148 Uncoupling of the beta2 adrenoceptor from Gs has been shown to
involve phosphorylation by beta-ARK at serine and threonine residues in
the CTT of the receptor [548]. Beta-ARK is involved in the phosphorylation
of SRIF receptors in S49 cells that occurs upon desensitisation to SRIF-14
[574]. Phosphorylation of the four residues Ser333, Thr335, Ser341, and
Ser343 in the CTT—which are common to 51YAST and mouse sst2A
receptors, but not to mouse sst2B receptors—might be responsible for the
profound desensitisation of these receptors. The residues in question are
present at the analogous sites in human sst2 receptors. Alternative splicing
may be a physiological mechanism to modulate the coupling efficiency or
desensitisation of mouse sst2 receptors [145].Using CHO-K1 cells stably transfected with each of the
human SRIF receptors, Hukovic et al. [407] estimated the
extent of individual subtype internalisation. Human sst2,
sst3, sst4, and sst5 receptors displayed rapid agonist-induced
internalisation of [125I]LTT-SST-28. This regulatory mech-
anism depended on duration of exposure and temperature.
Maximal internalisation of the radioligand occurred with
human sst3 (78%), followed by human sst5 (66%), human
sst4 (29%), and human sst2 (20%). Human sst1 receptors,
however, were involved in virtually no internalisation at all.
In cells derived from either the AtT-20 strain or a human
pituitary GH-secreting adenoma, internalisation of a radio-
iodinated octreotide derivative could be seen to be exten-
sive. What is more, addition of unlabelled octreotide, SRIF-
14 or SRIF-28 accelerated internalisation of the radioligand
[408]. In GH-R2 cells, which derive from a pituitary tumour
with high levels of the sst2A receptor, the susceptibility of
this receptor subtype to agonist-induced desensitisation,
internalisation, and phosphorylation came under scrutiny.
A 30-min incubation with either SRIF or SMS 201–995
tended to minimise receptor-mediated inhibition of cAMP
accumulation. Internalisation of the receptor-bound ligand
could be seen to be rapid (t1=2 = 4 min) and temperature-
dependent. In the presence of agonist, phosphorylation of
the 71-kDa sst2A receptor increased 25-fold within 15 min.
This phosphorylation, which was resistant to PTX treat-
ment, varied with both concentration of agonist and duration
of exposure. PMA also proved capable of inducing receptor
phosphorylation. Induced by either agonist or PMA, this
modification occurred primarily at serine residues [409].
Roth et al. [410] reported that four hydroxyl amino acids
(Ser341, Ser346, Ser351, and Thr357) in the CTT of the rat sst3
receptor appeared to be essential to agonist-induced inter-
nalisation, representing as many potential phosphorylation
sites. Following exposure to agonist and the activity of
cytosolic kinases, the sst3 receptor is internalised in a
clathrin-coated vesicle. Later, the receptor is recycled to
the level of the plasma membrane. Before it is internalised,
however, it is desensitised, and the temporary absence from
the cell surface may basically serve purposes of dephos-
phorylation and resensitisation [411]. It was shown by
Roosterman et al. [412] that recycling such as this is
insensitive to cycloheximide from which it may be conclud-
ed that de novo synthesis of receptors is irrelevant. How-
ever, recycling could be inhibited by brefeldin A, monensin,
and bafilomycin A1. This observation implies vesicular
traffic of acidified compartments. In rat insulinoma 1046-
38 cells, internalised receptors appeared in perinuclear
vesicles after half an hour, and the reappearance of receptors
at the cell surface completed recycling after 2 h. The rat sst4
receptor alone failed to show any sign of internalisation.
According to Kreienkamp et al. [413], failure of the WT rat
sst4 receptor to be internalised owes to a carboxyl-terminal
motif of 20 amino acid residues. Mutational analysis
showed that substitution of Thr331 with alanine overcomes
this resistance to agonist-induced internalisation. However,
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neither the WT sst4 receptor nor the mutant receptor was
phosphorylated in response to agonist. Similarly, as deter-
mined by the activity of AC, neither of them desensitised.
Schreff et al. [156] had to confirm the negative results of
Roostermann et al. and Kreienkamp et al. Unlike sst2A
receptors, the rat sst4 receptor did not show any sign of
internalisation in response to intracerebroventricular appli-
cation of SRIF-14. Breeman et al. [414] described internal-
isation of radio-iodinated analogues of SMS 201–995 in
AtT-20 cells.149 In the strains CA20948 and AR42J, which
both express the sst2 receptor, [
111In-DTPA0]SMS 201-995,
[90Y-DOTA0, Tyr3]SMS 201–995, and [111In-DOTA0,
Tyr3]SMS 201–995 were internalised in a receptor-specific,
time- and temperature-dependent manner [415]. Krisch et al.
[416] reported that, in cultured human glioma cells derived
from solid tumours or the strain U343, internalisation of the
endogenous sst2 receptor took place primarily in uncoated
vesicles. Gold-labelled receptors and native agonists rapidly
appeared to reveal a pleomorph traffic of receptor-positive
compartments, including vesicles, tubule-like structures, and
multivesicular bodies in peripheral and perinuclear portions
of the cytosol. Then, after half an hour, increasing lysosomal
labelling could be observed. In a subsequent study, using
similar glioma cells, the same investigators found the sst2
receptor to be internalised in caveolin-positive vesicles.
Colocalisation of sst2 receptors with both caveolin and Gi-
alpha, as determined by electron microscopy in conjunction
with biochemical techniques, was strictly time-dependent,
being observed after 5 min and undetectable after 10 min
[417]. The fate of radio-iodinated ligand bound to the sst2
receptor was investigated by Koenig et al. [418]. They
found that 75–85% of internalised ligand recycled to the
level of the plasma membrane. Internalisation resulted
in accelerated degradation of only [125I]SRIF-14, not
[125I]BIM-23,027. Nevertheless, levels of recycled agonist
in the extracellular medium were high enough to cause
reactivation of cell-surface receptors. In NG 108-15 cells,
phenylarsine oxide (PAO) and concanavalin A both tended
to block SRIF-induced receptor desensitisation. Either com-
pound is an inhibitor of receptor endocytosis. A similar
effect is shared by hyperosmotic sucrose. By contrast,
monensin, which inhibits recycling of internalised receptors,
potentiated agonist-induced desensitisation. Having consid-
ered PK-A, PK-C, protein-kinase G (PK-G), and the GPC-
receptor kinases GRK-2 and GRK-3, Beaumont et al. [245]
found no evidence that the activity of cytosolic kinases is
essential to this desensitisation. Hofland et al. [419] reported
that PTX (100 Ag/l) could significantly (31–43%) block
internalisation of three radio iodinated analogues of SMS
201–995 in AtT-20 and human insulinoma cells. An even
more outspoken response (92–98%) was evoked by PAO
(10 AM). Chelating groups such as DTPA and DOTA do not
interfere with receptor internalisation induced by SMS 201–149 CA20948 cells derive from a rat pancreatic tumour.995. Observations recently made by Schwartkop et al. [420]
are in line with those of Beaumont et al. The former thus
showed that phosphorylation and internalisation of the
receptor may be independent of each other. Forming the
basis of their analysis, the rat sst2 receptor is rapidly
phosphorylated and internalised in the presence of agonist.
Mutant receptors lacking the extreme 10 (delta359), 30
(delta339) or 44 (delta325) amino acid residues of the
CTT remained fully dependent on agonist for internalisa-
tion. By contrast, a mutant receptor (delta349) lacking the
carboxyl-terminal 20 amino acids appeared mostly below
the level of the plasma membrane, and this sucrose-sensitive
receptor endocytosis took place in the absence of agonist.
High affinity for agonist in combination with sustained
regulation at the effector level characterises agonist-inde-
pendent, constitutive receptor activity. And delta349 shares
just those properties. Apparently, it is not phosphorylated to
any significant extent in the absence of agonist. While
internalised in a strictly agonist-dependent manner, i.e.
unlike delta349, the shorter mutant receptor delta325 es-
caped phosphorylation altogether.
4.3.2. Regulation by guanosine-triphosphate analogues
The nonhydrolysable GTP analogue GTP-gamma-S, an-
other variable, binds to the G-alpha of the heterotrimeric GP,
thereby inducing it to dissociate and uncouple from the
STMS receptor. On the assumption that both ligand and
GDP-binding GP stabilise the high-affinity state of the
receptor, GTP-gamma-S and similar agents (e.g. GMP-
PNP) must reduce specific and saturable binding of receptor
agonists. At any rate, this applies to most receptor subtypes.
Although it is known to be GP-coupled, the sst4 receptor has
defied GTP regulation in a number of studies. In Ltk and
HEK-293 cells stably and transiently expressing the human
sst1 receptor, respectively, GTP-gamma-S reduced high-
affinity binding of the radioligand [125I]Tyr11-SRIF-14 sig-
nificantly [193]. In CHO-DG44 cells transfected with the
human sst2 receptor, Rens-Domiano et al. [196] reported
GTP-gamma-S to reduce high-affinity binding of SRIF.
According to Law et al. [198], GTP-gamma-S reduced
high-affinity binding of [125I]MK-678 in HEK-293 cells
transiently expressing the mouse sst3 receptor. Both GTP
and GTP-gamma-S significantly reduced high-affinity bind-
ing of the radioligand [125I]Leu8-D-Trp22-Tyr25-SRIF-28
in COS-7 cells transiently expressing the human sst5 recep-
tor [96]. In CHO-K1 cells stably transfected with rat
sst5 receptors, Raynor et al. [208] reported GMP-PNP
(100 AM) to reduce specific binding of the radioligand
[125I]CGP-23,996 by 77%. However, with regard to COS-
1 cells transiently expressing the human sst4 receptor, they
failed to find any evidence of such GTP regulation, testing
both [125I]CGP-23,996 and [125I]Tyr11-SRIF-14. The inves-
tigators made similar observations in CHO-DG44 cells
stably transfected with human sst4 receptors. In transiently
transfected COS-7 cells, however, Demchyshyn et al. [93]
reported both GTP-gamma-S and PTX to reduce high-
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In COS-7 cells expressing the human sst1 receptor, GTP-
gamma-S reduced high-affinity binding of the SRIF2-selec-
tive peptide agonist des-AA1,5 [125I, Tyr2, D-Trp8, IAmp9]S-
RIF. Interestingly, when binding [125I]Tyr11-SRIF-14, sst1
receptors defied regulation by either agent. Hence, the
synthetic decapeptide and the modified variant of the native
tetradecapeptide may bind to human sst1 receptors in
different ways [390].
In CCL-39 cells stably transfected with human sst2, sst3,
sst4, or sst5 receptors, SRIF-14 augmented receptor binding
of [35S]GTP-gamma-S to 162%, 220%, 148%, and 266%,
respectively, of control. The human sst1 receptor differs
from the other subtypes in this respect, SRIF-induced
binding of the GTP analogue being insignificant (Emax =
115%) [421].
4.3.3. Regulation by pertussis toxin
A third variable is the bacterial PTX. It shares the ability
of GTP-gamma-S to uncouple the GP from the STMS
receptor, with a resultant loss of the high-affinity state.150
In Ltk cells stably expressing the human sst1 receptor,
PTX (100 ng/ml, 18 h) reduced agonist binding to 63F 8%
of control [193]. In CHO-K1 cells stably transfected with
the rat sst1 receptor, Hadcock et al. [185] observed SRIF-
induced inhibition of cAMP accumulation, with specific
ligand binding being reduced to 20% of control by PTX. In
transfected CHO-DG44 cells, Rens-Domiano et al. [196]
reported PTX to reduce high-affinity binding to the human
sst2 receptor. In COS-1 cells transiently expressing the
human sst4 receptor, PTX reduced specific binding of
[125I]CGP-23,996 but insignificantly. Raynor et al. [208]
obtained similar results in CHO-DG44 cells stably trans-
fected with human sst4 receptors. By contrast, they found
the rat sst5 receptor to be potently regulated by PTX,
specific radioligand binding being completely abolished
by this agent in stably transfected CHO-K1 cells. In tran-
siently transfected COS-7 cells, however, both GTP-gam-
ma-S and PTX reduced high-affinity binding of agonists to
human sst4 receptors [93]. In the same strain transiently
expressing the human sst5 receptor, Panetta et al. [96]
reported any of the agents GTP, GTP-gamma-S, PTX, or
Na+ to significantly reduce high-affinity binding of the
radioligand [125I]Leu8-D-Trp22-Tyr25-SRIF-28.150 Early studies showed the SRIF-induced inhibition of forskolin-
stimulated cAMP accumulation to be sensitive to PTX [575]. In other
words, the activity of AC could be disinhibited by PTX-induced ADP
ribosylation of Gi. Subsequently, PTX has also been shown to block SRIF-
induced inhibition of Ca2 + mobilisation. But inactivation of the GP does
not affect intracellular signalling alone. From a pharmacological point of
view, PTX modulates the properties of SRIF receptors, lowering the affinity
for agonist [153,576]. Concerning such transduction pathways as are
operated by SRIF receptors, PTX sensitivity has become a handy
touchstone of GP coupling.4.3.4. Regulation by sodium
Na+, a fourth variable, has been shown to reduce specific
binding of agonists to a number of GPC receptors. This must
be due to induction of conformational changes. Na+ is
thought to interact specifically with aspartate residues in
TMS-II (Asp104, Asp89, Asp90, Asp93, and Asp86 in human
sst1, sst2, sst3, sst4, and sst5 receptors, respectively). Sup-
posedly, this interaction, which upsets the network of hy-
drogen bonds at the centre of the alpha helix, causes the GP
to uncouple from the STMS receptor by allosteric forces,
resulting in lowered affinity for agonists. In CHO cells stably
transfected with either sst1 or sst2 receptors, Na
+ reduced
agonist binding to the latter receptor subtype alone. This
result is in agreement with other findings: agonist binding to
sst2 receptors is reduced by a nonhydrolysable GTP analogue
such as guanosine 5V-[beta, gamma-imido]triphosphate
(GppNHp) and PTX. Substitution of Asp89 with asparagine
in sst2 receptors resulted in a mutant receptor whose affinity
for agonists was insensitive to Na+. However, the affinities of
the mutant and WT receptors for SRIF appeared identical.
Furthermore, GTP-gamma-S and PTX reduced agonist bind-
ing to both mutant and WT receptors [422].
High-affinity binding of the radioligand [125I]CGP-
23,996 to the human sst4 receptor, when transiently ex-
pressed in COS-1 cells, turned out to be equally sensitive to
rising levels of Na+ and N-methyl-D-glucamine (NMDG).
This observation by Raynor et al. [208] would seem to rule
out any specific Na+ regulation of that receptor subtype. By
contrast, they reported [125I]CGP-23,996 binding to rat sst5
receptors to be more sensitive to Na+ than NMDG. This
evident ability of Na+ to reduce high-affinity agonist bind-
ing to sst5 receptors had already been observed by O’Carroll
et al. [97] in COS-7 cells transiently expressing the rat sst5
receptor. With regard to the human sst5 receptor, Panetta et
al. [96] obtained similar results. In COS-7 cells transiently
expressing the human sst5 receptor, Na
+ thus reduced high-
affinity binding of the radioligand [125I]Leu8-D-Trp22-Tyr25-
SRIF-28.
4.3.5. Regulation by glycosidases and kinases
(See Sections 2.3.1, 2.3.2 and 4.3.1.)
4.4. Reclassification of receptor subtypes
During the laborious process of receptor cloning and
expression, heterogenous species homologues have been
compared for pharmacological characteristics in different
strains. However, binding properties of selected receptor
ligands vary with both the tertiary structure of the trans-
fecting receptor (e.g. rat sst3 versus human sst3 receptors
[87]; rat sst4 versus human sst4 receptors [93]; rat sst5 versus
human sst5 receptors [96]) and the cellular coexpression of
endogenous receptor-coupled GP subforms [196]. In an
attempt to correct the equivocal results, the binding proper-
ties of 32 synthetic SRIF analogues were systematically
tested in CHO-K1 cells stably expressing any of the human
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nM, respectively [425].
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formed by human sst2, sst3, and sst5 receptors, which
reacted potently with hexapeptide as well as cyclic and
linear octapeptide analogues. Compared to SRIF-14, the
present generation of SRIF analogues exhibits an approxi-
mately 50-fold increase in binding potency with regard to
human sst2 and sst3 receptors. Relative selectivity can be
demonstrated for only human sst2 receptors, being maxi-
mally 35-fold [397]. Similar observations, testifying to the
existence of pharmacologically distinct receptor subclasses,
were made by other investigators. With [125I]Tyr11-SRIF-14
as the radioligand, binding competition took place on crude
membranes from CHO cells expressing any of the five
receptor subtypes. RC-160 displayed moderate-to-high af-
finities for sst2, sst3, and sst5 receptors (IC50 = 0.17, 0.1, and
21 nM, respectively) and low affinity for sst1 and sst4
receptors (IC50 = 200 and 620 nM, respectively) [329].
As opposed to the traditional classification of receptor
subtypes, which is based on the chronology of their respec-
tive dates of cloning, pharmacological studies make out a
case for a subdivision of SRIF receptors into two major
classes. Hence, one receptor subclass would comprise sst2,
sst3, and sst5 receptors (originally referred to as SRIF1
receptors), and another sst1 and sst4 receptors (represented
by SRIF2 receptors) [192]. Actually, such a shift in nomen-
clature could be defended on structural grounds as well.
Structural similarity parallels pharmacological similarity.
The amino acid sequences of human sst1 and sst4 receptors
are thus 58% (60%) identical and 78% similar—the highest
degree of sequence similarity between any of the cloned
receptor subtypes. Identity of human sst4 receptors with the
remaining subtypes range from approximately 40% to 43%
(42% to 49%). By contrast, human sst5 receptors display
higher amino acid sequence homology with sst2 (52%) and
sst3 receptors (53%) than with sst1 receptors (45%), consis-
tent with the pharmacological properties ascribed to the
respective receptor subtypes [94,208].
4.5. Antagonising somatostatin action
SRIF analogues that compete with agonists of that
regulatory peptide, blocking the well-known inhibitory
signals for secretion and growth, may be divided into partial
antagonists, pure antagonists, and inverse agonists. The first
partial receptor antagonist, BIM-23,156 (c[Ahp-Phe-D-Trp-
Lys-Thr(Bzl)]), was reported by Fries et al. [423] in 1982.
At low doses, it could be seen to behave like a weak
antagonist and stimulated growth in female rats [424].
Pure antagonists finally became available with the work
of Bass et al. [382]. With a core structure consisting of a DL-
cysteine pair in positions 6 and 11, the cyclic octapeptide
Ac-Npa-c[D-Cys-Tyr-D-Trp-Lys-Thr-Cys]-D-Tyr-NH2
showed an affinity for the sst2 receptor comparable to that of
the endogenous ligands. Substitution of D-Cys6 with the
isomeric L form converts the full antagonist into a full
agonist. The observations made by Bass et al. wereemployed by Hocart et al. [425], especially the principle
of disulfide-cyclised analogues with inverted chirality in
positions 5 and 6 relative to the agonists (SRIF numbering).
They demonstrated that several D5, L6 agonists could be
converted into competitive antagonists by applying the L5,
D
6 antagonist motif. The most potent antagonist synthesised
according to this design was a derivative of the D-Nal5-Nal12
agonist BIM-23,042. Basic inversion of the D5, L6 chirality
yielded the antagonist DC 38–39 characterised by relatively
high affinity for members of the SRIF1-receptor subclass.
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Additional substitution of Tyr7 with Pal resulted in no less
than a 5-fold increase in the antagonist potency, although
the binding affinity for sst2 receptors was halved. However,
DC 38–48 (H-Nal-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Nal-
NH2) remained clearly selective of the human sst2 receptor,
having an affinity of 75 nM, and an IC50 of 15.1 nM.
Alternative modifications of the parent compound, i.e. the
L
5, D6 isomer of BIM-23,042 (DC 38–39), such as the
insertion of His7 (RJ 01-20) or the chiral inversion of
position 5 to D-Nal (DC 32–57) led to weaker antagonism
and reduced specific binding. Relatively so did a substitu-
tion of Nal5 in DC 38–48 with phenylalanine (DC 38–51).
Structurally minimised superagonists such as MK-678
proved to be unsuitable for modification. With there being
no position 5 in the cyclic hexapeptide, sole inversion of the
chirality of N-Me-Ala6 yielded the compound RJ 01-48,
which had retained some affinity for the sst2 receptor but
had no antagonistic properties whatsoever. In fact, it was
still an agonist. Some of the most potent receptor antago-
nists generated to date are the relatively sst2-selective cyclic
octapeptides PRL-2970 (21/H-Cpa-c[D-Cys-Tyr-D-Trp-Lys-
Thr-Cys]-Nal-NH2; IC50 = 1.1 nM; Ki = 26 nM) and PRL-
2915 (15/H-Cpa-c[D-Cys-Pal-D-Trp-Lys-Tle-Cys]-Nal-NH2;
IC50 = 1.8 nM; Ki = 12 nM), with the former showing the
highest degree of antagonism, the latter of subtype selec-
tivity [426].
Baumbach et al. [427] introduced the receptor antago-
nist AC-178,335 (Ac-D-His-D-Phe-D-Ile-D-Arg-D-Trp-D-
Phe-NH2), a linear hexapeptide, whose amino acid se-
quence reads but D forms. Lack of lysine in position 9
also distinguishes this antagonist from all other analogues
mentioned in the above. It is a compound isolated from a
synthetic combinatorial hexapeptide library containing
6.4 107 individual amino-terminally acetylated, carbox-
yl-terminally amidated, and entirely D-isomeric peptides.
Not only did AC-178,335 completely lack agonist proper-
ties. It also appeared to decrease constitutive signalling of
the unliganded receptor, i.e. what has been termed the
binary complex in the above. Particularly at high concen-
trations, AC-178,335 thus potentiated forskolin-stimulated
cAMP accumulation in GH4C1 cells stably transfected with
rat sst2 cDNA. In other words, AC-178,335 may actually
be an inverse agonist. Agonist-independent receptor activity
L.N. Møller et al. / Biochimica et Biophysica Acta 1616 (2003) 1–8458is observed under conditions of extremely high receptor
expression such as in the GH4C1 cells where transfection
resulted in a 100-fold higher receptor density than in WT
cells. Competing with [125I]-SRIF, AC-178,335 bound to the
rat sst2 receptor with a mean Ki value of 172F 12 nM.
Reminiscent of the results published long before by Spencer
and Hallett [424], AC-178,335 stimulated GH release in rats.
As opposed to the peptide transmitters mentioned above,
Poitout et al. [428,429] characterised a number of non-
peptide SRIF analogues with subtype-specific receptor an-
tagonism. They found that two tetrahydro-beta-carboline
derivatives, i.e. 4k (BN-81,644) and 4n (BN-81,674), bound
selectively and with high affinity to the human sst3 receptor
(Ki = 0.64 nM and 0.92 nM, respectively). In terms of signal
transduction, 4k and 4 n attenuated sst3-mediated inhibition
of cAMP accumulation induced by 1 nM SRIF (IC50 = 2.7
and 0.84 nM, respectively).152 In a review of their study, Bell and Reisine [168] stated that sst2
receptors, contrary to sst1 and sst3 receptors, bound MK-678 with high
affinity; they further claimed that CGP-23,996 bound potently to sst2 and
sst3 receptors but not to sst1 receptors, and they made a note of the fact tha
a structural analogue of CGP-23,996 (pentapeptide III) bound sst1 and sst3
receptors while not interacting with sst2 receptors. Their conclusion
amounted to the proposal that the properties of SRIF1 and SRIF2 receptors
were similar to those of sst2 and sst1 receptors, respectively. But, as the
investigators themselves later realised, this is an erroneous and misleading
notion, allegedly due to the use of radio-iodinated CGP-23,996 versus
unlabelled ligand. Hence, it is true that neither sst1 nor sst3 receptors
bind MK-678 very well [88,196,202]. But both of them bind CGP
23,996 with high affinity [79,282]. While binding MK-678 with high
affinity, sst2 receptors do not interact with CGP-23,996-like compounds
[196,202,282]. MK-678 interacts quite poorly—if at all—with sst4 receptors
[91,93,95,208]. Similarly, sst4 receptors bind structural analogues of CGP
23,996 with only low affinity [208]. By contrast, these compounds bind
potently to sst5 receptors, which only bind MK-678 with low to moderate
affinity [96,208,210]. In the true sense of the word, MK-678 would not come
out as ‘‘receptor-selective’’ at all: it binds to both sst2 and sst5 receptors
albeit with varying affinities. By the same token, CGP-23,996 cannot be said
to be anything like receptor-selective since it binds to at least two separate
subtypes, i.e. sst1 and sst3 receptors. In literature, display of high affinity is
often mistaken for selectivity.5. Tissue distribution of somatostatin receptors
Differential expression has been established for the two
native SRIF isoforms, testifying to tissue-specific process-
ing of the common precursor peptide [430]. But also, the
various receptor subtypes exhibit distinct patterns of distri-
bution. Reubi and Maurer [431] were some of the first to
investigate this phenomenon systematically, using the [Tyr3]
derivative 204–090 of SMS 201–995 for RAG in rat CNS
and pituitary. Receptors were found to be abundant in the
deeper layers of the cerebral cortex. Large areas of the
limbic system displayed high levels of SRIF receptors, in
particular the hippocampus (CA1, CA2, dentate gyrus),
most amygdaloid nuclei, the medial habenula, and the
septum. Parts of the olfactory, visual and auditory, as well
as visceral and somatic sensory systems were intensely
labelled, in particular the anterior olfactory nucleus and
tubercle, the superior and inferior colliculi, the nucleus of
the solitary tract, the substantia gelatinosa of the spinal cord,
and the spinal trigeminal nucleus. The central grey and locus
coeruleus displayed a similar degree of labelling. In com-
parison, the striatum did not bind the analogue very well,
receptors being distributed in a patchy and heterogenous
way. Cerebellum and substantia nigra appeared to be prac-
tically devoid of SRIF receptors. Several years later, Reubi
et al. [57,432] demonstrated high-affinity and specific
ligand binding in three separate tissue types derived from
the human GIT: (1) gastrointestinal mucosa; (2) peripheral
nervous system (PNS)/enteric nervous system (ENS) (plex-
us submucosus and myentericus); and (3) gut-associated
lymphoid tissue (GALT). By RAG applied to tissue sections
incubated with the radioligand [125I]Tyr3-SMS 201–995,
high-affinity and specific receptors were demonstrated in
four gut-associated lymphoid tissues: (1) palatine tonsils; (2)
ileal Peyer patches; (3) vermiform appendix; and (4) colonic
solitary lymphatic follicles. Receptors were mostly confined
to the germinal centres, the luminal part showing denserlabelling than the basal part. However, receptors were
demonstrated neither in the corona of follicles nor in
primary follicles without germinal centres.
A different approach was adopted by Theveniau et al.
[433]. Polyclonal rabbit antibodies (F4) raised against the
rat-brain SRIF receptor were able to immunoprecipitate
solubilised SRIF receptors from both rat brain and AtT-20
cells. F4 detected a protein of 60 kDa in rat brain and
adrenal cortex. It could also be shown to be present in the
strains AtT-20, GH3, and NG-108. By contrast, F4 failed to
detect any immunoreactive material in rat liver or any of the
strains COS-1, HEPG, and CRL. In rat brain, the 60-kDa
immunoreactivity was confined to the hippocampus, cere-
bral cortex, and striatum. Given our present knowledge, it
seems reasonable to conjecture that it must have been the rat
sst4 receptor [209]. Theveniau et al. [433] found the
cerebellum and brain stem to be devoid of immunoreactive
material. So were the rat pancreas and pituitary, which, on
the other hand, have been reported to express a 90-kDa
receptor subtype. In size, this receptor corresponds quite
well to the pancreatic receptor isolated during GE by
Zeggari et al. [320]. At the time, Theveniau et al. [433]
contented themselves that selectivity of F4 is evidence of
immunologically distinct receptor subtypes.
5.1. Discriminating between two receptor subclasses
Before recombinant technology could begin presenting a
structurally based system of classification, receptor subtypes
must be distinguished according to their respective affinities
for MK-678 (see above). In reality, however, receptor sub-
classes rather than subtypes formed the raw material of that
primary subdivision of SRIF receptors. By definition, SRIF1
receptors thus had the ability to bind MK-678, with the
remaining SRIF2 receptors being insensitive [181,183].
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cological entities, found their structural correlates in three
(i.e. sst2, sst3, and sst5 receptors) and two receptor subtypes
(i.e. sst1 and sst4 receptors), respectively. By quantitative
autoradiographic techniques, a high density of binding sites
for both [125I]CGP-23,996 and [125I]MK-678 was demon-
strated in the inner layers of the cerebral cortex, CA1 region,
and subiculum of rat hippocampus [182,304,434]. The
dentate gyrus of the hippocampus contained many binding
sites for [125I]MK-678 but only few for [125I]CGP-23,996
[304,434]. Binding of the latter radioligand could be
demonstrated in the central region of the interpeduncular
nucleus whereas the dorsal and lateral subnuclei of this
brain area expressed mainly SRIF receptors with high
affinity for MK-678 [434]. The locus coeruleus and regions
of the superior colliculus and hypothalamus selectively
express [125I]MK-678-sensitive SRIF receptors [304,434].
Limbic structures such as the lateral septum, the nucleus
accumbens, and ventromedial striatum exhibited a much
higher density of binding sites for [125I]MK-678 than
[125I]CGP-23,996. Distinct expression patterns were evi-
dent in the substantia nigra as well: [125I]CGP-23,996
binding occurred in the pars reticulata but not the pars
compacta, the reverse distribution applying to the other
radioligand [434]. The MK-678-sensitive SRIF1 receptor is
found in high density in the neostriatum as well as the
anterior pituitary [182,304]. The latter organ appeared to
express members of this receptor subclass alone. The
striatum was also found to express MK-678-insensitive
SRIF2 receptors. In the cortex and hippocampus, SRIF1
receptors constitute approximately 50% of the total SRIF
receptor population. However, SRIF1 receptors comprise
86% of the striatal SRIF receptors [182]. Binding of the
radioligand [125I]Tyr11-SRIF-14 to membranes derived from
rat nucleus accumbens was potently and monophasically
inhibited by SRIF. However, MK-678 inhibited but 58% of
specific radioligand binding, indicating that the nucleus
accumbens expresses both SRIF1 and SRIF2 receptors.
Inhibition of radioligand binding by CGP-23,996 was best
fit by a two-site model [56]153.
More recently, Thoss et al. [435] investigated the expres-
sion of SRIF1 and SRIF2 receptors in human brain and
pituitary by in vitro RAG. They found high levels of SRIF1
receptors in the deep layers of the cerebral cortex and
molecular layer of the cerebellum. Low levels of these
receptors could be labelled by [125I]Tyr3-SMS 201–995
and [125I]Leu8-D-Trp22-Tyr25-SRIF-28 in the hypothalamus,
choroid plexus, most areas of the brainstem, dentate nucle-
us, and both lobes of the pituitary. While absent from the
hypothalamus and locus coeruleus, SRIF2 receptors seemed153 However, locomotor activity was potently stimulated by local
injections of either SRIF or MK-678, not by CGP-23,996. Accordingly,
SRIF1 receptors alone are responsible for mediating the activating signals of
locomotion in the rat nucleus accumbens [56].to abound in the choroid plexus, substantia nigra, and
molecular layer of the cerebellum. The anterior lobe of the
pituitary displayed high levels of SRIF2 receptors, with
lower levels being labelled by [125I]CGP-23,996 in the
posterior lobe.
5.2. Discriminating between five receptor subtypes
For the explicit reasons stated above, the respective
expression patterns of SRIF1 and SRIF2 receptors should
not be directly compared to those of cloned receptor sub-
types. Results are too indiscriminate for that purpose.
Four techniques are used to define the expression of
individual receptor subtypes: (1) Northern blotting (NB); (2)
RT-PCR; (3) ISH; and (4) immunocytochemistry. These
techniques, however, are not equally suited for that purpose.
Accordingly, findings listed below must be treated with
some reservation. The truth is that NB seems to be too
insensitive to represent the actual patterns of expression. On
the other hand, RT-PCR has typically been found too
sensitive. In theory, RT-PCR might be an optimum alterna-
tive, but it appears to be a shared experience of the
laboratory environment that the technique yields too many
false-positive results, probably due to contamination and
other artefacts introduced during preparation. All in all, ISH
should be recommended as the safest approach, especially
when using riboprobes.
5.2.1. Distribution pattern of receptor subtype sst1
As established by NB, the 4.8-kb transcript corresponding
to the human sst1 receptor was reported by Yamada et al.
[77] to be expressed at the highest levels in adult stomach
and jejunum. In the former, human sst1 mRNA has been
found in both fundic and antral mucosa by the RT-PCR
[19]. NB and RT-PCR analysis involving subtype-specific
probes were performed by Rohrer et al. [91] in order to
compare the respective expression patterns of human sst1–4
receptors: a single 4.3-kb human sst1 transcript was ob-
served in brain and lung. During a series of further RT-
PCR experiments, additional human sst1-gene expression
was found in fetal kidney, fetal liver, and adult pancreas.
Miller et al. also used the RT-PCR to demonstrate expres-
sion of sst1 mRNA in human pituitary. In this organ,
furthermore, they found both sst2 and sst5 but neither sst3
nor sst4 transcripts [436]. By the RT-PCR and Southern
blotting (SB), Panetta and Patel [437] found the mRNA of
sst1, sst2, sst3, sst4, and sst5 receptors in fetal human
pituitary. By contrast, they reported sst4 transcripts to be
absent from adult pituitary.154 By ISH, Thoss et al. [438]
detected human sst1 mRNA in the outer and intermediate154 Investigating a number (i.e. 15) of secretory (ACTH, GH, PL,
TSH) and nonsecretory human pituitary adenomas, Panetta and Patel [437]
found the following distribution of SRIF receptors: sst1 = 73%, sst2A= 87%,
sst3 = 53%, sst4 = 40%, and sst5 = 47%.
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dentate gyrus, entorhinal cortex), hypothalamus, substantia
nigra, medullary nuclei, and dentate nucleus. In human
placental tissue and purified human cytotrophoblasts,
Caron et al. [439] found the mRNA of both sst1 and sst4
receptors to be expressed, though possibly with the latter
receptor subtype playing the dominant part. Highly differ-
entiated expression of individual receptor subtypes in
endocrine cells of human PIL was recently demonstrated
by Kumar et al. [440] who used a technique of quantitative
double-label fluorescence immunocytochemistry (QDFI). A
panel of rabbit polyclonal antibodies raised against each of
the human receptor subtypes revealed the local presence of
the entire receptor family. However, sst1, sst2, and sst5
receptors are expressed at the highest levels, with a rank
order of sst1>sst5>sst2. The sst1 receptor was thus reported
to be colocalised with insulin in all of the beta cells, with
glucagon in 26% of the alpha cells, and with SRIF in only
a few of the delta cells (cf. Table 3).
By ISH, sst1 mRNA was found to be widely expressed
in mouse brain, particularly in the supra- and infragranular
layers of the cortex, the amygdala, hippocampus, bed
nucleus of the stria terminalis, substantia innominata,
hypothalamus, pretectum, substantia nigra, parabrachial
nucleus, and nucleus of the solitary tract [441]. In mouse
hypothalamic neurones, Viollet et al. [368] reported mRNA
levels of the sst1 receptor to be 2-fold higher than those of
the sst2 receptor while expression of sst3, sst4, and sst5
receptors seemed quantitatively insignificant. Similar to the
sst2 splice variants, which are both present in the pituitary
[278], the sst1 receptor plays a part in regulation of GH
secretion. In WT mice, the relatively subtype-selective
SRIF analogue CH-275 thus inhibited basal secretory
activity of somatotrophs. By contrast, the same compound
failed to evoke any response in sst1-receptor KO mice
[12].155
Thanks to the results obtained with sequence-specific
cRNA probes, Bruno et al. [276] could announce a similar
widespread expression of sst1 receptors in rat CNS, the
highest levels being recorded in the hippocampus, hypo-
thalamus, cortex, and amygdala. If somewhat sparse, the
sst1 receptor was also present in both the cerebellum and
spinal cord. Outside the CNS, high levels of this receptor
subtype are found in rat pituitary and spleen. It also occurs
in rat stomach, heart, and intestine. In rat stomach, sst1
mRNA, while absent from the fundus, has been found in
antral mucosa. However, the remaining receptor subtypes
are expressed in both regions of the stomach [19]. Using155 With the rat CNS being a case in point, Leroux et al. [577] tend to
think that CH-275 is sufficiently subtype-selective for specific binding of
this compound to be taken as evidence of sst1 expression. Binding
competition with the radioligand [125I]Leu8-D-Trp22-Tyr25-SRIF-28 seems
to show a higher density of sst1 receptors in cerebellar nuclei and cerebral
cortex (IC50 = 10–50 nM) than hippocampus, immature cerebellum, and
pituitary (IC50>1 AM).oligonucleotide probes derived from the cDNA encoding
sst1, sst2, and sst3 receptors, respectively, ISH studies were
carried out by Perez et al. [442] to analyse the distribution
of receptor-subtype mRNA in rat brain. sst1-receptor
signals were observed in layers V–VI of the cerebral
cortex, in the primary olfactory cortex, taenia tecta, sub-
iculum, entorhinal cortex, granular layer of the dentate
gyrus, amygdala, and cerebellar nuclei. Kong et al. [277]
obtained comparable results. By NB, high levels of a rat
sst1 mRNA of 3.8 kb were found to be expressed in the
cerebral cortex, hippocampus, midbrain, and hypothala-
mus. ISH histochemistry showed the transcripts to be
localised to discrete layers of the cerebral cortex, the
piriform cortex, and the dentate gyrus of the hippocampus.
Low levels of sst1 mRNA were expressed in the cerebel-
lum and pituitary, and no transcripts were detectable at all
in the striatum or other peripheral organs. Activation of
PTP in pituitary strains correlates with the endogenous
expression of sst1 receptors in these cells. Rabbit poly-
clonal antibodies raised against the exofacial regions of
each receptor subtype were used to analyse receptor
expression in normal rat pituitary somatotrophs. The
technique chosen by Kumar et al. [443] was QDFI. It
came out that the sst1 receptor is the least abundant of the
five receptor subtypes, occurring in only 5F 1.2% of the
cells. Helboe et al. [444], with an immunohistochemical
approach to sections of the rat hypothalamus, reported the
sst1 receptor to be located in perikarya and nerve fibres of
the rostral periventricular area surrounding the third ven-
tricle and in nerve fibres projecting from the perikarya to
the external layer of the median eminence, showing
colocalisation with the endogenous ligand SRIF itself.156
Using gold-labelled SRIF, Segond et al. [445] identified
specific binding sites in laminae I–III, X, and on motor-
neurones of the rat lumbar spinal cord. Extensive binding
in laminae I–III coincided with receptor-like immunore-
activity for sst1, sst2, and sst3 receptors. The sst1 receptor,
however, eluded detection by subtype-specific antibodies
on lumbar motorneurones. The complete absence of re-
ceptor-like immunoreactivity in lamina X strongly indi-
cates tissue-specific expression of other receptor subtypes
than the ones specifically labelled by antibodies in this
study. In 1046-38 cells, though colocalised with the sst2
receptor, the sst1 receptor was reported by Roosterman et
al. [253] to be predominant.
By NB and the RT-PCR, the mRNA of both goldfish
sst1A and sst1B receptors has been found by Lin et al. [80] to
be distributed throughout the brain, with a single receptor
isoform being expressed in goldfish pituitary.156 It is suggested by Helboe et al. [444] that the rat sst1 receptor may
very likely function as an autoreceptor in the neurones concerned,
mediating inhibition of SRIF secretion in a self-limiting manner known
as autocrine regulation. An antiserum directed against the sst1 receptor
reacted with a hypothalamic band with an apparent MW of 80,000 during
WB.
Table 3
Tissue distribution of human somatostatin receptors organ specificities of
receptor subtypes
sst1
receptors
sst2
receptors
sst3
receptors
sst4
receptors
sst5
receptors
Caput
Cerebrum cerebellum cerebellum cerebellum cerebellum
Hypothalamus cerebrum (a) cerebrum cerebrum hypothalamus (f)
Pituitary pituitary pituitary pituitary (f) pituitary (f)
spinal cord
Thorax
Lung nil nil lung heart
skeletal muscle
Abdomen
Jejunum (a) kidney (a) pancreas pancreas adrenal
Kidney (f) pancreas stomach placenta pancreas
Liver (f) stomach stomach placenta
Pancreas (a) small intestine
Placenta stomach
Notes to Table3:
Receptor subtypes Organs References
Human sst1 Caput:
cerebrum [91,438]
hypothalamus [438]
pituitary [436,437]
Thorax:
lung [91]
Abdomen:
jejunum (a) [77]
kidney (f) [91]
liver (f) [91]
pancreas (a) [91,440]
placenta [439]
stomach (a) [19,77]
Human sst2 Caput:
cerebellum [438]
cerebrum (a) [77,91,438]
pituitary [436–438]
spinal cord [449]
Thorax: nil
Abdomen:
kidney (a) [77,447]
pancreas [440]
stomach [19,448]
Human sst3 Caput:
cerebellum [438]
cerebrum [79,91,438]
pituitary [437,438]
Thorax: nil
Abdomen:
pancreas [79,91,440]
stomach [19]
Human sst4 Caput:
cerebellum [438]
cerebrum [91,438]
pituitary (f) [437]
Thorax:
lung [91]
Abdomen:
pancreas [440]
placenta [439]
stomach [19]
Human sst5 Caput:
cerebellum [210,438]
hypothalamus (f) [96]
pituitary [96,210,436–438]
Thorax:
heart [210]
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NB studies initially showed two human sst2 transcripts of
8.5 and 2.5 kb, respectively, to be most richly expressed in
adult cerebrum and kidney [77]. Two variously sized human
sst2 transcripts of 8.9 and 2.4 kb, respectively, were detected
in brain by NB and the RT-PCR [91]. By in vitro RAG,
high-affinity binding sites for various SRIF analogues were
identified in human kidney sections (KD = 0.5 nM), sug-
gesting the presence of one or more receptor subtypes.
Radioligands applied were [125I]Tyr3-SMS 201–995 and
[125I]Leu8-D-Trp22-Tyr25-SRIF-28. Within cortical areas,
receptors are confined to the proximal tubules (thus, never
visualised in glomeruli). In the medulla, labelling density
was pronounced in the vasa recta, but also the collecting
tubules exhibited a moderate extent of specific binding. An
identical labelling pattern was found with both iodinated
tracers in all six human kidneys examined. Consistent with
earlier reports [446], attempts to identify similar renal SRIF
receptors in the rat have failed, the distribution being
seemingly species-dependent. The assumption that the renal
binding sites are identical to the cloned sst2 receptors is
based on the observation of relatively high affinity for the
endogenous ligand SRIF-14 as well as SMS 201–995,
contrasting with sst1 and sst3 receptors which both have
only low affinity for the synthetic octapeptide [447]. On the
basis of pharmacological observations, using a number of
relatively subtype-selective SRIF analogues, Zaki et al.
[448] argued that antral sst2 receptors are responsible for
mediating SRIF-induced inhibition of both gastrin and
histamine secretion in man, dog, and rat.157 By the RT-
Stomach (a)157 Zaki et al. [448] noted that SRIF must inhibit secretion of both
gastrin and histamine by direct interaction with receptors expressed by
endocrine cells of the respective types. Hence, histamine secretion is not
regulated via inhibition of gastrin secretion. Indeed, histamine secretion
defied regulation by an antagonist at gastrin receptors and decreased in
response to SRIF alone.PCR, human sst2 mRNA has been found in both antral and
fundic mucosa [19]. Apart from sst1 and sst5 transcripts,
Miller et al. [436] found the mRNA of the sst2 receptor to be
expressed in human pituitary. Panetta and Patel [437] found
the sst2 receptor (i.e. consistently the longer sst2A splice
variant) to be expressed in both fetal and adult human
pituitary. Using ISH, Thoss et al. [438] found human sst2skeletal muscle [210]
Abdomen:
adrenal [210]
pancreas [440]
placenta [210]
small intestine [210]
stomach [19]
158 L-817,818 binds to both human sst5 (Ki = 0.4 nM) and human sst3
(Ki = 3.3 nM) receptors with high affinity [389].
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hippocampal formation (CA1, dentate gyrus, subiculum,
entorhinal cortex), the granular layer of the cerebellum,
and pituitary. In the human PIL, sst2 receptors were colo-
calised with glucagon in 89% of the alpha cells and with
insulin in 46% of the beta cells. As for sst1 and sst3
receptors, delta cells showed but low density of sst2 recep-
tors [440]. When applied to the spinal cord or brain areas
involved in nociception, SRIF has been found to induce
analgesia. Schindler et al. [449] combined IHC with retro-
grade fluorogold tracing to define neuronal expression of
sst2A receptors and system-specific colocalisation in those
very regions of the CNS. In the periaqueductal grey, sst2A-
positive neurones could be found to coexpress calbindin
D28k (36%), glutamate transporter EAAC-1 (25%), and
GABA transporter GAT-1 (approximately 10%). As much
as 65% of the sst2A-positive neurones projected to the
thalamus. In the spinal cord, the sst2A receptor also showed
cellular colocalisation with EAAC-1 and GAT-1. However,
sst2A receptors seemed completely absent from primary
afferent neurones. The evidence available favoured an
intrinsic localisation of the receptor subtype in the dorsal
horn of the spinal cord (cf. Table 3).
Mouse sst2 mRNAwas detected by ISH predominantly in
the infragranular layers of the cortex, the amygdala, claus-
trum, endopiriform nucleus, arcuate and paraventricular
nuclei of the hypothalamus, and medial habenular nucleus.
Additional brain sites of either SRIF-like immunoreactivity
or high-affinity binding displayed no transcripts of either
receptor subtype, i.e. sst1 or sst2 receptors [441]. In CHO
cells stably transfected with mouse sst2 receptors (CHOB),
two separate antibodies specifically recognised a 93-kDa-
protein by immunoblotting. One antibody (2e3) was directed
against the peptide Ser-Ser-Cys-Thr-Ile-Asn-Trp-Pro-Gly-
Glu-Ser-Gly-Ala-Trp-Tyr-Thr (residues 191 – 206),
corresponding to a region in the predicted ECL-III of mouse
sst2 receptors. Another antibody (2i4) was directed against
the peptide Ser-Gly-Thr-Glu-Asp-Gly-Glu-Arg-Ser-Asp-Ser
(residues 333–343) from the predicted CTT of mouse sst2
receptors. In regions of the rat brain previously shown to
express high levels of sst2 mRNA, however, 2e3 specifically
recognised a protein of 148 kDa but none of 93 kDa. No
immunoreactivity was evident in selected rat organs that do
not express sst2 receptors, i.e. kidney, lung, and liver [450].
Although with varying ratios between the two murine splice
variants, transcripts (mRNAs) corresponding to both sst2A
and sst2B receptors are observed in the cortex, hippocampus,
hypothalamus, striatum, mesencephalon, cerebellum, medul-
la oblongata, pituitary, and testis (using the RT-PCR). The
pattern of mRNA distribution points to tissue-specific regu-
lation of the pretranslational splicing process. The cortex
displayed the highest levels of mouse sst2A receptors but
only little mouse sst2B receptors. The pons/medulla oblon-
gata expressed both isoforms to an equal extent. NB analysis
with a mouse sst2A-specific hybridisation probe identified a
single mRNA of about 2.4 kb. A probe hybridising to bothisoforms did not provide any additional signal. ISH indicated
that mouse sst2A receptors are predominantly expressed in
mouse brain and that mouse sst2B receptors are never
expressed independently of mouse sst2A receptors [278].
The sst2 receptor is the predominant receptor subtype of
mouse astrocytes, representing 80% of the total amount of
receptor mRNA. But compared to mouse hypothalamic
neurones, which display an entirely different expression
pattern, astrocytes express 10-fold less receptor mRNA
[368]. The distribution of sst2 receptors in mice has been
indirectly demonstrated by selective inactivation of the sst2
gene. In KO mice described in a report by Zheng et al. [451],
both GH and SMS 201–995 failed to inhibit activation of
arcuate neurones by MK-0677. Normally, GH-induced neg-
ative feedback would appear to involve sst2-dependent
signalling between periventricular and arcuate neurones. In
other KO mice, principally due to disinhibition of gastrin
release, gastric pH was lower than in WT mice, and basal
acid output per 2 h 10-fold higher. Both SRIF-14 and the
relatively sst2-selective peptide agonist DC 32–87 inhibited
pentagastrin-stimulated acid secretion in WT mice. But
neither of them affected basal output in KO mice [452].
Basal glucagon secretion appeared to be much the same in
WT and sst2-receptor KO mice. Indeed, basal secretion of
neither glucagon nor insulin responds to SRIF or any of the
subtype-selective agonists. However, K+/arginine-stimulated
glucagon secretion turned out to be 2-fold higher in islets
isolated from KOmice. SRIF potently inhibited the secretory
response in WT mice. In islets derived from KO mice, by
contrast, inhibition induced by SRIF had been much atten-
uated. What is more, the sst2-selective nonpeptide agonist L-
779,976, while a potent antisecretagogue in WT mice,
proved to be virtually inactive in KO mice. A relatively
sst5-selective nonpeptide agonist such as L-817,818, which
seemed well designed to regulate insulin secretion, shared
but little of the inhibitory potential of L-779,976 in endocrine
alpha cells.158 None of the sst1-, sst3-, and sst4-selective
SRIF analogues tested interfered with stimulated glucagon
secretion at all. On the basis of these observations, Strowski
et al. [453] concluded that the sst2 receptor would seem to be
the predominant mediator of negative alpha-cell regulation.
Using the recently developed nonpeptide sst2 agonists,
which display an unprecedented degree of selectivity, Rohrer
et al. [389] confirmed the importance of sst2 receptors in
negative regulation of glucagon secretion from mouse alpha
cells.
Leaving aside the mouse sst2 receptor, which gives rise to
two splice variants, other known receptor subtypes, rodent
as well as human, long appeared to be intronless (sst1, sst3,
sst4, and sst5 receptors). In rats, NB has failed to identify
any sst2 transcripts in the kidney [84]. With mRNA blots of
rat tissues, however, Patel et al. [83] discovered two tran-
scripts of 2.8 and 2.3 kb that are differentially expressed in
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levels of sst2 mRNA are observed in anterior and posterior
pituitary, adrenals, colon, cerebral cortex, and hypothala-
mus. All positive tissues exhibit both transcripts (2.3 and 2.8
kb) but with tissue-specific dominance of one or the other
form. Thus, 2.3 kb was dominant in hypothalamus while 2.8
kb predominated in pituitary, colon, and adrenal. The 2.3-kb
mRNA is preferentially expressed in pituitary tumour cells
(AtT-20 mouse, GH3 rat, human prolactinoma, human
somatotrophic adenoma) but not in rat or human insulinoma
cells. According to Patel et al., RINm5F (otherwise known
to be SRIF receptor-positive), 1027-B2, PC-12, and COS-7
cells were all sst2-negative.
159 None of the human tumours
examined displayed a 2.8-kb transcript corresponding to the
rat sst2A mRNA. In AtT-20 cells, the 2.3-kb transcript shows
4-fold induction by forskolin (16 h), highly indicative of
cAMP-dependent regulation of sst2-gene expression. The
relative potencies of various SRIF analogues to inhibit the
secretion of GH in pituitary strains (adult male rat) correlate
with their binding affinities for sst2 receptors rather than sst1
or sst3 receptors. As far as the CNS is concerned, transcripts
encoding the rat sst2 receptor showed a distribution pattern
very similar to that of the sst1 receptor in a study by Bruno
et al. [276]. But while abundant in rat pituitary and spleen,
sst2 transcripts eluded detection in the heart and intestine.
Unlike sst1 transcripts, however, they were observed in the
rat pancreas. During ISH, rat sst2-receptor signals were
picked up from the frontal cerebral cortex (layers IV–VI),
taenia tecta, claustrum, endopiriform nucleus, locus coeru-
leus, medial habenula, subiculum, granular cell layer of the
dentate gyrus, and amygdala [442]. Two separate rat sst2
transcripts of 2.4 and 2.8 kb, respectively, were identified
by NB. As revealed by ISH, sst2 mRNA was diffusely
expressed in the cerebral cortex and amygdala; it is dis-
cretely localised to the dentate gyrus of the hippocampus,
medial habenula, ventromedial and dorsomedial nuclei, and
arcuate nucleus of the hypothalamus. Levels of sst2 mRNA
are very low in the cerebellum, and transcripts were not
observed in the striatum or peripheral tissues other than the
pituitary and adrenal gland [277]. Similar to the human
homologue, the rat sst2 receptor is found in both antral and
fundic mucosa. In the latter, displaying a local distribution
pattern similar to that of the rat sst5 receptor, it seems to be
expressed by both parietal and endocrine cells [19]. By WB,
Hunyady et al. [454] identified the splice variant sst2A, i.e. a
90-kDa glycoprotein, in rat pancreas. It was the first SRIF
receptor to be positively located in that rat organ at the
translational level. Signals revealed a high density of recep-
tors in acinar cells of the exocrine gland as well as endocrine
A and PP cells. Labelling of B cells with specific antibodies159 In 1046-38 cells, which represent a model system of B-cell
function, Roosterman et al. [253] found evidence of both sst1 and sst2
expression, detecting the mRNA of the respective receptor subtypes by the
RT-PCR.was rather sparse, and none of the D cells were labelled at
all. By ISH, Day et al. [455] identified rat sst2 mRNA in
40% of somatotrophs, 36% of thyreotrophs, 3% of cortico-
trophs, 26% of lactotrophs, and 8% of gonadotrophs. The
sst2 receptor was found to be expressed by 42F 6.4% of rat
somatotrophs analysed by Kumar et al. [443]. Using a
polyclonal antibody raised against a motif within the CTT
of the rat sst2A receptor, Schindler et al. [456] reported on
cellular distribution of this receptor subtype in the adult rat
CNS. Intracranial neurones were labelled in a number of
areas, including the basolateral amygdala, locus coeruleus,
endopiriform nucleus, deep layers of the cerebral cortex,
subiculum, claustrum, habenula, interpenduncular nucleus,
hippocampus, and central grey. Intraspinal perikarya and
dendrites were strongly labelled in the substantia gelatinosa.
Antiserum directed against the sst2 receptor labelled binding
sites in the amygdaloid complex, hippocampus, fascia
dentata, and neocortex of both rat and monkey [154].
Subsequently, Schindler and Humphrey [457] have been
the first to report the expression of the sst2B receptor in the
rat oxyntic mucosa, exposed on the surface of parietal cells.
The sst2A receptor displayed another distribution pattern,
being localised to enterochromaffin-like cells and nerve
fibres. An affinity-purified polyclonal antibody raised
against a peptide motif located in the CTT of rat sst2B
receptors came into use during WB. Schindler et al. found
the rat sst2B receptor to be a glycoprotein with a MW of
approximately 85,000. As represented by IHC, the sst2B
receptor turned out to be distributed throughout the rostro-
caudal axis of the adult rat CNS. Both somatodendritic and
axonal staining could be observed. Somatodendritic label-
ling rose to the highest levels in the olfactory bulb, cerebral
cortex, hippocampal formation, mesencephalic trigeminal
nucleus, and cerebellum. The sst2B receptor was detected in
both cranial and spinal motor areas [458]. Combining
indiscriminate gold labelling of SRIF receptors with sub-
type-specific IHC, Segond et al. [445] have identified sst2
receptors in laminae I–III of the rat lumbar spinal cord.
Despite gold labelling by SRIF, however, the sst2 receptor is
absent from both lamina X and motorneurones at that level
of the spinal cord.
Using polyclonal antibodies raised against the CTT of the
human sst2 receptor, Helboe et al. [459] investigated ex-
pression of this receptor subtype receptor in the CNS and
pituitary of the golden hamster (Mesocricetus auratus).
They detected immunoreactivity in the forebrain (particu-
larly in the deep layers of the neocortex, endopiriform
cortex, claustrum, and basolateral amygdaloid nucleus but
also in the CA1 area of the hippocampus and subiculum),
brainstem, cerebellum (cortical areas), spinal cord (lamina I
and II of the dorsal horn), and anterior pituitary. In the
diencephalon, immunoreactivity could be localised to the
periventricular area, the dorsomedial and arcuate nuclei of
the hypothalamus, and the medial habenular nucleus.
Receptors seemed to be present at high levels in the locus
coeruleus and parabrachial nucleus of the brainstem.
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the sst2A receptor in widely spaced amacrine cells whose
perikarya are at the border of the inner nuclear layer and
inner plexiform layer. Immunoreactivity reached high levels
corresponding to inner segments and terminals of rod and
cone photoreceptors.
5.2.3. Distribution pattern of receptor subtype sst3
NB studies revealed the expression of human sst3 recep-
tors in brain and PIL. A single transcript of 4.8 kb was
observed in the human cerebrum. No hybridisation signals
were received from the liver, kidneys, GIT, or placenta [79].
As determined by NB and the RT-PCR, a single 4.9-kb
human sst3 transcript was expressed in brain and pancreas
[91]. Using ISH, Thoss et al. [438] found human sst3 mRNA
to be expressed in the cerebral cortex, hippocampal forma-
tion (CA1, dentate gyrus), several medullary nuclei, and the
granular (and possibly Purkinje-cell) layer of the cerebel-
lum. At very low levels, transcripts could also be shown in
human pituitary. By contrast, Miller et al. [436] found the
mRNA of sst1, sst2, and sst5 receptors alone in human
pituitary. However, sst3 mRNA did occur in a single
somatotrophic adenoma examined. Anticipating the results
of Thoss et al., Panetta and Patel [437] could demonstrate
sst3 mRNA in both fetal and adult human pituitary by the
RT-PCR and SB. Similar to the sst4 receptor, the sst3
receptor is a rather poorly expressed receptor subtype in
human PIL. Unlike the sst4 receptor, however, the sst3
receptor is actually present in all of the endocrine cell types
analysed, i.e. alpha, beta, and delta cells [440]. Similar to
the remaining receptor subtypes, the human sst3 receptor has
been found by the RT-PCR to be expressed in both antral
and fundic mucosa [19]. By NB, Corness et al. [87]
demonstrated expression of a sst3-mRNA species of ap-
proximately 5 kb in various regions of the monkey brain,
including the frontal cortex, cerebellum, medulla, and
amygdala (cf. Table 3).
ISH reveals that mouse sst3 receptors are present in
several regions of the brain, including the nucleus of the
lateral olfactory tract and the piriform cortex, implicating
SRIF in the modulation of primary sensory information
[88].
Using their sequence-specific cRNA probes for solution
hybridisation/nuclease protection analysis, Bruno et al.
[276] found the highest levels of the rat sst3 receptor in
the cerebellum, but this receptor subtype could also be
detected in rat pituitary, heart, liver, stomach, intestine,
kidney, and spleen. In the stomach, the rat sst3 receptor is
expressed in both antral and fundic mucosa [19]. With ISH
performed in rat brain, sst3-receptor signals were received
from the olfactory bulb, primary olfactory cortex, islands of
Calleja, medial habenula, amygdala, granular layer of the
dentate gyrus, various thalamic and pontine nuclei, and—
conflicting with the findings of earlier studies—granular and
Purkinje cell layers of the cerebellum [442]. A single rat sst3
transcript of 4.0 kb was observed in the hippocampus,cerebral cortex, midbrain, hypothalamus, and pituitary. But
the cerebellum may express the highest levels of SRIF-
receptor mRNA, the latter being localised to the granular
cell layer [277]. In normal human PIL, transcripts of sst1,
sst2, and sst4 receptors are expressed. Evidence of the sst3
receptor has not been reported. This particular receptor
subtype, however, is amply represented at the transcriptional
level in rat PIL [460]. As determined by ISH histochemistry,
sst3 mRNA is widely expressed in rat brain; sst4 mRNA,
however, is confined to the telencephalon, diencephalon,
and granular layers of the cerebellum. sst3 mRNA displayed
a homogenous distribution in the cerebral cortex and was
expressed in the olfactory bulb, pyramidal cells of the
hippocampus, granular cell layer of the dentate gyrus, motor
and sensory metencephalic nuclei, and the granular and
Purkinje cell layers of the cerebellum [356]. The sst3
receptor was expressed in 18F 3.2% of rat somatotrophs
[443]. By ISH, Zitzer et al. [149] showed that CortBP1 and
the sst2 receptor are coexpressed in rat brain. Unlike sst1 and
sst2 receptors, which Segond et al. [445] identified in
laminae I–III of the rat lumbar spinal cord by immunohis-
tochemistry, sst3 receptors could be found both in those
areas and on motorneurones while absent from lamina X.
Using Leu8-D-Trp22-[125I]Tyr25-SRIF-28 to represent the
distribution of SRIF receptors to individual organs, specific
binding could be obtained in fish brain, liver, heart, spleen,
and stomach. However, Siehler et al. [89] reported binding
in fish gut to be nonexistent. The pharmacological profile of
the sites labelled by the radioligand in brain, but not liver,
seemed identical to that of the cloned fish sst3 receptor. The
RT-PCR tends to confirm a distribution pattern such as this.
Biphasic binding curves in the brain, as obtained with two
SRIF analogues, combined with the distinct pharmacolog-
ical profile of binding sites in the liver suggest the expres-
sion of an entire family of receptor subtypes, of which the
sst3 receptor is but one.
5.2.4. Distribution pattern of receptor subtype sst4
A single 4.6-kb human sst4 transcript was detected by
NB and the RT-PCR in brain and—to a lesser extent—in
lung tissue. Transcripts of human sst4 receptors could not be
demonstrated in heart, placenta, liver, skeletal muscle,
kidney, or pancreas. The respective expression patterns of
human sst1 and sst4 receptors show a conspicuous degree of
overlapping, though clearly distinct [91]. Using the RT-
PCR, Miller et al. [436] failed to find any evidence of sst4
mRNA in normal human pituitary or a number of pituitary
adenomas examined. Panetta and Patel [437] found them-
selves in a position to qualify this negative result. They
reported that, while absent from adult human pituitary, sst4
mRNA could actually be detected in fetal pituitary by the
RT-PCR and SB. By ISH, high levels of human sst4 mRNA
could be demonstrated in the granular and Purkinje-cell
layer of the cerebellum. But Thoss et al. [438] also found
transcripts in the hippocampal formation (dentate gyrus) and
several medullary nuclei. It has been found by the RT-PCR
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fundic mucosa [19]. The sst4 receptor would appear to be
the least abundant receptor subtype in human PIL. Thus, it
was detected only at low levels in beta cells. According to
the results published by Kumar et al. [440], neither alpha
nor delta cells express the sst4 receptor at all. By NB,
Demchyshyn et al. [93] found a sst4-mRNA species of 4.0
kb in select regions of the monkey brain, including the
hippocampus, hypothalamus, cortex, and striatum. In MIA
PaCa-2 cells, the human sst4 receptor is expressed as a
single transcript of 4.8 kb. Neither sst4 nor sst5 receptors,
however, could be demonstrated by Yamada et al. [94] in
human liver, kidney, GIT, and placenta; the latter receptor
subtype, along with human sst1 – 3 receptors, was not
expressed by the MIA PaCa-2 strain either, for that matter.
The reason why, in women, placental secretion of GH defies
negative regulation by octreotide appears to be tissue-
specific expression of SRIF2 receptors. Both sst1 and sst4
transcripts could thus be demonstrated by Caron et al. [439]
in human placenta. Nevertheless, the investigators favoured
the notion of a predominant sst4 receptor on the basis of
pharmacological observations (cf. Table 3).160
Bruno et al. [95] reported the mRNA of rat sst4
receptors to be expressed in a number of brain regions,
especially the cortex and hippocampus. But no mRNA was
detected outside the brain. In a later study, the same
investigators had another go at adult rat tissue specimens,
verifying some of their initial findings. With the exception
of the cerebellum, sst4 transcripts showed up in most brain
regions, the highest levels occurring in the hippocampus,
cortex, and olfactory bulb. Patterns of expression were
now found to be practically similar for sst3 and sst4
receptors (see above). The latter, however, did not appear
to be expressed in rat liver [276]. As determined by NB,
the preponderant receptor subtype in the rat hippocampus
is reported to be the sst4 receptor. Furthermore, it is
expressed in regions of the rat brain such as cerebral
cortex, striatum, hypothalamus, and thalamus; outside the
CNS, it was detected in the rat lung only. ISH defined the
areas of expression more clearly, signals emanating from
neurones of the hippocampus (especially the CA1 area),
dentate gyrus, lateral habenula, neocortex (especially layers
V and VI), striatum, amygdala, and pyriform cortex;
signals were barely perceptible in the cerebellum [209].
Using ISH, the highest density of rat sst4 mRNA was
observed in the pyramidal cell layer of the hippocampus,
especially in the CA1 and CA2 areas, anterior olfactory
nuclei, amygdala, and in layers IV and VI of the cerebral
cortex. Coexpression of sst3 and sst4 mRNA was estab-
lished for single neurones in the CA1 and CA2 areas of160 Caron et al. [439] explicitly refers to CH-275 as ‘‘sst1-selective’’.
But, in reality, it is subclass-rather than subtype-selective (see above).
Because this peptide agonist interacts but poorly with placental SRIF
receptors, it is concluded by the investigators that sst1 receptors, which have
been detected at the level of transcription, must play a part in human
placenta subordinate to that of sst4 receptors.the hippocampus, in the subiculum, and in layer IV of the
cerebral cortex [356]. Similar to rat sst2, sst3, and sst5
receptors, the rat sst4 receptor has been found in both
antral and fundic mucosa by the RT-PCR [19]. Using
QDFI, Kumar et al. [443] demonstrated rat sst4 receptors
in 23F 4.7% of normal somatotrophs. Using antibodies
raised against the CTT of the rat sst4 receptor, Schreff et al.
[156] investigated the expression pattern of this receptor
subtype in the rat CNS. They reported sst4-like immuno-
reactivity to be most intense in various forebrain regions,
including the cerebral cortex, hippocampus, striatum,
amygdala, and hypothalamus. At the level of solution
provided by electron microscopy, it was disclosed that
sst4 receptors are confined mainly to the somatodendritic
area of immunoreactive neurones. Receptor-bearing den-
drites are typically found in close proximity to fibres and
terminals with secretory vacuoles containing SRIF-14. All
in all, sst4 receptors seem to be distributed according to
strictly postsynaptic functions.
5.2.5. Distribution pattern of receptor subtype sst5
A comparatively large transcript of 4.0 kb was identified
in normal human pituitary. The RT-PCR disclosed expres-
sion of human sst5 receptors in fetal pituitary and hypothal-
amus, not in cerebral cortex [96]. Later, the RT-PCR has
also demonstrated the presence of human sst5 transcripts in
small intestine, heart, adrenal, cerebellum, pituitary, placen-
ta, and skeletal muscle. Relevant mRNA has not been found
in kidney, liver, pancreas, uterus, thymus, testis, spleen,
lung, thyroid, ovary, or mammary gland [210]. Along with
sst1 and sst2 receptors, as reported by Miller et al. [436]
using the RT-PCR, the sst5 receptor made a steady contri-
bution to the receptor population of human pituitary. Fur-
thermore, the limited number (i.e. 5) of somatotrophic
adenomas examined by Miller et al. consistently expressed
this receptor subtype. Unlike sst1 mRNA, which could be
found in three adenomas alone, sst2 transcripts could be
detected in each sst5-positive adenoma. Panetta and Patel
[437] found sst5 mRNA to be expressed in both fetal human
and adult pituitary. According to Thoss et al. [438], who
used ISH to define tissue-specific expression of SRIF
receptors in the brain, human sst5 mRNA is found in both
the pituitary and the granular layer of the cerebellum. The
mRNA of the human sst5 receptor has been localised to both
antral and fundic mucosa by the RT-PCR [19]. In the human
PIL, Kumar et al. [440] found the sst5 receptor to be
colocalised with insulin in 87% of the beta cells, with SRIF
in 75% of the delta cells, and with glucagon in 35% of the
alpha cells. Thus, it is by far the most abundantly expressed
receptor subtype in delta cells (cf. Table 3).
Lublin et al. [461] reported the presence of mouse sst5
receptors in brain but not liver, heart spleen or kidney of
adult animals. In mouse, sst5 mRNA has been detected at
higher levels in pituitary, kidney, spleen, and ovary. At
lower levels, it has been found in brain, thymus, stomach,
and intestine while completely absent from heart, pancreas,
161 Alpha and beta cells of the PIL illustrates this point very well (see
above).
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agonist L-817,818, Strowski et al. [453] argued that sst5
must be the predominant receptor subtype responsible for
SRIF-induced inhibition of insulin secretion from endocrine
beta cells in mice. Thus, both SRIF and L-817,818 potently
inhibited glucose-stimulated insulin secretion in WT and
sst2-receptor KO mice. The sst2-selective nonpeptide ago-
nist L-779,976 had but little inhibitory potential even in WT
beta cells. Putting nonpeptide sst5 agonists to the test,
Rohrer et al. [389] could easily verify the physiological
part played by the sst5 receptor in negative regulation of
insulin secretion from mouse beta cells.
NB analysis led to the discovery of a 2.6-kb sst5 mRNA
in rat pituitary. However, no transcripts were identified in
the liver, pancreas, small intestine, kidney, cerebellum, or
cortex [97]. In another study, NB analysis of sst5 mRNA led
to the detection of a 2.4-kb transcript in both normal rat
pituitary and GH3 cells [96]. Analysing the tissue distribu-
tion of transcripts encoding the five known receptor sub-
types, Bruno et al. [276] reported the cerebral expression
pattern of sst5 receptors to be distinct: transcripts occur
primarily in the hypothalamus and preoptic area. Outside the
rat CNS, sst5 receptors were expressed in the pituitary, but
detectable levels were also noted in the spleen and intestine.
In GH3 cells, sustained exposure to SRIF led to net
augmentation of specific receptor binding and a concomitant
increase in receptor–mRNA expression. Application of 1
AM SRIF for up to 48 h induced a dramatic and sustained
increase in the mRNA levels of sst1 and sst3–5 receptors. By
contrast, sst2 mRNA displayed a biphasic response, an
initial increase being followed by a decrease below control
values, with a prolonged course towards normalisation
[406]. Raulf et al. [279] found the mRNA of sst1, sst2,
sst3, sst4, and sst5 receptors to be expressed concurrently in
adult rat brain and pituitary by the RT-PCR. By ISH
histochemistry, transcripts corresponding to all five SRIF
receptors were demonstrated in the anterior lobe of the rat
pituitary. Relatively high levels of sst3 mRNA were also
expressed in the pars intermedia. Somatotrophs displayed a
relatively high level of sst4 and sst5 mRNA expression. By
contrast, thyrotrophs mainly expressed sst2 mRNA [280].
All known receptor subtypes (sst1–5) are expressed in the
anterior pituitary and hypothalamus. In food-deprived rats,
pituitary levels of sst1, sst2, and sst3 mRNA decreased by
80%, as compared to fed controls, with levels of sst4 and
sst5 mRNA remaining unaltered. Hypothalamic expression
of SRIF receptors resisted alterations under these conditions.
In diabetic rats, pituitary levels of sst1, sst2, and sst3 mRNA
dropped an entire 50–80%; sst4 mRNA was unaltered as
were the levels of sst1, sst2, sst3, and sst4 mRNA in the
hypothalamus. However, sst5 mRNA decreased by 70% and
30% in the pituitary and the hypothalamus, respectively.
Insulin therapy partially restored pituitary sst1 receptors and
completely restored pituitary and hypothalamic sst5 mRNA
[281,462]. By ISH, Day et al. [455] identified rat sst5
mRNA in 70% of somatotrophs, 57% of thyreotrophs,38% of corticotrophs, 33% of lactotrophs, and 21% of
gonadotrophs. More recently has the entire family of known
receptor subtypes been demonstrated in the stomach. Using
the RT-PCR, Le Romancer et al. [19] identified the mRNA
of sst1, sst2, sst3, sst4, and sst5 receptors in both human fundic
and antral mucosa (see above), rat antrum, and the human
gastric tumoural strain HGTL. By contrast, the mRNA of
only sst2, sst3, sst4, and sst5 receptors was present in rat
fundus. In the latter, rat sst2, sst3, sst4, and sst5 receptors
occurred in enriched fractions of parietal cells, with rat sst2
and sst5 receptors alone occurring together with endocrine
cells. The most abundant receptor subtype in normal rat
somatotrophs, the sst5 receptor was found to be expressed by
86F 9.7% of the cells analysed by Kumar et al. [443].
Helboe et al. [154] first provided immunohistochemical
visualisation of the sst5 receptor in mammalian brain. Anti-
serum directed against this receptor subtype thus labelled
binding sites in the amygdaloid complex, hippocampus,
fascia dentata, and neocortex of both rat and monkey. Mitra
et al. [463], using ‘‘double immunostaining’’, reported the
sst5 receptor to be expressed exclusively in beta cells and
insulin-secreting alpha cells of rat PIL. However, it is not
colocalised with the sst2A receptor which has been shown to
mediate negative regulation of glucagon secretion.6. Conclusion
To begin with, pharmacological observations lent them-
selves to the proposal of two receptor subpopulations, i.e.
SRIF1 and SRIF2 receptors. With subsequent isolation of
sst1–5 receptors from mammalian genomes, the original
system of classification seemed to be temporarily outri-
valled. However, compiling evidence from inhibition stud-
ies has shown that pharmacological and recombinant
nomenclatures are really complementary rather than
conflicting [192,464]. For obvious reasons, receptor cloning
has been the pivot of investigation. Sequence analysis of
these polypeptide chains that traverse the plasma membrane
to form highly adaptable relays of signal transmission has
bred speculations on phylogenetic relationships and condi-
tioned the detailed study of functional specialisation, with
great emphasis on particular amino acid motifs [186]. It is
evident that receptor function, from a physiological point of
view, cannot simply be reduced to the accumulated oper-
ations of individual receptors. Far from being isolated
functional units, receptors cooperate. The total receptor
apparatus of individual cell types is composed of differ-
ent-ligand receptors and coexpressed receptor subtypes in
characteristic proportions.161 In other words, levels of
individual receptor subtypes are highly cell-specific and
vary with coexpression of different-ligand receptors. A
maximum of physiological antagonism is thus ensured by
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receptor dimerisation, not least heterodimerisation, has
dramatically influenced our conception of receptor function.
In reality, an entirely novel class of functional receptor
subtypes or metareceptors has been introduced.
Observations regarding GP coupling must be treated
with some reservation. After all, the pursuit of function-
specific peptide motifs has so far resulted in nothing like
definite predictions of subtype-specific GP transduction.
Our present knowledge is mostly based on R–GP complex
formation in transfected cells. In reality, we know very little
about receptor-specific GP coupling in WT cells. As
regards some receptor subtypes, furthermore, it has been
a painstaking enterprise to reconstitute functional coupling
to key effectors.162 A truly fascinating discovery is ligand-
specific GP coupling because this phenomenon helps us
appreciate the dynamism of receptor function. Apparently,
synthetic analogues may stabilise such active conforma-
tions as must be assumed spontaneously by the GPC
receptor but which cannot be stabilised by native agonists,
though presumably by the individual GP subforms recruited
by the receptor [465].
Homeostasis represents the product of delicately bal-
anced neurohumoral signal transmission. We may define
the cellular response to individual transmitters in terms of
transduction mechanisms. But the function of entire receptor
populations is mainly known from pathological conditions
characterised by abnormal synthesis of the endogenous
transmitter.163 It is known that some pathological conditions
(e.g. inflammatory bowel disease, rheumatoid arthritis, and
schizophrenia) are paralleled by alterations in the expression
patterns of individual receptor subtypes. The pathogenetic
implications of this observation are far from evident. An
attempt to define the physiological impact of individual
receptor subtypes is represented by generation of receptor-
deficient KO mice.
The recognition of an entire family of receptor subtypes,
itself a member of an extended family of GPC receptors, has
both shed light on the bewildering complexity of SRIF action
and prepared the way for fabrication of subtype-selective
SRIF analogues. Insight into the subtle interplay of ligand
and receptor, initially spelling out the structural components,
may at best provide the means to manipulate the latter at will,
interfering with physiological parameters in a predictable
manner. Ultimately, this should allow us to bridge the gap
between test-tube discoveries of the laboratory and routines
of medical practice. More precisely, synthetically adjusted163 For instance, shortage of insulin and thyroxine results in the well-
known symptoms of diabetes and myxoedema, respectively, while surplus
of the same transmitters results in the states of hypoglycemia and
thyrotoxicosis, respectively.
162 This is an allusion to the difficulties of functionally coupling sst1
and sst2A receptors to AC (see above). But the remarks could apply to
nearly every effector system associated with SRIF receptors.receptor agonists/antagonists may be transformed into both
diagnostic and therapeutic tools of benefit to the clinician
and his patient. In the case of SRIF, this ideal has long since
become reality [39–41,43,58,104,203,235,238,283,319,
329,432,450,460,466–500].
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